var title_f39_53_40784="Nail plate post-surgery";
var content_f39_53_40784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail plate replacement after nail bed surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whenever possible, the nail plate is put back in place after nail bed biopsy to protect the wound and act as a biologic dressing. The nail plate can be taped or sutured in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40784=[""].join("\n");
var outline_f39_53_40784=null;
var title_f39_53_40785="Linkage one pedigree";
var content_f39_53_40785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75378%7EPC%2F57437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75378%7EPC%2F57437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linkage in one pedigree",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    All affected subjects (denoted as shaded) have a presumed disease genotype of Dd (ie, assumption of an autosomal dominant trait). The genotyped marker (with alleles 1, 2, or 3) appears to be linked in this pedigree with the disease locus, as all affected subjects harbor the 1 allele - this marker tracks with disease status.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Linkage to resolve location of disease gene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With successive meioses, recombination narrows chromosomal region harboring disease locus (+).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40785=[""].join("\n");
var outline_f39_53_40785=null;
var title_f39_53_40786="Sodium tetradecyl: Patient drug information";
var content_f39_53_40786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium tetradecyl: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1603?source=see_link\">",
"     see \"Sodium tetradecyl: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sotradecol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trombovar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat varicose veins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium tetradecyl or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active infection, active health problem, blood clots, high blood sugar (diabetes), diseased arteries going to the legs, poor health, or skin disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11321 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40786=[""].join("\n");
var outline_f39_53_40786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016560\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016559\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016564\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016565\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016562\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016568\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016569\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1603?source=related_link\">",
"      Sodium tetradecyl: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_53_40787="Churg Strauss PA";
var content_f39_53_40787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph of a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40787=[""].join("\n");
var outline_f39_53_40787=null;
var title_f39_53_40788="Modified Hadley with cutting setons";
var content_f39_53_40788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Hadley procedure with cutting setons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 285px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEdAX0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDoobiN1znawIG1xjB9KZDIkcCiTcNwHzY61XkfeY0hV2QnDFlyCPUetLBYJBbxm3JaQrgiT5j+B7Vws9BR6F+2lZ1BVMo3AbPPWppoPKhygJ54FUY7+KJMEqrrIqOpOcjsc+3P4CtaGRJ5CR0xj6D0qoiknexDGkkMhijGBJ0X0x3z75p7xkLtjUpIQTkDAP8AnirGY55I/nCuuSBkZ/yc0+ZsMpXGcgHPoeP8KHoOMbmLqDyPCYr+HahztfPyv6Z9KqWMQOx1bLE4Y9csM8r+X5VvXskU4Ee8Hf8ALjaWHTBPQ1lR2dpbOBGV8sn5gcAjjHI79aT3NouysGoS/uHjt5DKeG4PHPY/4ZzWZNI1qJlcfvWTvxuYk4P5547Vs+RB9kiEZVPNfORwpGcj9MVjeILhWZovkd1UKF6kHdxjPpyfpTtdku1i74Bt49Ou77xDIS8WlWrbA38Ur/Ko/Hn866PRJ20Xwhdak7/6ZfsSWbgsOrt+ZrI8uW28OaFocKE3eoS/a7lOp25CxAj3xux6infFC4QT2ujWjgRW0awBR/Ex+8TXqQioU0n6nzuKm6tV8vovnucX4ege61S4kdWDT/vEXvtHAxXVm3FvaSsq7V5YZPX3/QVStLZLSWGQEMqcDcc8cdK2Xj89UtkXzCTjqThRyf0yPoa8ycuaTbPoKNJU4KK6FXTUkuoY13lYWGfcsOufzq3LAiyDH7x8j+HkfjViS0ZCGjfO3GVzgHA5/StNUhmQEPsjI4OOcdOlTuaXSZzhjw7qLcDOOT2P1qndS5zG8RbHBboV9xj863Lg7vMUlT8xAK8dAOazZYkm80DYAhH3Tk9Cencc9vT3FJMtq5mXlwU3bZGk4O5W7D6j8fX+tZ0d28yFRGCyj5SrD6+nFabRRStu/hYDchH49PUciswW6Wsk2Qyq4+Ug8Egj8ehzSua04pGv5U09rIWAhWNsghSSSRnGeRwSOp6Adc1zb3fmHJYoEdWZnyMgkjv7HP4V0MA82wmSBZS7jJcsSqrkAnGcHkLzisafTW8/fc71VWaBRIQdmST1/i5cgE/3eOla/ZFJe+a08qSQQiMG4Z4wAwBAj9fTpT7GN40YKu3D5MmQM/WrMGoGbTLUBkkaMhFXGCATkYJOcZLDHbA9ar3F3GsF1AcLKpKr8wHORxg8/wD16TFyt9DctGkTyrl0AbO0ZG2rc5BlBC4LAbsDIBOe/wCtUNMm86MxbsSctg8KCACBwO/I+taEQQxTSGRQWc9MjIGc/Toe/wDLND8jPks7spTbwf3Z3csFKtnHXv8AgeO9DsnlsSFVQoIAOcj0P5frTzcSSRKkCK6ByGJ6NgFunUdOv9KivLcvEGDAznJHmNgcA9s9eOuB2qballK1k867ZmI8vG3kHHXGenT3HpVmaRJJUkYMEjGSxUqNxHTmlhjW2RNsO1im5grkBh0xnPPT/Oatpbsscgb92rMHIf5SecEHP48mlcTWtxbcNKm9SBtA2beMkn14/Ws+/m823jiRSd2CzEfd5zxxwe351fhPkSfIxUKGKjccdf0PXkDvWfp0HiHXNHt9TsfCOrTW9/ElzDKJ7Jd8bgMpwbgEfKc8jOSciqUW9iZTjB+8UZUQPdsoGxD8pA+6SMZPXjt1NaejDdpyYzyMkEZwSAefY9aS30HxbFHID4M1clsf8vdjzz3P2irFvoviiGJIx4O1raqgZ+02BOcf9fIzz60ckuxLq09rkF9Yxzh9rLtYbnfIGB1/Dv8AlXMy2DTzysWLBQdqyLgsMA7vY46Cuvk0rxXJknwXrAO7cALuxxn1/wCPioI9F8WC58x/BmrlByALuxyDjH/Px060+SXYydWD6mDfW4nGTAqZyGRGwAMg8encd6NBSNNNu94LoZHDs5GT61vzaL4sEm6DwZqwDDDqbmxAPHtcfSs278KeLmWRrXwjqySuuDuubEKSepwLj3NCjJO9gc6co8tzxnxX4bfRtZfULS3ElmzKZYwSAo9Cex+nrWdfSwbEu41kcSxxHcIwgDjhuD0zgfiD2Ne13Hgvxjcw+TN4R1Mx45BurE5J6n/X+5/T3rmU+FPjRDcRjwdeCEkyQML60Do/H/TbGOP5e9dFJyi7dDjrwhPW+p5hrN6sttH5IIdo9ruTgEdOvXjp+HucUdMnGba0ju2s4plBuWbld2SVIB9io9fvdeld5ffBT4kTs5i8MSx72yQL20x3Bx+9447VUb4GfEsMdnhhivByb61BJ/7+10cyOB0pXOIW4jhfynLSQliy7efl6k478gdPQ0XiwQR+UyhQoaSN1GGDEA7Wzzkcf0r0HxH8KPGln4VbUtS8MXFvNpltJJcTrd2rIYYxu3ECXcSFBzgEnA9a82eMtEkm1sooO44+96Efh/KjctR6DZpJb+OWWWRA4G9iR8z9M5Y9c9fzpJbl75ZZnlQShi6x7dvUknAAwME5x71PZwxwxpPcqXjkjPlKDjD8Zz6jIx9PpWnZaTfazqsMhgyrZLZAHrnJqJS5dTaNJNXZzq2yztuiBID7SjHkYx/iefar5tJoxn7BJMHOQwfbwOOmD6V7HoPhHTLCIS3MavcSEDIXAU56ACt9rWG3wphVvYAcVzSrSvpoZuaWkVc6IlYiylhITggd+O38qjTMLMpBHPyKBnGecVYkSNghgfbt7g98Uj7cAzMFc8ZY4DVzPc9hPS5QvrJLq5UlV2bCc469APw5rRtj5SmMIww2za2Dn8fp/nrUFpGzXhwJTEgCgld249fr6flVk3EbagFDBQfmAz0YA5P8qd7BZsu20W8kyoAWGMYxx6U+W1STekZA45Vz8pqRP35wA25cAgdD7j24NQSyiGTaAWZ1+UHjB/z9aCyKHzYZUWUZBU4ZSD+nUflS3MybW2wr5h+Us+Bj69+ntUt0z3a+W0kccaZBC4LD8aqw6bFC5llQFnb5Bu3dPXP0qktATTZmyBHtizs7uF5WPgAjjr1NYumabNq3iqwtJgiRvMfMIHCoqkt7dM8+1dBe7IixmYIVB8s45B9iO/f/ADzS07dp3hbVtUclZLhv7PtSepL8yN+CgjPrW1CHPNI58XU9lScux13hmePUNU1vxVOMRREi2DH5QoG1Bj8M/U15y9w2t+Iry5u5fMCEJufpu6nH04Fdf4gWLw/8PbSAvta6Y3WGJztCjAx+Vcz4T0yU26vPkSMxk68DPP5+9deJnyx9TyMBSc6t5fZ/Nm3FZNKA8G9dq8Fs8n6fp0osY7r5HaQhoiRkYHUfh+taVv5tu5ScscFQpB4x7/kKdErFWlXaEABA/PBIrzmfQJdCKRZZUDopUN/E2Cf1xVO0hlS3lMhB2lm5UHpng/lXQkKIgFOd3OR2qgsaMbmJg+3jp15zjt9akNCgEysgVVwC3YZJDH/P4VBBC0kQIfy95xuY7QFJwD16dDWgwW3hXzS33sEjk5JxUNyrMgQMCGOOD05Ofw/xoKUrGFFpsnUB1xxjcT9f61W1KMh4lwScEEE8dgD+ldQoOCAmWXkjPXqf5Vz1zIr3JyoOAwYHrxjFO2hoptsl0Lz45xAZigeKReGxwBvxj329DVi90zdp9um+MIVyAevykjnHbIPJ7n0qtp+ZpDcKirHv8rOQCp4z+Yz+tadxCkunysjbfLLnAYkn5MnjHY9fr0rSEbxsbSdrSM/QZPtWlXZXyUfyVIyoBKpxjIPHXsDk4zwM1Zs0jv7y4uphDDLMSxTHBY4Y4zwOp61wWtz3Vjp0VrZC7N+sw8pYAGzuK7Q64yQcsBjuMGtn4Y63ql1rq2GqaS0j2+7fI6eUUI/v5xg+3FZ82qiztng5eydaD0/Q9F01YYtPikQBpSDEx3YUDoOOnQZyffrWapmleS3kci2jZdyqOGJwQDn6/r7Vas1Laa4k2iIojDkjJ8tegyMjgdRnn3p6WUnmM2wx/vY2wVHPTr09BVtHkrqW2lhgRfMB3K+dqkncNp4xkZH16fzytO5hikml3hkOVQk7OAeTn0UgfSr9xGyvI0xG8SqCfQYBPIxTn8oAEqm5ELFygyMDaO3H4e31pC6FWRGjudjwloi4DAcBVBJH15Hv1qWRFkMySZRF4VxjbnIPAOM43f1qFpJZW8u2XIjXDZUBR03HkEk9e3vVWRI2+0K8u91YBc5PVegHHHGM8dKW4c3UlilEgihljDDLMpUjKk8A8Anua63RPEMnhb4CeFdWgs0vZY9L0uFIHmMKs0vkxDLhWwBvz909K43TY5bbUbkSx+Y28Rx/OMA/KSAR0wfTOcGu58L+HLHxZ8DPCmjar5hsptJ02SQJty3lrFIFO4EEEoARjkE/Wt6PVHHjOhPYfEzTUF7B4gjax1KzupbWaCyWW/U+WkbvIrRx7vLAlQMzKoU8HHe1qnxG0O1stUl083mpSWFs9w32WyuJICRD5oQzrG0akqVPJz8w45qTVPh/pVx9l/seW48PG3t5bQf2QkMKtDKVLxlWjZQCVByAGB6EZNUH+FmiPqcd29zeiOKzNhHAiQRhYTCYdhkWITOoUkgPIwzg44GNjiLVp8SvD0lrZyXUt7ayzwxzPHJp1yBbq52qZGMYEaFsgO+1WwSDirD+PNGkvYrayuBK39oNp0zyQzxxpKpdXQSeWULgoflJAx82cEZwbn4PaLeXlpd319eXt3bwJbGa7s7CcyRoSUUh7YhcAkZQKSOpJAI6A+BdKazjtXkunhTVptYwzL80srSMyH5fuZlbA64xz6gEcHxH8KzWlxdDU3jtoY0nMk1rNErxM4RZIyyDzIyzAb0yvI5xWnqHijStO8OHXb+W5t9NDKhaW0mWTLSCNR5RTfyzAD5ecg9Oa5yD4X6Wln9luNU1i7ijtorK1E0sWbWCOVJBGm2MZGY0BZ9zEKOa6rxLolt4h0o6fevMkJnguN0RAbdFMkqjkHgsgB9s9OtAGFZfEjw1fXa2ltd3S3TvJCq3On3NuolRGdomZ4wFfapOw/NjkA5FZGu/E+zg8PadPpTJc6pd/wBmyNHFbXE9vFHdSxDLy7FCZR2KeZsJ+X5edtbtx4F0yeXe894D/ar6vw6/654GhK/d+5tcnHXOOccVkJ8KtKitba0ttV1mCyjSxWW3R4Sty1ns8l5CYy27EaA7SoOOlAEegfEu1Olz3fiSS1tVgebeYEmdtov5bSL92EbOSiDIYncT8oHNbf8AwsDw6bJLlbm8fdO9sLdNOuWuRIihnUwCPzRgEEkrgAg9xWevwv0VYnjF1qOHdXP7xOovjej+D/noxH+7x1+ao/EHwq0DXJJpbt5zPJfy6gJHit5wjyRpG6hJonQqREh5UkEcGgC58Rr+11T4N+Kb/T5lns7nQbuaGVejo1u5B/I18G6chlKPc5WPYWTA3KzY6EHoeP0r7t8e6bBo/wAFfE2nWuPIttBu4lxHHHkCB+dsaqgz1wqgegFfC2lRNLPFahgBI4QNjOMjnj16VSdiXG7Rq+DtDl1i4eHy3Kx/dGOMZ9f89q9MsdLl029jRGeOLbyW+4xwMde/HatzwXoS6LpcKABn6u3fJrS1hYpoSjnDEcEZ9RXNUlc3hd+69jJW5Z8rKcMOu0/dPY/59KnVXulWQ79xAOFJGM1galDc20Urox3qRvGMBlB7enGc1c07VYL2JpVV1bOGTOSpHrWOjJnR5XodnafvliEkQJ78jI4/Wp28oSNHDG7OOqgAfrVHS5ma8kjkO1Yyy5Hc5HSt+OOMpj5Tjt14qbdjt66lC2lZJXwsaEtwB1PGOnFRX9qZ3YKwmk6fLlQvOTzyf8+lWL5GKNFHGxLcg54H09PrUkNvPDL/AKuPZgsAWxn24H6UtTaGuxmBLtQVDyErwFwXwPTGc/rSTahcwjbeWMoAOBJCoVc9OQRx+tdBM8kLxb1hUZK7d3bGfSpEuIo5AGYRYPBYjGfTP+NNLoJuxf8AA0EeoO1xPh8fKqnoB+NdnPpNjPgyW0ZYDAYDBH4ivPLVptPm8/SZChX70ZGUb/D8P1rp9J8Z2VwRFqQFlNkLuZsxk/73b8cV6ClGcUo/ceVKE6c3KXXqZniPwG12JZdPuv3hHEc3T8//AK1cbqGkvc+KdA8MPlLPT4vMuJCM5kb5z0+gFe1GeL7OZ/MQwhd28HK49c15HBfxC11nxBcygTXchSHcQNoBPr7ACtaEeW7OXG1nJRi35nK/ErVF1jxbFbwcwRAcKRgKvQD6nHFdBocflwxn73l/KcDPGf8A61V/CXge91fTzrrvGhu5N0cb5B8pThT+PX8q6EaNdWAmNzbSJtO5doyDyT16VzYm7l5I78vUY09Xq9SGZFeNlfnP3Tnnnt0qxajJ+UZKjY2Oc4H9c1zOi+MdJ1zVdWsYL1YpNPfy5A525xwWA4zggj8vUVv2bxFZBHPFIF53Bxzkn8+1cji1oz0Y1ISV0y/5aYIRcAD8h2qk9vkzMh3EjGR7cd/erLjy0lKEEKCFBxyealtFxbqQCxU4LZ4PBPP60rA5K+jOc1Bis8YA3BBvIxznoP6n8KYsMi8s6+YCeB0FaZsQWluXYOpYso7Kvb9Mf5zWfqJERVlcHZjABzwR0p26ivcilHmqChxkYPPeuS1SRo7p0RsgjJ/U/wCFdBPO27qVjQ7u3Q965a9Ej3QkY5X5vbjb/wDWps1ho9TasBZ2mgyyXMpzuY4IODn0I+vfiq9r4iF7LJEgQQXJ85Fyu7BDZ5UYGOQQR0I9KZ9qgj0yKNCSF4dG5B6c4PHNef6Vq8dpbpJKw3RoVRVwSRk8n8gKJzcLJHq4XD/WqU3bU9EnsPOaO7inkjuY8NFKgG4FSe3ORzk59K6J2mht/PguITPPG/mRxxlNwY7iSeQRgkYGOn5+S2Him+uTJsMgVOVVFyAMEHP+e9XLfxk8UcUcsolRGyQ3BIPXkAE8dOeKhVo2Oh5TiHFRdtD1zSXb7PchPJeLYSzhzvwR8uQBjAKt35resTLOltLIkO1j1Y5IbGMnHC84/L8K8Yt/FiR+Q9tn5MKxVidxycH26jj1z9K6jSPHaeSqsCG3cEngDByMdOcj8quNWPU8/EZXiIptROyv1ZxcyeaWEbqMnGHPQH17VVvLSW5dzNJKfMyGIQ5xgE9fXP8AM1mprlncGcJMAGVPlQA/MAOufbPr1q+dVt5p7mKOdVV9xRcgsTjsO2M9QKrRnBKE4aNBNsjicwJuj3CPeUAxyOcjjPX6e9ULOxuZ9WcpukgIWJFII5IGCQDjpjHPOa1L65srQA3eV80LFaxRIzzTsDlljjAy5xwcYVc/MQOahksbm6gzqmLHT2Jzp8Nxh5AflP2idOo6Zii47Fn6U1DvsZOsloldmfG8aRmGzijv54HPnyu2LW3bABWSUDLuMH91Hlv7xXrV/wAO6x4x0bQ9K0jStS8Pz2VlbpaQvPpM4k8uJAqs4FzjnHUevvimWLRz2UCSwqioirFbxKIxCAR+7VVAUd+AB/OtKyEUeNpKGMFcjIGccHI6jG3oec/jTUn9kmUE1epqyOTxl46jYKb3w0WOCQukXBKjI5P+k++R6jnpzUsXizxy9sJDfeHFbA3KdInG0ntzdZPT0quoiia3aRUQRPsMucFmIO4ZwAf5fhTNOMkfmWkjbo2f73uR9fUkc44Jo9pK+rL+rU2rqJYn8XePIXYNd+GmCEByulTnB/8AAqkt/GfjW4Y+TqPhtlBOT/ZE+VHHUfauOtQcyI7fvRhsDb69cjr6Y6/jWNZRTw31yz5AG1mjJ+WRc4BwPQ5/Wh1JEvDQ6I6iTxX40j4OqeGy3oujzn/26qrN4z8cxJA323w2RK23P9kzgA/+BXvSweWQ4TbkcjI+99KiukiluYgyKox2AGCR7Ue0l3JdCC6E6eMPHJYqb/wzkf3dJnOf/Jr/ADzTz4t8cY41Dw1nqQdInH/t1WZIGEhZcgjgY5yv0p8M7Oh8zAIGNo6/j6UKpLqynh4dEOv/AB347tASbnw0wwcEaVPjpkf8vPT3qg/xK8ebN0UnhqQf7Omz/wBLnpUGpzF7eY5G3naPp1+npVWN0nf5FAKjP0/zij2khPDQtexheLvip441LSNV0PUYvDkdtqFrNamSO0mVmV0KttJnIVsHjORnFcl4E8ORMftjxGOc4YKw43evB969FvNPs7jaLi0WXacg4A/+vSCxhg2CECPJO1Qf0FPnb0ZDpRWxGPtIlQEybF5YIQf6Zq+4ikT5WG89T6fUdazkZ4nkb5m5Ix+laMU8cyfMoJHZhzUCnTcdjmvF0jxaVIVC8nblVyV5xnrXKfZ4lwwkZMqPu5GQPxr0LVLZb60niVXD4IwD1rBXw9qFwMR6XeSInR1t2IOfcD2qWrsXMlA66zsZPs6xK7I2MgAdK3dNgATy5HZpFGc5xu9DSWUCtIzjOwHrj/PvV6TaYztYbwRgr69qjrc3k7qxFc28kQDbvkcYbf8Aw54z/n61oALg7cufT0+pqCF/tCYONqqcg9z0/wAadZXErW4LwrlBtIU8g5wPTn6VaI1RXurd1u0lEeSSSG4z0biua8U+JF0y2PmoCyjHIDZyOtdRqLyuIiriMbs7SMHGCO+fft+NeZfEXQp5ll8rzCBnGWzn+vrQ9FoNPmaucwvxONs7RCMFM5U5wcelejfBnV4fG2vzu8IEFjGskisch2OQuQfTBNfL+vWlxaXJVwQ2TxXa/ALxpq3hnxlDZaVaQ3n9rSR2zxSEr34YEdMZPY1rh7yauwxEIqL5VqfVPxXvRp/hwWdkvl3F7IFxH8uVH3s4/AfjXEeMYYdRudD8L2AjE5ZIyYuQCQDI34DPT0rV1G+bxB4vu7m5aNbDTlaJFViwcg8kHHPzD8hVL4TxN4h8d6jrlzLuTT1MUK8Y3uCDx7Lx+Nerbkj6HzF/bVfJ/kj2OG2W1sEtrNFRIohHEp6AAYAryPxJD441a3ijfXj4dgO5JkijVmyrfKVYfMAw/wBrsK9Wv7sQgGNgWHUetcx4iuIL6z+QKWlkAZe5I4/pWFNST5jvq1YODpta9/66Hk2ifBTQ7x5Jtf8AEOo395M26R7fZGGPvu3E9av6n8AvCrw77fUddV15wZI23ev8PXrWxrclro8JuJmmgjXrIqllX646fU1z5+J1paKAup206E7RmTv7+laOXdnPGEntH8DnJ/g49ogn0PVNYt+flkddxUjgg7CO49e1WbfQfiBofzWeuR3sSjmG5ZnUkjjIYZA57N+FereGPEtkNDjU3UMs0rGWQxtlQT0A9QBgZ/GtNr+3kxhlIqZQctOhUZxjrbX1seceM9YuYNEF0v8Ao0wUB0KklTkZIGenXrnj3rmNJ8VQyaPaC+ZUuwcEKM554PHUkc17NdWunX0ZS6tradD1EkasD+dYV14G0O5uEYWNokQk3bUQoQu3GAVIwc4OfwriqYSo/hZ9BhM0wip8leLv3VjlGuBLH5soxF2yMEDqCR+Fc1qepRSSLHF87yHAPbA/+tivWbzwXp1xbyRJLcwq/Uo4P8wa4vU/hNGv72w1u8SVSSvmqrg+xwB6mmsLNGCx9B63sef+JtQNvpE0UJAkVS5YDHH+Qa4HT/Esmj27y6cxkuZ0aJ3QqdsbDkDIyG9wenHeuk+IvgrUbKNT9suLrcCJERcRoQCQWPPGN3X+tcXodhJHcCGCOKVjyzOpwvHTNRVpqLu90ephcbNw5aXwvr/wC/b+KbS3EIiguIgxxcLKA6sMDkDjnJfH1HPUm9LrNjfzySWnlRRlz5aJHtbbkfeUsQO54J59sY5TVbfUP387BDBE5X5BwRnr9KzrRGuZlEMDlh1MZIP/ANap9lFxCOb4inU1bf4f5nrdldIoWS3uINkcihX8sRkNg7e2f+Wed2cA9SDWvpXiHSPKt47uO4ZzIfP5BwvYoT35b6cHNeVWSa359vDHFe3Bf91DEAWZsscKvH94ngd813cSeHYryw8Jan9su9fnkRZLuyuUAtbguAtsGYhGyCQ7k4ViMZ2ndn7G+kTsebwSvUbudHfLb6rqTxeGftEhPzLGcHbGFHzu/AUjndkBR1zitvTANKsY7u7u4bgN927lQyQ5OeII+DcHg/OSsQxwZOlczd6y1lcLoXhvSDqMsUm2SJY2eBXUEklXG+5cAE75QEXnbGODXLQ65Pqd69xcak1xNISzm6YljgHqe5AGKTgoapXf4Gv1h42KhP3Yr/wJ/Pp+Z7b4W1+wuru5ETSRTTxhJLu5Pm3M2Ois3AC9MIoVB2XNdIk37mLE6EqrHZnsRk5XdkYwe344rwHTdUSfEtlIBIDkp0IrpdL8Q3ErpDHM6EqUmQfxp9O/+IqFVf2jKrlsFrReh6fHeBtPiNhM++DLbo+Qr5x2PqOuM9etQLqckdxOtuJRdCRYdrMOhY8oODuDMeOvPY1wFjd3EepiWBpIw2Ayo3HTPr65roTdyy3bW5UMTJ5oaVyBnAGPr8qnt0FNTuctfCqi9dTshaK4Ks7SLvYkyA/KQVJOB056keuOcGrxgNrLaqGPn5IMaMM9cnPB7HHf6Vzxv5/I8wwxkODGvlHDJhl5x+HUnn866CEXt0u62066DgbAfLOGyeTu6fn6e+Rta5yObS1Me1vpZLqeNoxKxJ3IoV9wJJBJwF5OffHPSp7ieM3guFMYZyYpmYYKHOAT+f5HJzW3ZeE7+GRmhijjk3sVlaTbkZIGcAnpj8zVt/BMt1cRzXN1CjKcsFjL7+5ySQeTz+dCpzsTOvS5tGYbKPLWHAdUZh93JHBIA5zyR19z6VWug3nReXJlcjjGeCO309/Su1Pg20dQHurpWAwGjKqcfka0I/DunIF3RPJtAA3ucAfQcVSpPqYyxMOh5tdIFaOTJJAIK56j+lVYxI2541eVhnARNxP4dzXriaZpsC/La24HqyAn8zVe+1/RtKT/AEy/s7VR2eRV/Sr9hcyeNtoeVweHNcubQxDT5xkEEsu3JOcn5sf5xVy38A6y0u5o4YlwAA8o+UjuMZre1H4t+FLMsq3zXLjoIImfP44x+tc1efGtn8s6XoF5KCTu835QR7EZ56dqPZQjuzRVq817sfw/zN+08A3+0i7vbcZxygZsdPYVpR+AbX5ftF5K4DbvkQL2x3z615xcfFvxTcj/AELRrSAHvIzOR/Kufu/GnxC1CUKbmO1jYkYhjUfzyetK9JEuniZb2XzX6HuEXgnQIT++WWXnP7yXHP4YpZo/COkqTONPixz+9YN/6Ea+etQsvFd/uN5rF22eMee2B+ArnJfCd695tlvPmGeeTkU/awW0WL6rUl8VRfiz6Yn+IvhDTRiC6t/pAg/pWFd/G/w/DIViiuJAO+FH9a8JPg+RSri4Z2HzYx1HcVB/wh1upJku5RnphaFWl/KRLDQjvNn0FGNkIVioYKOCaSSIySq9smxzyWJODx3Hfj19KrSwXLSRvC6H+I+Ye/t71KpuPs5SVAHf5UMb5IGCO+PrXNY6U9LlzSmdg/mHbK3zYwOR049Rgf5NIVeK6CmZFAHmKSuR1AOef97pUAOwIu4ypGCp3cOo45P5dRUJubgNHLcsGj6CVGyyAkfN/njGafkCV9TVubpjE6qkbuo2gMOo5/h79axrm2lvoijQbucA7tgXv06kVp28zOrAIGUAshVgQxznHv8AgTTZrsyycqsceT8mfzA9B9K0M3G2iPGfHPhTzBJKIkIQFTK3Az6YH061ifB3RTomsa34lmKn+y4DDbnHHny5VSPcLuNeo+PJSNPcptLMvYc5x3/P9K52LS/7M0LRNFVf9MumOo3S9cl8bB9Qo/8AHq6MJBSqX6I4sbXdOg7bvRGlcaimk+C3jgeRby8QMZo25ZcncpOQQOTWP4T8N39mqXtuk/26ZdzyhiNgP8Iqv4k8q61rT9KsmIDY8wHsByy5712Hi74hWPg7w0szQm4unPlwwqcbmx3PYCvQbV9Tx6MJNXit9CDW9cv/AArpTX+raoI1A+WN/nd27Ko7mvO/A/xeuE1a8HiCOWWGeQvFIv8Ay7g9toHI9+TXn+q+L7vxPrJvfEGZgP8AVQpwkQ9APy5612uh33hhpXIhVHx8hYcg+/r0rkqYm7tHY9ejgYxjeort/ge/6dfWGsQ+fayxXCum0jIIYen61554++FmnavJ52hoLG7bJ+Rf3Ln0IH3Tx1H5VPoOt6M1on2KWOCaMDcAdqnsD/Kus03XVZcZ84Ac7RyP8fwoU6dVWkRarh5c0GfM954U17SNSFvPBPDKCQGBwDxnIboRxXSado/inyhJDfXkSHuZ2Ufzr3m/gt9ZTY9ukkLIS27s2QBj3xmsj+xZ7aPfIgkyo3ID9047Vz1KEoaxbsd1LGxqaTSueVTDxnZbzFrc42DcAzbtw56bgfQfnV3TfFHiuOLc+tLKqkgl4BgHAJzwOgPtXdSWiXbsDhXXGD68n1rntajs9MiEM8Iy+3eWTK7gflJPuAQa5nVqx2kethaeGq+5Omm/RFKH4keKILBbmd7B48jd+6cEAjI/iqpffFrxJ/ZV7crZWYFuVBOWIYMcAj8wfxrG8YSxQ2j21uq5nfKxIfuAKOvvgZrEtjG3ge8jkcsbi+8rPYqqg/lkGuilXqbNnNjcHhnZ06drsqXXijU9Xma81WVHMmY/JUlRsI+YAD8M59qoCM20EqiW4jicHozDnHB9MdqdZQwWzo6OkccaZcu4PmNnpg/XH4D1xXRaZfWdxZm2jtIhdrOPLuHn/gwcoP4eu053fz4xnOUneTO+lRhCCjBGZYpGlujpHMySLt+zkZDkjAA/Os69t4tPuZJdN8yN0baMAAuO5xz0NdTJL9rsZ4IdiTKhKZbaDjJOM9OMnHtgZOAWweHBNpCpPL5sqB22x/wgZJIPQjr+VZczW52QoRnG1tUdP4Z8V6PYeBpFnvL4a9eNy+m2wD20WCCqzSABHbP3lD4HTnkeZzeLbLR5D/wjHhbTrF0bAvL8G/uM+uZB5QPuIwa1Lm1a5gkCQLCOApVsYx6iqc+jTyRReZb27JIpIyoHTjJ71pCvbQ4MTk02uaO5yx8RalJrVxqt1dST3lw7SzM+MSu2clhjBBJ5GORkd6bDc3ly088UDFQC0rRRnYox3wMCrt3pMJ+RZI1ddx4HXjOOn4VJpE2taSHFpM0cTAs8LcoR7qfwrdThLc876riqTsi34M0rWtXvcabZ3E4wDm3iaQrk4/h6dzzjgfSvcfDvwd8XXLRyXa2VmpVWLzSHccgEjaoPI6c46VS+G/xtXw9bJZa/pmyFQNslogA/FeMfhXqsnx08KR24kBvJGIGESIbufqRTdOm9U0XDEY6k/ZqD+65Z8OfCa3sHSTVNSe8YDlI4RGvTHcn8+K6+28IaHb7sWEchbqZSX/Q8V5afj3b310lppOkv50jBEM8gHJ9h/jVu78YeI5WCteW0UrgHy7NFfYD0UuSQSc546cck5wJU4q6Mq0cXN/vdPw/BHrtpY2dkMWltb24/6Zxhf5VDdavp1oSLq+tYiOoeVQf1NeLXVzd6jG0eoX17Jnk/vGPA5PGcZxjgdM5PSqVtpaW1p5iFVYkJgAsZmzxwe3oBg9T24XtV0RnHByl8TPXb7xxotuhMNytywIGIuevAx6846fWsuf4hQsxjtLSQyBdxMh2jAODXnyWt7NMrajK0ZBUR+STyeg56lhggduMCtS2hktrnyJGBl2EgPHzwwBQuTx0XJ9QM5OCZ9s29EdH1Cmlq7s3J/HOo3NvutRBayN082EuqDsWIYdvY9/qeXtPGup6kksd1q0qyxkh1gCorAn5SpAJx+Nal3EjA3FsitAmSNh+cPuJBxnAOV9zt44xmvLNQtn0a3ne1XchuBMgj3DyUIO/pkMm4quSf4RjqamVaa6noYTLsPVi01rpY764nnuFRJLm6ui6jrcOwz1yRn3x0HSq8Hh21jffJBC7kddgPf1HrWToGpWQhmnjulYycEsCCefTjPbrmult7+O4ibyd24HB+Vhn3yQPas41nMxrYT2MmkjGuNOgidzJGiJ1wF659vX6UyfTjPIXYCGBcskKALg47/kK17rykhkuJR8yKSO+3/wDXUGJZEJfEa4GUU8+vX/Cm+5KumZ6II8ny42ccneMEVNJC7wQFeJFOcnHJwc1ZubYxIpDBc45644zmoZiCyKxCOjEDv2NSm+pUoJ6oYZJZIiph2jGCzY4H9ahmgVWncchgGHHPp/jU7yDaM7to4JB7nj+Rrd0Hwzd69LG8WYLRTh5mGcj0Udz/ACq4xbOarONNamHoGkXOrT+RZRGV85Y/wgHuT2r1fQPBGk6ZYLHd28N5cNy8syBsn0GegrX0rTbLQbHyrVVjiHLMercdSe561S0fVIfEy3FzpkxayhlMCzrysrD7209wDxn1B9K7IU7K7PIrVuZ6Hn8V3HISJCfNXhgATjt16c1oAuJNxhZguQPmz2/XpWbYRotxDIp3+ZnceeTz19+MfjWyJgkbtLIiAfLgnByeCPXpn8vpXFueotCNpWldZHjBABRSvJznpzjnpUEE5hbcvzw/LncuNrc9V/X/ADzbhaMxKzOAzffJPf1/SnNcRR3A8tTuIKsgB5Xrj/P1qkmS2ugiWqybzEiwncOUfaW6nJABHXH17VUnTfJumeE/d3EMAxH/AHzgVcgjeFuBttGGQgwcdAR/tDHQdueMdK0txL9s8uGQGFCHMzHKnryADzjpn29Kojcx7+1gub23hkmVYs75GkG792vzMfpgcVh6bfJf3mt67cbVYl1ggAHTGAPYAD9Ku6pDstLgCSMXFywt4QSFGT80g9+AF/4GK5jxiz6PZ2lpYRGGa5JARWLFmIAyRjpz7jjvXpYaHJTv3PAzCo51FBdPzZ5Xd+Irq08ZWuoRqZRC7MY93G1gQQPwJNWtbhvfG2sxvbwSJaxLtjR+T7se2T7egrsbH4bXY1KKa5i8+Bwu5kGCM4Hf6j0616hoOh6fYpG0CQiRD908HJAx+Bz6V59SrOpJ9j3qFKnQpxS3SPDIPhhdFSAcOBk9sf5/rVGT4f6pbySIIizr1CnOK+l1tBEEVV5kcHp+P5YGKUwQxu4cANjdk9+On6CsJRT6m8KskfJs1jqOmXA3pIrA4OB+v6irS+INWsl/dyy5A5GT09K+hdf022nt2QwRl9+B8nOSBx9OlY6eEtLn06NpbaMNyXPA5yQf5YqXF9GVKtFr3onl+hfE3UtJ2eaFmiHUNxn8RXr3hDx7pHiVkEU5iu1HMDttPT06EV53q/gLTp5JltndGzwFUsoB78D14rnZfAN1ZL51lcjzk+ZdpKOMdx3rpo4mcNJao5K+Fo1tY+6z6NuLGC4Pmw/JL/eHevLfiRpN7tleWTy7ckEkH5SR0Oe3JFc94W+IWt6HJ9m12KW9tVOPNXmRRz/310Pvx3r1PQ/EmneJI5TBLb3FoyBSpPzZOchlPTtwa6J06WJXu6MjD1sTlVVTmrx/rY+adf1B454pt4O0EAZ5JI5/DJroLK3luPCyKEC+RE0vzYA3E7v0/wD111vxJ+FNvdQyX3hr91MDuNoW+Rv93+79On0rzbUPFFzYadNpLWbwM0flSJKmCBnnk88gY49TWSoOkuVnRWzBYmp7WJVubqC7mjtFcxorMVyBt3ZwSD0I46+1W9As7yZnVEjktwm9mBICEjg8dx/SuRup/tF2CP3aD5VUdEHoPxJrc0rUdU0VDJbTI1uDloyAcjOe/Xmsp07qyOrCY1c/NNad1+poxJfzamRPL5uHJLu+7Pue9dvp8GoWltJvEjxTIVO3KqQe3GDj/CuXg8U6fd3MEmTZXBXEkik4JGcZBP0HHpVi68fX09v5BmeW2LHy1aQtg85JB75JP41ztSTvY96lXpKCUJp/M6SfUoLHTY7i1spUuLeYkXLMQGIxtCjHykdTnJ6dO/O6lql1fq0jgLETgR28YUdenAHr7npU8l+n2NLq9e4mhkVovJjcgZzuOOCFGSTjnqegNUNPuBqJBNofM+6hiyGZuwxyKiV7HdCUVKzeoqmGYsi2aRIvVFTLj8TzVfVXjZBHGoQD+Fe3165P4mtj7PLJcsJiwIJQoVIYD3x+Hes640uWO7Eaq7KThW2nn2+tZ8zNvYxbt1M63sX1CdI+Bk966O1020jZyW8wxfLkHrV+ygs4oEigTfcEDe6tn8Bxkf8A1q2bbQhvQRqEt1mbKnkA5xyeSQPX2pLmegONOGr0OesNLaC/S9Dcggxg8ED3969f06GAWrXZDtGpI8oZZuR8owSOOD349qy7WKzjt7QpAYr1M75cn5m3EqyjtgbRx3Fa0yI8HmRt+9DgkoCAgzyv8s8V0p2PBxtaNV2W46SSY3YW5DRhlBkYrtBB4AAGMjII+q1oFrd4WMa+bLJsWItwBxlyD2ycY/2R74rCuLoCCUuxFxknei4VQcDA9OMAD/65rQ0m8MQAiCG5lQwh2OQoznluQPTA56e9UnqcHI0rm6nlxWrCb5YwmJHK4LgHG1Vx1UnAzjPtyaXwo08s7Qi0ij2KD5ssu2VtpPfnJIwxJJ68Y4FQQr/xNvIvLjLLklvu8kDG3PAycZbLHknoBUI16KDUZLK7ljjjuFZ4m3BIdhIJI5AJ+RuD6AAZ4rRaO4+RzTjFXe42+tJZLjbaQmdxGsjhlJSIHG3aBnpycdgM8dK4rxMzXk08V0zSgYiAhLFeBkdW9T/gK9E1toreB7NGPmkkq79XO7ACLggDB9umBXD/ABDVtAtopIpmuJXRA0ZVvv8A8WMcccD8uuCayrQbT5T0svqXnHm+RwehW19Y6xHEhkEL87WOwsvt/wDWr0mwnWdX+y3Odpw6sScH3BOc/XmvLrbxRC9zvuUcMT1DcDtyOM11Phu/t5rlmh2CUgHKsVLDrzn255FclNtM9nMaSqx57apdDtb0uYNj4bzCELA9icdKnkTgPjnt+Fczd69arcRqjhghzhPmOfoP89Kuf2/C6FkcbjjgnH0/HrXVzLY+beHmtbaM1UfzIIycjJPDjnA7/SsbV5nmgKxlRPnI3DgN61c0+4NzLBFapJLcONojTqcDn/8AX04r0nwX4Qgsbh7nVIvNv0CkZU+UmRkbSeGYdz27VpGm5nJPERw921qYfgnwVcalBDf66r20DgOtryGb/e7qP1+lehaxquneHdKe4u5YrW1hXHTAHoAB39hWN4z8bWHh2F0Gbm+x8lvGec9ix/hHufwzXimrX9/r98l3rdx5jhsxwg4iiz/dXP6nmuxRVNanjyc8Q+bZf1sP8ceLtd+IF5HpGkLNY6ZPIIVVeJZ9xAG89l9vzr3/AMIaFbeGfDWn6PZj9zaRBM/3m6s34sSfxrzz4QaFHc6hNrUsOI7ceTbkjhnP3mH0HH/Aj6V6tNPFDjzpFTPTccZou5GbSi9Dx+xVba9mjyRtkEigcHkfN+uT+NakUjhWeNUdWIY4fjGOO3H51z9rc79WGIy20lmOQQOGHQfUflWtPPJaI0tszNGzjMTfKDzng/TBzg/pXIlod7bHX8UUwYMrefnCqpKtk9OeuMUsUckZaMuJFGA28ZGMA5wOfQfTNT2FwLv98/mC5h53HnggkKAOQCe/f+VhZA8TSRoFLZ+cH8eu7qfw6dKr0BPuVbUAWwSfEcgfcoR23KCOeOmcEjr68VDqZTa6s0sWVDfKwIAB5OCeBjvz9etakds6ojSEloDuYHPQ4B/9CP8A9euS8U6rJYrM/mSOsa5xj7p5/TirjG7SMqs+VN9jAjuW1DxfY2zRtLb2K7nDHGXPXPTnoP8AgNZ9s/8Awk3xElnhSQ2liiwp5zHIPQcdMDk4yKyLDV/7OsL+8Moe5l3K2O+44JP5mu38A6MbfTBPLhbycrMU6kN1HuMDH4/jXdiJ8kLL0PEwMHWr88ump3VranygH+bOOSMA/gOv+eanurGKMtLCqxtGCD0z6HI/z17cGnmcmJXYklV67WHHp/X/APXVdbhnuHLktGjZ3FTkn1+ma8ttHvqOl0ZZuG+0Rv5ZUhsMM+qnGPbjj/8AXUssonVZgQOQNvfJ/wA5qHVWTO+M4wedvbGOfz5/OqCXSyfaSHCgRlgGPGcH19cDH1qWaxa3Hz5M6SMCzE5GTgdCM/rTLS3EckgkAdj86DsMjt+IJpI/J87PnLIUUjIPA5wP5GoJbxRvYuFK7UBUZ3deP1x+NITSZn6kyxTiTdtyDkjj6fpmqrqkqsGGVY8H0Psat39s1xGrlgACQVB6HHQn/PSqDQQRqSiqrhdwIGKETJaHnXiINpGsSC4ZhBIhMTBR6/zH61xV1Fe2WqHUdGuJI2ZvlaPKnJPQj0PpXsXiSxh1FAt0quMnr27/AMwPzrimsjApCkb0OwhwGBwTtY+h6c8dKI80ZXielHEUatBRmtUWfD3xJ1KVXtNVt0a5RRtaI4Lckcqfp+tec+P9X/tbWjI8LRsowcjBI610NxDGdWivoY2i6bowNwCYIb9efwrd8X+G7a/0OLUYbXYYW2tJGA4PHQ4798HBrv8AazlG0jwHh6aneGh47CkjyAQqzOBn5RWsby1kt1zBIT3HmcflisycyW9yVAaOSM49xUSuVyOoPWoauaUqvs7ruaS3NhCU22/ng8kMSMe1P0OHzL+VUUED5uv3R7nt9ayUBLqF6k4FX7xVjRY7dxiM8kdXbAyfp1x/9c1Mo6WNKFSSmqltjolC3Y8zeGZBgkIFVRzyWyOfwrT0bVXSRSQxto2WMbhwo/ixjH4+7VzWma69vay2wgh3SqELNGrcZz3HXt6+ldVo9lJqkNzLczXMt1KqiMbiAoHHzk9sAYAz0rB0z3IY6MrSv6m1c3x1nV5joMTQ2sUKtJM0R+QBQpdguQMk9vWriavcabPuK2skqTMIkj3GNM7wflbORzwTzwKuWNtJZ2eyGKxSTLc+SM4IGQT3HbBH9ax9M0a+fWTNPahYxIWbZgo2fT0/Kol7mq3OqhiYVpe9sjr/AAvoyLturuFQswBC5z75/wA+tdJJaokYfYiEfMQOmcVS0V0mtrfJCpb5UjPQjgfzq1qcnnusCEYIy49B71lZJGdStUqzbbILFWvIZJ3wqkEqoOCy9v8A9XWrBE/2dT88cSgM67gSucjqOn/16cHEH7yI4IGQc9PpQ7qId8zc9wemfSktDF+89EPtjDEhJ8phINoD/wAOT1I/H8fzrQisUhiWYTsZ1UYy+4EnICj6f56DODZzLDMrliJkkfbGCDgAnbz9MfTpWuJXvJxKwV8/PnAOe34+y/T1q426hUjKLsje0lbRmR5kjnKpgFmX5uCW+U9iB1PSsXxJaR3YuWhsVjvOWS43goz5ztZdoBAwFGBjIq4vnLuZSI22EBVY/ulHXknIJPP4GoTDLcKI8mVVckKDyOOuCeuOP8mtJS05bBh70589zjrDxA9zNNYatK1vcLHsjkEgVZW2nGSOSAcnHPQL1IFZ+s3dx4F13Tm1CUa7CytPNaTAiFZDlWAyTzgDJwO3BFdtqejpo8VsL14zMIy0Kkk+QGx8xIHJ2qDweMAdK8a8aa2uoyIzyklQVSLPKg45J/AVneUF5ntU5Uq93FWh19elnuvkZ+rzwXOrXstgv2eymbeIgCoA64Iyeh9zVAXcMZB3Nu55UcdPrTbexnvHC2bRTOcAhjgKT7HGa0IPCl9LqCW9wQCRzKW+UAD1/Dp70OKm7l/WnSXJG2i6jdJ1AxyM9usgbI5x0/OtvwhpviXxbrr6fosZfdzM4bZFGvYu2D6cAcntVrxBFpXhe3tAN10E274rgZWUggkfLyAemc+nSvq3wdp2kaBocVpo9mtoj5meMKAzOx5Ldee2M8AAdq6aWHPAzLOGlbq/yKnhDwLpfhzR3t5lW7uZkC3M8gwH6ZAXPyqcfdHXvmsbxf43by5rTw/hmiYxy3GAyx4/ugdT79B74Irz740eOPGME0tkNJuNJ0guALncGMwyOrqSqg/3c59euKh8NX4vdFScRLEs+fMIJwWHORj2IJ9ya3lNU3yrc8alh5V17Wo9O3+ZkXKMblp5ZHkmmfMkjNks3b8ev6elaelaPca7q9pa2zKbiTpIQcIMfMT+GT+GO9Z2oRTS3MQtEZrh5AFCDJZsjA9694+Hnhb/AIR3S1e8YS6nKg81+y99o/rWNNNu7N8VONOKitzoNLsbfR9Kgs7VdtvbxhV7k+59Sev1rxb4h+Iv7b1xltZnFpa5ijKMRuOfmP5jH4V2/wAT/E/2G2Gk2L5vblSXIPMaZ6/U9B+NeMPm1kZVTchOQDzjjmtak/ZrzOXDUvaO520Glwr5s0qIEeQtubJZBwR1+vet2xjTasbxkSqMFSeBnJ+X8h154x2qvIHlmSNoyUflwQBgcYPPf/Cqtv8AboGEygyKRu2qPnx3/l25BFYJJGt29Gy9rELQRCa2wHBwGLY9MEe/A/OpNCd5AsNxEQAuQCcAkDGcDOcEH16VFDdW9ytsH+cMdx3Ac8EDjPIBB79ugqWFEjnijDKpKs5kZto+Vc4z0A75xnI+tXGN3cHdIu6xhYI5XBWH7+UUFQflPHr1Ht0968l8Y6mp06bzGHzAtsPPOQMfXH8vxr0HWnlutKuoLhpFIUxgKMmRt2CVwcL2/T1yfF/G7R3Wt+TDkxls5zuOKqrLlV0KjDnfKxPBmhpqF2kl08zRhw/l4yrHqM+v0r6B0tfJij3YMi8qoPOOufXOSa878D6XGscEqbo8fKWweQcccf56V6OLeK4RxIJVY8rhj79uuM+mannlJe87keyhSdqasiwxKwhnONuAGJ7Dj/CqU8nzKI2HlsPmyen0/wA96jAZUVJZXZOiuXb5eBj8ODzWfqskttaOiSyGYkLGrc89PrwAelZPU2jfZkXiK4SK0GCGk4CIRwc8EZ9O/wCFc6StwEA3rcFdoUgqGC4BAxx2zViZCzu1wrebzgF84J9e39PSmwW7XsEjTsURmAwBwFGMc+5BNTI1iraMs6LfwvAyOPLkwDnBx7fj7UlwjMZJJsLESduT6cZ+vWoJ9PjRZHI3SE8EnrnnH481XnJMTfZ2xuG0KeQO2MH0+tRfQu1ndFGeViDGSyxoSSSBz/gfWs+XatvK48xGUZV92Bj8asyyo9swlG0HOSDnJB4NUdYxLbxWqqo81hkD88E/lxzVIxqa6GaNRu7y0yHjDF+D5ROQOc5yPpWJcSSreNFcMuHUEsPr0/P+tdNs+yhEAURhSE4xkjHFcp4sQtKrF8F9qlV/GrjruZv3VoZZkZdSwmcLIc7eo54xTtQmFld+c92Y8ENJEmGWRO6lTwT16jFVHhNpcrPJjL4KnPQEA5P5isPxFcSXF6E2RTFP7iHBz2GOh/Guu1onFSl77Ze1y30TV9TvriymKO0QnSHkjAHzYYkngdAf5VwsiqGOw5X3610+gaINVnim0sTLMG/1THcQw5yCuDj8OPU1R12yjm1NP7MgdVmYRtFt+VJv41X/AGc8jPIBwckE1KavY6q1OfIpyW5nWHlfvPNjLtj5SDjafWugtfC+p3FvHdCHZFIP3ZYj5gR1ArtPCPgFUsjJqEkYkcg7AAcDrya66fw2v2VQjKsePvDg5+g96jllLVHRB0qMUpu76/8ADnmmj+HY4p4Tfw5YD5guDg89+RyCO3UV3GnQpaxJGse3pg8dPU1Nb2MsV/jcXC45Y43H+QpkcJimlUH5nPK7s988Y4xn+Qpv3VqZOaqy93RD7ouWMeSpcEo+ccjtgcVqWVubEhYZW8k43K5zj3Gaokqsdo0uOJh79QR/UVonzFYtDwVPBz09645K7PQpStHlJJLWEXkrSSBIgitgFhuYtwMjvjnnsPXFblnBGkRCRjuoJHOP8gVgW2xrVhKSScq2e2P/ANVbtrcOLIMSu8iptfU3qVJKNrlfUnWCIGVykecuQM8d6w9S1mC0UM77sEkZGCATjdj3x+tWNb1M4dCjKFTkYIyOv8hXkdxcvLcMzZLMSSTUVPd0R6eXUY1YuVQ9Dtdc+3ySCFHLxoXVgec9l4/Pv+lehaLdSRtIhkjeFfnUiLGW68eoJx+Q9OPOvBWkSC23FSpkGZN47dlHf/P5eiWiXFrGk4CKyjCrxnqOfp7fX1xTpXIzB0lLkh0OhiszdQyPud3gHmStGxLLgn0blcDGfQjtVF544Jy6xvbXMZG0Qk/LjknJ+uOvQD3NZdxfajEZU024e2BT5yq8lckhuR175GMVk+INaEepm1ukM0ysoaJTy2B93IzjOOvPtk10XjbTc4adKc9Djvif468rz4bO7kl1CVmV2DE7AQQcnvkEjH51h/CW3sb7UZp9eSWWIj7+0OQcH1PPOM+1c140s7VJ7qaN0aV5QyCGTzFywDbScckA4ODwRz2y/RdY/s6CXTfs8klwWwzROCAfT3/CqaaV7EzdpukpaWVrHdeONWj05B/Y6QlS3ljKD5evPHQ1yunalqT65DaWIbVtWuDsjSLJIPoD0Axz7Yyax/FbX1rc21peou44f7Pvyw5x82OnfA/Gu1n8NeNfBy6fYafpcsWt6wpihulA3QRsASkZB+VsZ3scEDOMck3SpucryOXFY2GHpuEHrtfuanxSPhfQPCy6DPOmpeMbl0N5NbDzFtcNkxgkj8upI5wMAcZpPxb8W6bp6WTakXjiGI3uULuMdt2cn8c13PiLw7a/D3ws9jpEUF9rjqG1LUpFyVyQPLi9Pvc98A9+nn8cGkX+nEzyJa3AGDubGPoK6KlRU3ywPNp4Spiaar1rtdL6/wDDI9K8D/HFrpIrTxvBC9jcB4hIAGjY8ffU5I64z05PpXc6Npuha35U/hueS0tXYhozzGmMjgZ6dcY4xXyvptrBMhgIJO8neFGccdPyNdroWh69ZqbnQr2SGEsQAsmM49R06evFRKvCTtJGtHA1YRcqcrN/cfXXhbQdH0L9/wDLLec/vpMZH+6O1ZPj/wCJNhpETWOnSLd6rINqwI3Cf7TkdAPTqf1HgFxN4yuIjHNq1wkZ+UlGCk59wM1p6FotvpFykrN5rlW3uTncTirdanFe4jmjg6jlzVZX9DTtjqVxqs91e3HnXEoDSs/Uk9MewwelXp4WG0uwZjntSQoQNzYDE5wD0yP8/lU0m7jc+COOtcc5OT1PUpx5VodvFLEPtTyuMgBFBO3+Ef4mnF3eMSW0gYuCSWxtPcfj1/l3qPSLbdKZ7lUK+YRjaDt5/Pt3rXMMbTKkkcTJuzuK525Hpjrjj/8AVV3bOTlSMQxTrdhY0URzqXGRjL4G7IzyeT+taiaW6DyrmWVwMAMw4JA4wQQOOPz6VDqZltRaSxOTF5oJDcjc2FYKTk9CfUce9XZtRCxkSRybypCBRt5PTPXPp7cU0rDlJtaGLrGnSy+fHywdiF25UjG3nC8E/Lgkeh9q8+fws8OredIxXphSeR2575r2Eb7bSjCZdzMCQApzvOeOnUjORVT7NLcSxTXAty+cMiJgAY/hwfl6fj79lOPNqwpzcU7FHS7E2ilERponKtuIIOOcfKD7+vfpS3CX4nVople0GfLVgFKt6c/XJyeMd62bTylR1BaJQQAoQkH3A6H6Hmql3AzeZKAEXPzRKpGRzgHk49qUioaS1M9ftkYkiupjISAwVhuzkcYOAfQ96gt7aZ48SPhkYKS4+YjGBk/Uit+3tYYEAiT73YjOB7fr+VZbvJ9quUWHzAVwCSB93Ayp+pP5VLRTab0MfUnOw7FB2jaxUfeBxxz1OearaXewtapAxOWyDuyO5xz0zzWlqMZewCkYBQs67slcjkVkbfIEYQKVkQMSM8MQDnnuM9fao1SuWkm9C9LcRmT/AFbMhXnjAB4P+NYl2JLef94mYZDkjJ+Q8Y5Pr0/zmr1vbSm5jd8s6ZbGcAcEcUmrwF4Ms5G4bQd/Iz149c4PrUiZj3duZ7lYEKncuPk4De/8656+R4LhVVyEhUscc45HOP5Y9K1dSkmtYhcB1MhHzIw6nv0x3rH8ppVlluWMnmKuTjgc+lUiXsVry6CqrqxK5JaQ5P6fn+dcxfyNfTtJK+NowiE7dpPc11OpSJ9n+VQQTuyeTx29q5DVZ/KsSTx5gwGHcDgge3b9K1gtTCpKyMi0iM8wMgOBgjy+oHQj/Pqagv8ATpba9jchhE8mRHnJJHc9q7ayisIfDzGWCGJmRY9qL5ksjEgjbk8dDkjB9M9sLWJp7a7ScW7mQqrIpydmffue3HQgit60uWNgyvDe1qXfQxPEMwsbpb3TJXgnkB37Gxz0yD15qv4CZpNRunchiY8hm5IbI5H4ZH0NQa7veSXzHUmRt644GDyOB047dulbnw9WG0Mz31uHjkKeWSSAGPbnjtWVJ6anZmEbVko7djsLXUr23WRXEjRkYDhSRke+DjrWm2vz+WFQFmYYVcA5NW7a6tLlYEheLK5jAT51RR3HY5qrLDFNeOX3OYlwAnGT3/wrpvY8lrmdmjEt5b9STejzAzbgV7/h/nitC33TXHmS5EingVrQ6dmL99/CflVQPwP8qiuLQQryeoJPb9a55O5104KKKM8oKRxkD5ZlIJPuK3Ul2McbRz0z371zl+rboHZBtD5IA6Dk5P6VoQzKYiqnjsc/yrNx6nTGeyNUr5iIW3Y+8QO5q/vKRLwSvGM9qz7O4DYRiSMda0onX54xgj2rLlNZTuVrnTJb0MdxKMdiozEA8cnP0PSsuy8F2cN7JNcwqzEjbEfug9+K6FZjDJ8pbaccE1PdBpUyjbXHIz69qOVPcqGNq048kHZDLOxNrI2AvB+RcZHT/IxWwJxgl8A4DFv73v8An+tZRuGC/OgDdCN2T+lLPL8itks5GSMAd+g/yKPhHDmqyvIdrV6oQsgeSRl+5xksR/8AWP8AkV4D4s1OJmluLS5kaeWRw27GFQMQuMHJyOT0xx1616P4qmvxbxvawok+xjtBLM7EjKqcggYPYduvQV4bqay/bP3u7e+WwfXJ/wAKuEVJ6nZiJPC0uaD1Zc0+K/W7s5hHLcMuZYI3G8cHOdpzxn86mu7TVtMk35Uy3HzlQuWABOODyBgZ6DjFbXg7XLHTLSYXM3l3suVLsPuoAMYP58fSsD+23m1G5vJbqVX3MYowvykNnPOeMccY55/HeN5XTPJbhTtZ6+up7r+zp8PBrV23jrxNHLLBasTbwsm4TSJ/GFHJC4AA7sPavafip45sdA8P2sltLDJfXwzabjjC8bn5HHB446n61g/Dr4ueCk8CWUSXq2MunWipJZzf6z5FwdvZ84zxzzzivnHxT8SL3X/Fkuq6iA8GSIoig/dIcfKD6DH8zxk1o26ceZb9DGhQjWqXqr3U/wCl/meki9sFs4UgWW4ST9/cfaXVw7gkkKfQ7j1rgfG8+jJpRjit4Rct93YMEc9T7fWuf1vxl9qctZRi3LLh2X5d34DgdO1cjeXzz5JZix6k965IwnN3kevVxNGjD3Xd9jo/CdiTqCN5i7XwFyOAT65r3/S7Wxh0e1jiDb0XcWx9/JOCT6+2P5V4H4cvUDxYDqg6qCM4+pH9K9d0S5Nzp9vI0UiLt35lckgbsDnAz2ORxzU3993NHh19VjUi9GaU8kbalHbnPCNJkeoIH9f0qvFLEXMs+4qjiOED+PtkD8f0/JJJY1O5STJJgKgGTjH8qugPDbl5Ytwx8qh/un/PU1bRwK2yLlvED5ku5ScADB49TzTmjUDDAFgxBG6q9vNNygVVRifm5PP5U+eJCRtTPHOKHZFpPY9B03MkHlEhRuLqD24B5/SmxGSGdSHkZN4BlGFaMnIAz0/HtwDVbTbqKJDHAjFiQ2dh54+7wPQZ/OpdS1C2S2dFYqxj5DKeR1yePUVRw3tsMvrdmvbRIJ3CpKuG2/Kn58e+PXOaltNzXUj3BG8N8inLIzbf0OOg9Dj1qvp08t4HvxLGSW3EEDluCcgdB6Z7CtZ0aaMxPBGSp3fuy2B6kZ9cdcU13E5O1itFlL8sTL5aYAyoYqPcd+nXH5YrRglxtjlGUBz5vABB4zn3wKrQgRGRLo5baHBXDArng5yMHnmk8x0kRI2ZiwJi28ZBznGDwT7dvzpbFJX0Ls1wGBMJKyHnbkZ49B7Aj/OKqiZvLKSoPM5RjggHj0x+nb8jUJkhGRvfaz4x/Eo9cjtj09Pwp0wktguWeRCu5yoxtOe/c89T19e9Go0ktEVLVrkRP5UweRMHATp16cnA/wAaqJdypqVtGsu4uGGWAzjGc4HuBVzZJcXcnlNGERegy2Sc/wCfxrNayWTXoRK8snlxuCC+3BJGBxgdj1qdUNrm3JNWt5hDdFMCEoX6/MTtOTn39P1p01rEsbIFQjp0yQKnuLG0LLG8MfzMACVGTz6/h/OkuLOKJiEZ0Pbax4/DpSaBO2hSDfJu2HzMbTyBzWFrJnVHfywTt6A59h9P8+1aV3LcRyuIWNwMcho9pwPccD8qyb/UoxGVuIJYj375H1FQ7DV76mPeSxMP3xbc2SMjP8qy57oXCrDESIUO3JyMnOcc+gyfrU11exxhltiSH4XAz+P19c/41VEawrmUfu0HzAjPP/6sfmaIkz0MvXr1VURWy7pG4HHAHTr1rjtWlln1BDLF5wUg+XGpwORxgc+g49a3rm6kuFeSMZD/ADdBkDrx+n5VnLI6Xs9qwIjuQqqyMckjPIx+PPvXRSOasvdNHSJZtRu9umC1gvDxEWfakWBzyxJGeB17HvirA0y40KK8e7le5NyCsjxLuRmU5AwfvLnB6enSqdy9pourGS7tVtvnWKVFk+6SDtdBndt+U56gcZPzAV12q6nFa+HGa4llks4vmADYGTjt3PFXOKlozqy+tKh7yWh5h4hsnSKC8gjeO6IO+Mj/AFeDzkH6jjArClF9aWzm5nuUnDgIrseB3OD06gfnXa2uo/areaK006R4gxLzSy9gd2ATk4rjtV1G61jUp0lto0uW4UZ4UD0J68d6mEeVWRtiq0KknJp3Z6D4aL3NrGsDAEKpYqSOoznHSuysdMYRBd8uxgeQAeT16V5r4V1CXRZLeGdUEcu145BnDDGCD79K9f0i/U2wZNv95VNX5M5Yq7ujOTFpOkUpdj3LcUt9MJbmJVTJb7pPbGM5/MUa1dwXpNyoRRu2k7eAR/k1EA32pJnKBY0wSrZ3E9P5flUO3Q1lGW73MrUdsVwYnyMfr7VjLNJHdMY8NF/CAeldHqmxoGd03bT+dcleQrHdqQ20EAg56cf45pO5nsb0E4kgR45Aj5yExkde/cVswNOQrkx7W6EA1yMUxAjTaMrnDA8sc1vafO0qqob92h+b3PpUNApHQGR/KxI6MwHYYOe1LHcsbfDgDbxwcgfWnWsoZdqqPrT5HWRCjAgEdj2qL9y7MngxOuFxlec5qpfIZxsEjKQeox69OR7Co1SSFVeJsq2CUz/KpDMqqCUIHb5ScmokdtCXKzkfF0N1KfKuVUQuT5cgcoI2x8obg/Lkjn09OteSa6uoaNqaLcBlk8nEXmLkorZPyn8cgj1r6GkjiuYsOrBW4O5MHp3B/E14f4+0UW+qyLbH5EbADHoCNw/Dk1pRnaVmdONg8RQfItYnHSyG4lZ2CgnsowPyqW3t9zkEEsp5A9Pb1otpfsk2/wAtHbHG7kCtTS7t77UIo5CsZGSpXgN7GuvfY+epxipe8MW2kVx+6cKRwDxmo5muIIJYRIESQYZOua7G90+WOBS0eAwyCRx+BrmtUSK3062khd/truy3MbpnG05R0bHAIbGOTlCT1AC9m0zvqVI+z90zFtRDKCxDpyGDDBB9PY1AkTXLrFBGMrnLZ7Z7np+PFS2VhcXjiOJG2k/hmte30x4bk2saGWXdg7Bkkj0qZ1FAyw+BnidbWRueF7RjKfNmsUaUMB5uNo+U9+x6YHqRXb+HjePp0QKQwiWMY2R+XuVWY7mxjJ+fGTk8/lg6DoEtzfwrAfNsUbK3A3Kpx/EoODnI7jtXokluYpYFAG3yyufTBH88/pXPCV7vqe7jWqEI4eL0sN0u1ZRIdy7t3B2+nfr65q+8U8u77QwKopCqBgZ9aZaxLFCHdBliSARnOTkdauSxmO3c/wAOOhNU2eZazugZdqBF9fTpUUk8kTYiB3EZbaasS7GVVHOP1qG5xCV37iWGcgZqGi1JM3Y7mRr9RZRSYGeApVTnnufb9T9Ksl5hI0dzCiguJHUD5QM9MAnP449e3M0peNjGhDFDxt9eMcHvU9vLCocyMXebk5BJwe/A9f5YrQ8+12aCyos6NbOihhnGD2x1HsSOPbpVuyuwERzNBvb5tikZGOOntyPeubj80ag6pcRkFVZQRzjccg8552jjAP6VeDSW0Rhu41BZ95AXGTyeOcd+w71SauNx0NeWFZC0iN88ZDKR0z9e47VSlntpJ9lxEtq4H3WyVPHJBx39+arBL2A5iTKy8hTITkfTBrOvL2e5WceRG7bseWpGBjv2+g+h9KJ2S0HCLZpand21tLBMplaNePlAYr7gd/p7GrFrqKSQYTG7GRMWP4fKOn49+uOlc9pGDIDBdsZyCSkiCN14+9gjB5z2/E0srPBPK0kgXGCzTrtDfj0b8CD15rNye5q4x2NSMzwrNLbzI7s5/dKPlIIGec8GqUE8kl+Z1VE2yDPP3eCAD+PNQWeoRojtveOQNlR94Nx2I+n1qveXUQRHiuIVcDAfODkdB7/lSbHaxqyGZ9ShTduVQ0gZXIA4wO3fOfwpl7K6SGP90eOjSHge/FZFhqG8yXLRGR5CAIixIAHfptxk8+mfz1Y0Z7ckRLGxOWUdSPQnFJsiz3MtoQ7SO0qbWOAI48kj9f8AIrMvrON5R5kWIz/z1OQf+A10CW0gfaGA5xnqT+NULuJPMLzMxPRe2TnApPYnqc7qkVpGDJFsa4PBdRkj6/4VzOqb/smx3YNKfkiTqT3JPFdlq1kGjPlpslbOdvB/GuQvFljmYS7WPTf02jrjFNBZM52G2dLcIY2QKnLs2cgcfr0rGvbINJcRi4USxy4EikY3j+meK6i9up2dbaRgQkeIl4+VTlhk+o3E89MkVgWVgs1xMARvwMbTzjuf8+lbQskc1W7lc9E0a503U9NV3eP7csIeQqeUbCkc+oyefUVymg6ZG8MSSXLTpNO62sMh+QRqeH9+vX0HvVPTNLih1TfeedJaMjJLBDLsLkj5ST3APUHr7V23gcRXd3eOtpI1rCgWOIx4YYJDEdTxlTgA5AJ7ZqrczN6WiZn+I5Eh02O3jWJIo08tngXBnb+97nnPavMLOxsrjxba2eCYwrB3Vjy+0kAHvjGK9N1a1Ou+IJbWweS4wxSAs3LE5yT7hATjrnjFQ2nh/UNRkurayQJi4We2RpFRC6KFY8nAPylf8aaTB2m97HOWvhWy+03VpczTF/llimU5ZQcjAHTqD6dKsaPrF1p7Ppmoh451UhJf7w9Qa1d6vdw3dsP3yIyOgP3gDyv1Hb6H1qv4stLTV9JW7syxmQl0deoJ6gipckkdMKLclbr+Ze0rVbe8aaKFTtB2lAQfm5yQB2NWVLT6lJEsZijijV0TGMkkhm+vC/pXjEOo3unagssbGKVGzwepr0vRddOszsLy5MV4iho3HAVsYK4+vX/61SvM3tGbfLo13NW5njmYo6o2GI+buf8AAVhTTLFKzRyggcFc5HuMVa1Vo7eOeds286R5EdwvyPgdAehPH19q4iwuZbu+klAKwodi/McnPVh6nvVLVHJWpOLOuM/mIJl2g9wBgD8K0tKuGjRZGG1XOTzjHNYEWFYuiswHTI6/nWpZSK0SIMFc7sc8CoZhsddbagYQXSTPHXGcj296sQTyM4lAX/dIBxWNCcyqiuAR8wY9D1HA71rWySscM4UAdhjIrNrU1UlYv2hcvl8hPp2+lWo1UOzE5OfxNV0m37VY9PlzVoudhww+p55zQlfQ0jK2oXDqsfyqCTyenTv+NeceNdIe4u2nghlkEhUhuSFAyCMfl+Vd8ylDuiLGZTkNnG33zWPNHKpeNZt4Y8luw64z6fX25rOaPXwVdQ21PEtR064tpnjSJSZGUqojDsTnjHGRn07+9ZTQu8zvujV85OGA5r1KfQZ7m6cv5SxOxG3bjcOoJA/z0rO1P4fs04NmWTcFwhO8Zxyd3BxnPboetbU6t0Y4zBR524W18ziotS1JI/sy3kzRHrGW3qfw6U83V4fkYoox0ESr/IV6d4V8CNpE8OpNfwm4ifKwfZVlHB5z5ny+44P0rpfGGjWniPVJ9Wu4Ut76UAfuRgZHHKj+ftz76Ob5b31OenQjGSUnoed+CPDtzfTxXd758dkJApnPEaE85PrwM4HJrdstJN54rLxGERQ3BdTCrJvQcAY9Dj68tXSw6FJMsb6ncmecqkSCJAvyqoUcc84ApTpNxH8kU6xQQrtI2BiMnOc9M9unbFY2bep6MsXClTdOmaloYowIYChcHA2YAH9PrTbgC4dQwZBnhs9x/k+1U9L0+C1j2xFlj35D8szN+v5dKvS+bsMbQlixwu1gCTz2/Dr2qrroeU4/zFu0txGgQyM7cnMjZNSTEyZRjjPBqnHNPbREyQyO56sABj261LZLc3Uh+QRKD1JyT/n8aAu0S2YwojON4O0Y9PX8qlv0VHQOQDtBAz2PNSfZo41G0nf/AHu5/wDrVk6o87Tb2aJ9xPXIxTa0I3Z2El2htZSI7h5EGFGwKD7c4PX2Of5usZLi3BWZ0Zm+ZjjeWccHHT29sDrUd2I572KyYkpu81wG2/IF46dMMR/3zTZmNrNOGudki7RC3GT0yDx6E9evHvRe5go6EMRkXxQvnSKrvD8qlsbsE8jtxyPxPfmukiEc6NM7nznUbW6YHuB7c/41mWqW4g/exmWWQ7wV52DPAPQAnAJ5PQVLbyKYHt44pIZ96xFckBjnAIA/E4z2qdi3qrIsATS/uFfZEcbz5mWHHY8Y4+pHb2sSWtvDanDhXHzK2SCp7fXnA/nVX7PBCoiMjLnOAZeWGMk9ev8APJ96iviyxOJUeSPbtQh9xz3HI+vH+S2w5WKkcd5ZlbpYysfILEIUOTj5s8HoePf0qu0zweUxl+0Wu7aZsZK4yP8AgQ4PzcAcZNVYILZHiiED4KjJZt2HAx6dOAfzHPFacUCSTiYy7REhB+bIyecDHsMd+tSncqUeVGdLp9nLe7fsoyw37ifQ8cDjuPypl1pzPGY4bqV4gSdjuQD9M/1qzcRzadKklsm+I8lDgBOvTt0zx2J7VoCb7YnAhKnqoOMf8Bxx0p+RF2tTBs9PtogbYiZGVtw+c7iGGemeR1FX7O4MiLG7MspABPBDHnof6VWvYZRI52K8ZUDYT1AJ9enU9+Kyft3l2arvZLhU3eXIucnr8vcjPcZx9eKV1exag5LQ2Z2n81kBiLMcD5enP1qneiWMoWVWIHY/0xUSXiKGMhJfcRkA9f5/pTZ2a7++cZ6qDxTaM5x5XYytTvgVZQkm7OPlwTn0HP61y+oOH2GXhVP+rHOPTJHWuuvrVdrBeePmJOa5TWSUVI41BZvu5xn/APV70kZs5a7uI9+XUkbju2cFuT+Q7Vc08/6O02EVpYsrsHAbsB7c1BqsK28CxxRhywI3YHPvUlmPKs4ZMgYfkA+vGB+f6VrHRGbV5KxnS3UsWtGV42W1QbAR/EW7/pW7a3LQyW7ROy+crDK9cjkD8RkfgK53xLcRrpywI2JI0Viy8jcO3t1rY8HJJrP9nwCQxzRvHINuAPlJYsSQccgDGPftgum76HZiY2UZpdLHT+GbfF2dTjtZYPs6OsrsQ2+U7sDtjtnGcBeetZHw7vfsvivVoBMIhL86lk3hldTxj9M471s6a+1Li2leY2om3vEjY3ZAyeeBnGM+3tXFh2s/F93Mkbb0jjfaOrR4wcev/wBanKVmmiKdO8JRZL4p02bw9etfWMnnWE5DblBxHJjJB/UH15rNtbqKaUXdhPLE03Ekf3gr+jL7jODXYX+o28c0TXKRz6ZqHDEjKpIRwcds57d/rXmHivSpdD1hzaM/2djvicfy/CsnG56VGs4xUrf8H/hiDUIt7PEY1NyjFg465/wqXwnGrSTSSyk3attCk5JB6H8xVM6uJVLTwHzz1mTr9SKzJp0fccuZc8MOKqMGlZmWIxEJSVWO57dc6nazeH7yLUgnlGEht30/nXkfh0Mb1VXLsvzIu8Acjnse1Y9xcXEv7p7mWVc8AsSK2NG+0/aI4hDDE4BJlkyuRjHP/wCqra5UcUarqS2OvgkMa/vWXczcqQxIPqSRip5N7OjRqySBgCpIwf0HaqodGxuCuoGCyyZHbgevPrWppYiDDM7I+PlLZXHt9Ki5nKFjTimW5RWXCyRj5jjH5VtWkpMZzJgdcE8Cuea1Ijy7lgM7WLYPPcf5NNtvNl2ieOQtyck4Vl/z61D1YR0VjrYWaTD5xG3TjBPvWmCIYgyMzMowvzdeeP1NYlilykSyB3jQ/wBwkZ/HqavxMZpoZJWZiOFz2ABFNaDv0LTfvowfLctuGR1LE9c9P0pk+mwNC4iDtk/Njj8SRV0sfMj27VO0tg/hzTvMDjbG+1+7Kf5jvStfc6Kc3DWJmPpkkZ37F2qAo+YjtnGPyp1jYSNC7TSRg88CPAwDj1rVhby23t90jBYLn/PWrsUfmEghkXaWwV6j6AGhRXQt1ptWZz4K27K08DOpbjLbUPHc9QP85ramUT24VEjjYkMedx3Dvk5OT7cfpSiFYzgqNh6YQkg+1WIrYRu2FdMdgR/9f+tVFEylfYz5YmwpEABUYCg9T9T/AEpogYzACMvuXAGM8gc8fn+VaDAtsyQGJ/iOKyPEc0q2xW1z5zkJHgbiDxk8Y4xVLTUdOLm0jP064WOK2JOTKS5cAYUsCdp98kf/AK+utaqrXJZgCc7QDxjpk/59KpvDFHaR28capn5SnoO9LFu2mWMgRnoTyD2GKhabmlSUZvQ0Lt0IKg857Cn2yyt90FCOmepqvh9o2urOTksF7/nV+zD7QHwMihPUycWokcikKwwOmQT3Pp/KsjWoGUwonJAOTjOelbdwVkuI0XkR/M5Hc9h/X8BWVe3khun8tA2MA5FVLYyu+hpKsk0UOosTBKSEdV+bCjoOR6kH6njjgLeWLNM0kszNMMOgzxuHYY/2cZ/GpzLJHNGfL3q6+U8agkcDkj1OM/n2qZJ7b7EouGYEP9/Yc/KeeSOpH86hRG5s1LBLdV+ZEIIDEooDY6jBxx9KzGhW51oNG5EKJ7H5uRnt7ii1uJH8qDesaOqo+W2nH9B1/OrFtBBJc3MksEexWRFkAU7cKeAccdT09KHroKO92PeOVJN0bREldpbJOcjkdagnedMEiSPH3Sp2Fmzkcf57VfECwSboo1XcN2PX/ORTr7To5ljJd33DaFDMAp/kanXoa3T3Ofe9vZbhxFbRGReH3SfKw9QMVfsBqJiUzRxN1JIOMjtg9vy9KrXVlLa37SCTDIucSAtt5xgnr2Pr/WpbTWEkhzcSiMg/cbGV65H50le+o5aqyJry6uIArNbFicnaAHGOfQ+vt3rKhvHSJAyYdQdh2k5GehIPbgfT8a3IbtbtX2sXCg8LzkAe3bis++iimcq0hglXvsIOfy9qtmNu5DHcy3LSLEjuw4cZwqHsMc8+vP8ASs2/hOoTrBMnkqp3K4zuJHoexGRUp1D+zxJBEsYMuMleVI9fQHj+hq1H5csIlg+6vCk8E885B5BpbmkHy6ozbKNdPJaUZUnDP3J9T/n8q0LmRJVJGET1POal8pTBtdg0jEkoBkn8KyW862m2EhLc9Gbkxn0wOMenpj6UbIib5ndkd7cCNTDapuOPvEZ/z+Nc5qETLE7GElyOGLf17V0urPieNQ5Usv1JwPU+v9a5zWFeSMRJKwlPAj4AH44p+RjJWscfeTSExFQPMPRAO3Ymi3iuLiF4nHzMrYCHaB+NMuoZWuGit5AwRSsj44BJ6D36dadow8vURFdzOyKGOGPX5f161fTUzTtK6MbxdCLDTbe0U/vHbLMB98nJJruvhdBbRw38bSsk8sG1FwSzrg/KO3XbnP4d6858QNLfa1ao67EY5VCc/KD3+uK9C8Krd2Fg12luXachYiCA2BnOD1AJPUegHY1dNJanRXnLSNzY1q3itpphEym4QqWUZ5XJ4A49/wAh05rhfFTT22uWOpWg8wJCVkUfxJnkf+PV2MR823e6fabwAq8TcgD6/qD6ntXJ3rMNWuTKqGzERQoxwSCMsw/GplpsdFGN1aRPaTwNayfMJdIujuC4/wBU3cH09fbmpLiPfDH5Z/tTT16AgGRTjGP9oe/BrB8w+HWiubZxc2F195M/dI/TNallpltrUEt34fvWsr9fmMG75X47jtzmoTudPI4e9/X/AAH5nO3+l2Ikae3JiCn54Jchl9sVR1fT4bZfPMYdMf8ALNwRVptfuUu86jbo0ynBkCDfn15rO1olEBmmZgTuCZwy56jHp05q0uwqlRKNminp5jty08iLsUgq7c9+QB3NdLo09heRyg5WRxneYyCw5zjHFcPM/wA7gElQcD6V1Xgu+SOVEleUANsVtpZVB9cZPr2/lVOOh5qqNu0TrodNtcqGjSSMYMfy4I9s/wBa1RYQTxptjdJVHVcAimyqUhDQlScZAGCORU0d9DGkbshLNwcDAFQ42IdVyepWTTXR/lILeqk81pWMc0cjYdQirt2uOn+eKaLlo3MkcXDcAB+cn0+v+NWbS1mbbJcAnDbsKeOn05/+tWezL33FkuHNufLUkSbd2wMuQT0INa0cu5EcxzRgNtLtng4/Sorq3cwKV8zAx6fhWhbwLNH8w3Iw696q5MbDbCxe0gjzcyXXlkktKwLMD1Fabi3X5wy/MMjYOPyqtbT+SES4OABkNgYI9xVmKOJ5nlgk3EEEgdulI2j5jCdskatKNkmM4BHHUg8+1acZXA+cMSMgj+R9e9Z94Udol8s7ywUZ5zmpVCLCSh3c8jPAoV0a2TJJ5vKxHIwIIyQWOM+3SooJJrkDyVbjqSOPypbcQzNvfPycD0PsB/nvUthPEFaGRwpB7nbkevpT1HbQkW1ELbpjuYgqT1K/gOn0qLyU3DeDIOQAc4A/P6VKtxH8yrtbBH3FLH8xVaaZ5JFjhXYc4LHsP8aLjRRvolklMwDK8eY1b09f6D8Kc9vLhY4ipjjA5xySR35x0/nT7hZWtGUbRGDgDnoD1/nVvSR5VkrzMSX+Yt/Q+najclrl1KMcXlFShG/OfmIUED69Ks/ag3Nuecce2e9WL0xmRsHKjoQMcVjxubeGJxgM2ABjOB70ti2+bVlrzxCjLk+Yc59z71kWrxMrmWVVO4nqAT781X1JpLljHDxvbDnru/8ArVTXTN0sskztvYjkHHA4FCYko73Ot03U9k4eYgMqlEG8g+ufT2/zxqzLsMV5+6Zc4dgONmeo9xx19O3WoNPiVZVFwoKEkjBIGSPY57+p6Vaktoo5nUpE0cg6MO+eB/n2p3ujmlGz1I7pIbtFKbXIG4FeQDxgmrNlDNaRxmF8xYzuPBH1NRQ24i3LIhjkC43xHG4dunXpjmrMUl2YYj5iXKkfKXGG446//WqdDTmZGkvnXLRlzkH5BypbPb3H0PcVqrJHEhy23A45rn7jy1uIlMTwrnoeR09RzTNWuJZYhaxOvlPkENyVHGeM9+lC01CT5rJFu4uUmEqkMTjcNmc+i/hk55qta2KWrsYyyCX5pQr4yeo5+pqpcI08LvFLIxyr4DAbsY7DHoaluC6IskMrSk9pMc/iP/r07gvJmtNYRFC+91m5ZpDIwLfX361nRJILtS8su0xjbuAO4c8+vpU9ve+dABMrRmPAfjdtz39SKqxT210gW2kVijEK4fnryPcU2Sr63EXfMzSNF5ysMLtUHA9cN+feqn2Fo5FktJPkBy8bEgf/AFv5VtNMIBGsinLZ2hTkn8OtZ2o6hFMjpZxPJJjiULgD+n4VNh6rYsRTQtbokKASt/BjBz6mq8+xInV1MjsefQ/WoLLcp/fCQTN8xIXOcdxjt7U6WXzQAg45yRTMpb2Ma8Nxa71lMaxD7rgk/hmsHVi85NtZKRn70p4wPY+tddrEAntBAACxwORkDuc+veufklhtEKM2XT+LGc+5PrQZt3ZykkHlLMVxGiDLDvx/+qsrSZ3keaZwUV87CepHQ/y/lT/EV5JfXMkcORDjLru+96cf0rO1e8eG0h2hUWJ2ZmGDkkZOPz4FaIjluyvbxJq3imeIoxQJ5K4OMttJz9BjH4jpXs+jWqyeHJEt3IMZBlg2hdp7e59v/rgnyr4VxPeavdmdtsESMzyMct5mMnn6ACvWor+QaZdXLRqqXOFQEYIYZ5OAM8Hv7fha00OpXmuY5rVUit9SjkhdWWSMIzBcbjgdvY5/WsvSkivW+zvNCUbJkEnO4HuPb8+lWdSuy8gSEksylVXux45rnta0caJeaZe2Nw8VtdcHBB8uTbnv2Pp7VEjohrq3axW8QKfD8bWs8ZuNOuM+Xn7yY9PWuJtdZuNOvRPYSNEwPH0r03V7+LV9MNpqcEBvkOxHjG0D/a+mOe9ZNz4a0qz0tlnuo5LyThH6KvGR9e9SkovY2lUdSCtKzKdm9uI7ifVXtZbuUZxnlcjPIxx+FcvqsrX7LDGkYjiJAdeMirFroT39+lrYMZ5OdzDgAetd9ZeAYoraP7RM4fGcp0yew9cc0c1vhBwT0rO1zydEjS6Rrjdsz82DzWtpZOmXBuIpFkiYDacHDAnlTxwa9BuvCFrbg+dbLKJUG/CkHGeWX8+QPw6c8fqGmXHhudoLxPOsJDw4GPzqlK+5xToqDvB3R0NvdyIR9lbzLV/m+bllz2GOtXDqEckEb7tgztJxnn0Pv7Vx/wBolsITNZP51s4zjJ+X8v5/nVP+3N1z5wQxsQASp9KmSdtC6UKcn77selabPGt4hbDk5wFHP5fnXRRXJz8oLJySp5I/zn1ry2w1pZYw3llnB3N2xx1znA/Ktm18VxiaNVwT1fbkhfcYrN3N3hnf3T0eFpXBBIA/hyM5H4dKt2OYXHms5Q9s9D61zOm6zHcbY4rpVfsrKQSP90kE10K3Py7nC7cbiQecfTpSTOeVJo1EigmHSNx9M09rSEputyE4wQorHgZnJm5Ck/KpGMj1IrXs7omJVMchzzktx+ANNMErDo7XzFcMItnTbsGKesE0Q2NIfLbsozn2P+NSGWcSAKiRuh+96GrEDzmYNNt25yxC59+9NFWKK2sTsuDu9RgdfXNWltraRmEcG3+5jgj+v61ZnEDuZCGzgdRn8qgCLu4CgDj6/qadi1qhWiKROS7Htzg4/rViJUiTBVWJXufXv/I1UMm19qr5jkdB2+tWl+dQzYVsAYA6/h60yXoQPHG8LoFYqQQSf8+9RtcSQoqeUwOOqjOPqB3p7TRbMFsqp4weAagkuGkLCNNzsOOwA9/rRawPUp6jPBbWTKjSh2OAArc/hisNpnnkitnklZhwxPGBnPHTA6/5zWr5MrXUbSMHMhOOMqoHfH+e1TW1jCr75cszHfg0bhdR0ZR8hzKhiARFXr16+34U9VTGGBYjjIOKu3Eqq21mVUZcZPbH/wCuqCywRxgzyogYkqDgcf5xVJX2MXI6URMqo6edvXk8oQOPX86huZLuWUu42DGVxy3saIb2e52rIPJRuFxn5/Tt/Pn+dXYzAWfd8qrySCQWP+FTboDk9ylLqNztVpY1OwYZSwRiO+MZB7VoQ31lKAkTmKVedkgCk/0NMjUNM0kSYjUYUBcZ98f5/Wqd7LEYf9GJ+1KQA6k/KM9/w5oM+buWpnM9ypcMU+9xzz2/rUV5axCMzLtZlHGTge4OO3SpYLhAywyn5v8Ae4NQ30Vz5o+z7jFjewz7/h+eaRonqZ8YYM06tIhT/WDJznIyeOuOv05pYoJBK6QXGYwAy9CCD2/z2IquNRZb2OfymQOSHUEY6cZz/h3rVsIllgeYxKVK4Bx16n9Mj9ai5u48upW+zSSxgxylZ1HTAyf8/lVW1topEQGTkuxeNcgg888dD9MVt3tsJExAQkuMKwxVG5kWN4ZYYgsqEJKob7x6D6daoyuxJI4rZ+XaaIHhnJJ/DPNSTXVpGitJPEM9AWHH4VWuLi0lcK6AluqSLypzz19v61VaPZKYrcBUJB+UdQR0GPpTuVFdy294LiFJbRGkZTuA2kAEHnJx7VC4luFeSELEygFTnnB/nV6NmaEJbQhMDB38Afh1qvbWTOJhNKTh8Y6DoDj8zQuxhUtcyJruLBju5QJFPCLjnj6/zrD1Sxlu3LzYS2UcKWzj8B1rpmEEYYQxAMTyQPT3/rXOau05jVghMe75xuxn0z707GT3OT1KDyw8gOAp+UDgL7f41yHilxFaSCN13K6uFYA7gRycH3/rXca5AiRAygKMZ+X/AOvmvPtahjkmTC/6xvLGcADODz+VXDRgtUdZ8GxJPqLSS28Zs7qfy/IjXHzYHC/UE/lXoniy/tg9rpukymaOME727E8nj24H4VyPwqEFl4VmubmVsiYmBI2UktjGT6AfN174rM8QeJWS9eKwBkkY5mdfm8pP6mtNXdmkmqUVG52Gh6MdRFzfyOjm3Ighy3IxjJx1A/h/A15v8TdYvYZ7HTEkVYYWaddowclmABPtzXp3hC9s10lHtnVlKBSd+d3U5P515brFnHq/ip7m6lR42LBUZsZ+bCj8zUwV5XCtVcaTivIpDxGJNOEF3DiTB2/NjHHOD+Vc+WlkKNNM7g8jL7uMkdO3TvVrxVbLp2pTWdtKs8MQDFgM7ScZGfTPHNW/BNnFd3LyzBX8rA2N7559KuSsjDD1bW5j0DwJph0u2E7f624AJyPujsP1ru7RlaWNWJJzx35rmtPvUS3Ixu4x/u10GmOmQ0h+TqM1il0OmpU9o+ZmmbRJYwAAU5GW7Vz3iDREuraSCSMzQMo3ZP3eeP6V1CXizsVjRE3N91ePb/6/1p9xbbyVYgKwyTjH51UkZxlZnhd94bl0tpXs2OxSdyPyHXHX8MkfyFcpqVkCyyRxmNmP3Bkg+4PfNe96jpEUzR7m2AgtjqPb+tcbfeG0eVgyHa5ztUfd9x6j/Gs03E6ueFRe8rHndrol/Ko+Qxq3RTkE+2K6Xw7oDbVkZCksZ3YIHPPpz78EVvR2dxZzxiSVmtSchtx+X68+9aYjCzR7Xc7xn5W69PeolJs6aVSNNaLXuVEhkhUJPH9rgyMh1G9B/wCzevb8a6DSokEZWJppLZ8YYtkr7YPUexNMazk8tZCzADBwCNzY7YJqS4uYoYwqSOfmUsEjxkZGR+Wfap1WpXtFUVkb9urKciMgHkMedw/P9KtI+6XZtAfbyewFZEV+ZJRHDE7Z5Vm+X69ef0rRtLeWRiZZvLDdRnA/+vRcwkrblhhFG48yVtzcAZGT/wDWp7rOW8xHdUxndk5xTEhCDzFZFAOUB6D6f1p0/wBoWP8AcnercL8oAP1qyUPRB8yyuHk5wpycfrjH51NatLINi/JD1LLwv4f5+lULeMIGylxHJnJClWDHPU/4CmXF5IHAWAuWICqXGD9R1/nTXccjXZ0RcxzIQMj5WBx9TUf2lbhCDvkdR1ZiBj04H/1qyjFPMpaeRgW+UxouOD+pqzHaRpH+5g3dv3nzcU1oSyN5RLIIQUiAGDhs/h04/wA9KuRmG3TZGykEchBuP41FHbRwxF3+U46A4x7cU63hjmyCh3Hn1NNA3oVLy9VHjYPGqoR1fnB46ducflV6G6ja035V1A5IORVe9WBEP7uMnBUllzkViRyNgkRMkWcI4ADY9ee/+fq0ZVJaKxT1+4F3NArs4AcbEUldxz39umfyqf7S8jHy1jUj73mnms0XsReW4bImBIQlQAqjjKj35JNStcWzBTNLHkjOCw4z/P60ti+RySZ0C6q00BhClm4zkkIPcNkA81HaXl4W/e5AztLkKQfTuT361cME+FeRxJIBwrg4J9P16+9X7e0RSdwjG8DccHHc9T9T+lPc54+6OjlkW2YTJMUzk7Wwo/Dqfzqza7DFMh27sYCoPlHXkc0WdwJIyklzECCUY9c4OM9azZbgWjl4pFn2kqUXJyOvHYH+eKGg0bLt3aGVDMHK8ZUheQanj+1RW52yqGf5SpBJ6fWq1tqqXEZLEom3KgoVP69TVq9SSaePymAAGc45H4Z+tQ9FdG8bt2Zl6hZ7cfOxkIDlh2xyf0961YpWhjURP8uMBGG04/pVW5jdYc3EmRhjlBg/cPrn2rbto4RHgjdkYJNJLsXOWhUiYqCsi4fsnfHoO1Y98zo6sqDfKdhCgjkcjr7Z/Ktm/tyIT5ZwvX72P0rDina4kUyjaNwERx7gE/Wm9DKHvalW/tftDJP5DmWPlSOf896taVPE0jbpQrbRtL/KW5PGD3rU3eVERGMt0JxxWJdefAwkLQLG75ww4H+HGam3Uu99Da2gXKAEhSccev8AnNRogE1yCDtEmCD/ALornr67ktfmsyvAJ4JAAx1PY/XFVIdT1aCFvtixLExyHtxuIJOcEtwevbNWtDGabOhuhGsQbCj5cnI4rktYukd1SEgqTlmJ+U0+4gup4GlluHMYPBJ/TAAwax5bGe+ClpbmKAEk4br7Y+9jpzQibLdlHWLq3aZlBLNwGYDIA9Pb6V5x4w8yKQMChikYOMHJBAIOf8+ld9qIt4IZHjLyKp2EDLAe2RXF39g19cxRTEqrBmAB+6BxgfpWkdHchrSyIvB17PHHLbG4SCJ1MhZj2HBNdlp2hw6hfwJapJAmx3LhsFty55Pvj+XeuWn0mCceQONoADAfd4A5/Gva/DthFZeHIGiPmiUGR0LBiGUYBx1HBJGfzrVW3OWo5M8ytvDc1nPJb6dcTBDuIBY4x15wQDSXFvZWmyR7dopoMhy7Aq4IwcN/+qu31G0WOU+WSAD1H61i6nbGWzlgJXgZJYgD15P+elJvsOnZq0jzWOAXcmsBSPOcAog+64JzkHt0HB9e2Kk8KLFY3EyTSkTOoBAyFXjoT6/1GO9bOr6eg16CKRGBKMoUkgK/OVOfft7ntWXapHDrjSXczK5Y78YU8jIb0IPf1zUuTOyFFN3R6BpNxHG0yXEeA/zI3bjtWvp9yqxKsxZQxypZSB9MmuRjumiVV8tTtzlscp0/T/Guk0e63wrMTvjxlh/dqdCdToLdngPmBVaPpnORn04rU02/nubKHz7aOKeMkOFbcGHY9PbP41mmbzrZQQDER1A5ptnceTcbd5IUBg3Q9/T6VLbKT92zRq3EUSjzM44G3nv6e9YkgHnGRkdQoI+YY5rVt5I7lllc4eRQ+F6KCM4A7f8A66meHjGFcHj1JB6CoeokzmdUtpmG/wAsbFbIUndkA/zxVSWyEgXALAsHTYcHPp6888+/4100u6IAFAU6HuR/iKqwQqZCiBcquVIbjBz2/DFS9TSlUkmVYrYgK6iVlYAj5t2fqD9RVtoYiu64C4ByQY8N1+vTjtVq1tjGFiLqFPIJ7VNqZCQqjRZLZIxznH/6qmxv7UWzsUG6eB156BhkAZp95ctFCTtRgoGQCDnn0o0yEkHZu6kBSKs7Qbd9xAy3zAjOADV6ErcfDPA0YklYAY44IA9qlimt4tzEpuYYPPTmqbnYQp+VVwMdCT/jThBbyjMriWTsCxKqfYZ5pj6loO0gJAwD3PU1UaSGOdX67fvfTGPwqVbJGOFlO1cZAO3HftTbkxRNHbrIcN1BA6fUf196Bl22CyANGpVSOD3b6e1BmdpSdw4wvT0FZ6yyndGGR1HBfcVPsB1qWO7d5mCW+GUD5RjCgk+/86pMlRH3CPcTKOqDnP3ecU6RfKhKjYueuG/nTJZWZcrIRgchFyazL6eRYBthw7HauULfjyfqadiW+wy5kF0rRowHzgNjLZHp/So9WuohbmNUZ5ARtKgDBB6YzVd5LWKBYXkmLA/3D165OM1DFeQrNkyJ57cBASSvc4H0H6U76CUXfmObuXnRbXzIzFKg8kpu+Y4Hp74rOeyurgiQyJApzgypkvyQSM444966fUYLe5uvMKtJIqEEscbc+nccA5x2PvXM6ha25m/feW838QLH5fQdfShxSNYTclZ6HsLArCVRcvnaRxkHPHU0+CaJoA0xAkJ2gEjI/wA9azb22hF+LcpvCL87MActnB5/KpbGzxNMIiIthGGjXbzjvj6VpiafsargeXg6vtqMZlpnDTmDyx84yZCuMAYyQOvp6dastp0SyxfKqjBBJwO3H0qorvHewidFWYowVgMq/I4xmrKEsm4so52lT8p56ZNYvVHXFWY+4gjilZSqmJx6dD7/AOe9OuLnyJkKDehO0t/jUaTwh1glHPIIzknkcjNS3OPLG/bt6lT3I7j370mrrQ1g1F6lbUZAwZU5LKRgf0/Wk0gtb2RkuJWeR/mYnse/T6Vm2lyouZZC5ODswwwcdsf4ev4UqXsReRXmWNGO8ISF579f881KNXFyVkX77UQ4IYP5Q+6MfeP+FUtRm8nTw23a6MJGYdiDuOPbg1PbrGzs8jb+AVbPGD6Vl6o26OT7P/qeEZc5XLcHnscEmhu4KCirI1pJ/tDrHaTK0YHzFPlx/PNILPzVV7ggbeFx1/M1JHqWnrblhMiPnBU/eB9MVTudRiaNQitOxOFUEc/h/XFUZ2sMnhtHnVI1Z1By2zLfhUsyKIvmtZHJGPmIOfzNJpkbIp24JHLbgQST3NW3nWMHcAGHvwaFqRJWMWRXCiQ27OyEqy5zx2/HGDmqF7KJSIpY5I0I5PAz+OeKuz3lwbm4SGPbuwTjlun6dPQn6Vj3UUsSESwMxBI4IHf15zTsYNtGJrFupBiCsUxuLAZ4H07ZxXNT2ubsXCHJcdMH5eTz+PFdFeFrMSOpK7lw0bdPbHcc0ktnEDktHGqDaA78yegAHJ5z09s9qpJ9DLnsc1eK1vcBHRldlG8N2BwR+mK9V8Kzh9GsgsgknduVLBgozhRjr26V5HqAlN/Ik24FflO4859663wj5Eltsnl3KWBKnJHoOPrWiZLVzpdTR3lEUMckkxGTGi7m6ZyfTjmuQ+0reTzl2HKNkA9+g/Wut8x7lHaxTZaqSF2jaOODwPfNeL6tLcaVrN0sRaLZISEzwQTkfXjFJzVtDahh+dSbdrHWXEcDm1eK3jshAvlsJW3AkJt35xnDOCcdt2O1cdr1xHc35kiRow/8LdRg4x78jFM1PxHeXq+Q7nyVQIoPPyli4/Vj0rOhU3V+gLhGfA3MTjPvRLfQ6aLSS77HU+H2AS7RWd1XBR2XDAcgZGT27c966nTLg25GwkKSGCjgH2FZOieH7i2Pm3XDkY2BhyPr09DWybIzAxRcopDHPBx6evY1ne4YlxjO8XdG9b3y4AJDEn7oOcGtu1uYXRItymPJ99p/w9q5yzHlIsSrjbwARyK17WKNsyuq7m4PUfQ1HUylqrk1iVhZIGdVYAY56gZ71tRSc7CD7eornlEc7tGwYqjkdMn17fXrWmmn+VHuSV8kf3s4/PrQjNlwxgIAOJHzjH8P+R/Oq0Fts1GZ3AbCJk9c4J/xFPklkURgKGmHIHY8dfYVbg2RxZmf5+cknH+f/rCn6FRdtx8hRV+ZcAA/jWYtxG0YuWJJZcqgI+6fxHBGam1HzWhWPITzTjHcAdj3zgdKh0awWRtxVjFGAqbjx0/TrSsXexGuqFD/AKmYKOGOP1AANV9U1i3ttJlupJV2hd33++M455B9sZqfVoJJIWhiBjlBDK4faQOOnHPf9a5XWjJfa7Z2rrH+7bfINoyyjoDxg/Nt600jojFNXO2s7cOoaV3aRmLEN95Oc4x071rxRQOQHUZJ/i6ms7S7tbbIuWUt383jP0xRNeCXckIdVznnNDRMX0LTrArbdihySNuKzxHEGkuEISTdsXB4AHr+ppl9a5TzAXyw4yWOTj8zRb2M1jKjXW0MAB5bDBx7A0vUt7XuW7W2fy0wrZyeWAwR6j179sU6aLdcNDA+xP8Alo275voPfn8qd9tiPMjSRhQSQwIxVC11aNbdEhjnlJxIyquMueSSTx34q0rmcpM03jSCJShARRkjoF+ua5y4uZ729MqhRBEdqk+nc/U8flVm9mur0N5gSKLH+rDZz9T/AE4qOO3aK2WMuoTvg/p7UMUZWepXa8XcsECDeflLdQPWqeswm2SOS3VZLpmAU4Bz35Hp61rWoiQkCJRH18wdMCuY1vUZWvxFblB5qlVBP3B3Y46ZpxiVKWvulLUrma33xvIJH+8WhXG445JPJ68cfT2rHkHmEGeRVb+7Iu4j8zxU0IILPJKZLhj06KgHT3J/+v8AWqV2s00gDMdqDaCpAJ9SeOtWNHqMnjS0kMMUdq6rIoVm6gZYHnr6Ace9bWkAR+fJbjZ5j7trsTuGMe9cC+kJBomn3Rld/OVQUPQZ8wcfTg/UV03hfVGv7VHlhTl9vqc4HOf8K7McpTalPc+eyycYpwhsbl/cIf3bgqVwcN1Hv/n0pkcv7+NbtWkLOAGDcgjnH6f5NTai8bW7I8QJXjIwMgj6e1c68s0A80zyElVICnGDx9e+OnpXm7bntJ32N+9lG1niYuQwCBhhuvP4dOfaklmeWIvKPLbrx91sen5d/wCVPjCCBJduSyB+TkjvjJrTnjRgIyo2uu4gjI7VdhXs9TKNus9yjEkFhtcA+gyM+3f8RWZqFrci4DwCI7Tkoy4yBgcc8nFOune1zLG52qACh74PHPXrW4DviD4AI56Vm0dMJ2VzHBunhMgS2jgAJIGX4+nGPzrO0/ShqV0XkuJniU5ZQQg3e2OSMHHvzV2+kNtcR+VkHliM8HBIHH4DmtVF8pTsAH4dKLFKctbEDada2EwkhU8/ICpIJOOOBxU5s4pG8x8tIw+cdwB2BPNNS4JALqGIIwfTrTYdQ3uw8oAfXrVJWMG29Sq0s0UwhMYDgFo2fqR3Bxx+Of5VLHGbyRGySo5zjBHHQf5/Oq1xM093DJhVAJBXru7c/nVtCY4ZQDxkdCRjP407ESloTQWscQlOAqbuoOSeO/45rMkiSSaU/eG78OlRz3ZjVkRSGX+LcTzWUslw0Jkln3IST5YBAOT3596b0Rz76la+toL6Vt23yl754z+P+fzrkLmZo7w2kTOWiXCAE/h+Qz+QrummL2E0iIkZTKgBeK4y3i/4mczsxLEqWPc5BP8An6UJWBmK9iscmGDFiep+v/163vDCokbFFLzhgUycAYPPT/P5VXuEElrKzfeViVPpyRV3wxiIyHG5pEbk9uOv1pq4HaxRLDZKigDCivPfFHhW2vb6ScSyKxHz7eQfz/CvQzJ5jbMBRtB4/H/CsPV2zEwAAPAyKlNbFwk4PQ8ci0hbvxFcWEO1QQAhYn5en9M1LceHL6zMkhjzHG2D3OOu4evFb+kRD/hLb6QfKVMfQf3q9LsLWO8svMlAO9fmGPTof1NNs0jU9mZOkMwhhZwG2rkcZVh7eo6fhVmOCMzTNCuFZwxHpwP65qgF+yXHlg7vLbhuhOR/9b9TXQaeiyyYIwSmc+4P/wBepuZszjC6tu4PpzyR3qZLkKCDw56ADJP4VY1NAkSmIBXkwQcZC59qzlLW0LOhDMoySwyW/Gpe5pGN1cbY3N1JqNyIIkEbbXYyNyG247ey1twXeoNIsUojZeQu3dj6dD3qpGi2c1vIgJ3Lt2k8ckc/pWynyphuRycUIqybLA+UBjHJC6LkMBuGfr74FWIZIpYlkOGVhgkdvaizG6NMcZLdeTxTmbyZpI1VSHwxyAex7fh/OmiHuZl9eLEysRu/feWMdTlePbtUugNK0CkKpAG7G7kDGBmuQ1i9kg12C2XOxnSZcn7rMQpz68cdq6fSZ/It7liociVlGewI3Y/DJFNauxpOPs4KT6ly5BN0rRk8LlwQTuzxx9M1zduYDr93INyNEqnecYAYnAIP+6fzrf1bUGhsA/lq+cDDHseP61Q8NeRdSec0JDsqt98nHzED8fm60eRSlpckeaUw5hQSB+G8zGD+B5HbpTROYlVtqpkgABiD+HOD+vtW1eSCCKeQKGKKTg96yb8LC0KIo86chTKeSufQdh7CkVbS5LBcz3UZdU/dgDJKHgnt1FOaUqQUAaUZ+8OM+/GBVa6823mitUl+UlxnGMBewH4+9FnaLN+9lYuwbaN3OOv+FO1wSshHu4JYmBljUsOTu2qT+PX8qoW2sWx2xPNErKAjMXAXgY4556fT+VaSBJ4Q8salF5Cdvx9awNamW1ZbqOJVEp2lE+XnBwcj6VaiQ3qXZdUs496rIhOOCWGZDz+lV11JLshmYMq9VUHA9j61XtrFi4DXDlQAQAMDp+vSrUKBEJXIUYIXPuf8KdrohySZMbqEROztv/2EGT+OK53U4P8ASZPN/du6ZwOp9T+gFb0sgjtI2VQCznp2wcVxN5fz6hflVYQsyZ3DkgZIx+lWkZubWxFeTFY1+yRuqqNksnU7vUZPt196yktBJlriWVAT8pJBY+uc1HeyTi9mQS7RGQvyoBkE1o6FajWRcSTSPGVYEbSeh4xx6baT0KnV9nHU/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intra-operative photograph shows a cutting seton in the mid-line of this complex anal rectal fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bradley J Champagne, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40788=[""].join("\n");
var outline_f39_53_40788=null;
var title_f39_53_40789="Mitral valve disease PA";
var content_f39_53_40789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 343px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFXAVoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxDwdbM9rIQDtBTPHtXQm0kJYspHqBWt8KdCkutMnmFrJMpl28KSOB7V1D+HJzdSBovJVj905yOfSgDirKNoVxjj8asSW32m2J2nrgjnGK6W68OXIilljxKic4UEMo+hqrYIbcNlC6nqhoA83k8EwmdyvnLHxhQc4qnN4NVSSJZV5xgivZFUSMC0ewE9vSo5dFguVYqfm7HcaAPFZPCTL0nYfVP/r1EfCk2SBcDj1jI/rXp2s6ZJpzEvA8ikZDLnA+tYElzGzkldo9KAOQbwje87XRh67TV/R/DJty8l4dxcbV25AXnr/9aulhvUjGPN4ORjmtPZFfoIoJI1mH3VYkZ/GgDnJtEuY4jJb4mX0TJb8qypopI2KujIw6ggg12H2W/sZ8ESo2fcA81oDTU1GMfb4sSf8APReDQB51ubgc0/ByCche9dVqXhO6tU82FfOhPRkBJH1FRadoM88gAjKj1bIAoAxYIWdwFVsnpxW5psTx7Sud/Yj0ro7Dw9FDs8xSzdyM4rYttFEXzLCqLjqc8cUAcuIpsZCux+hOKrXbyyOYnDkj1PIrrri7sbdnP2leB8wUk1kyTaddyMwJEmMhlJFAHJMZIbgMsvynoDkVrW+q3NiglkaSMA43DPGT/jUGqWGFYxsHAzgrnP4ireh5kaNGyVPbuOaAOl069uLiLkkt13KcZq6buFAq3NtI0wP3nkPr6VNb6Wi25ePcQRliB1Oe56etR6pbvGiSDaxHA56DtQBJ4k8aPa6Dc6dEhieZFZShxwG6dPb9K8a13WZ76RGuSzsq7BuOcAV0fjCeYXUeV48vA468muHuxJvIdCjDggigCaxlUToYkKODkYOa7Oy1SSKLDPIzcnGfauS8Pp/p8Y2568Z9jXo1joqyWTyNkKw3fhQBVTxBcEHa8gU8Yyajn1l2Y7ix9y2abNbpFlI4jx3Ymqc9uS3yqWP0oA0IdVlDeZucd+uOaYl/HgeaHLddwY5qmbKZtgO5mOcjk4/Cphpc+R8mSfTJoApXRJYmIlkJ/Hr3qlJHkDKnmuhTS5YyTKCo7UXWkuyZjGRjJUZOaAOTljAGcZHpVKRFHGytm4t2UspB645qGHTp53Agidz7DNAGSkS5Hygj3WrCW0LqP3K8+1dBb+GbnerXTRxKeepzjHpitm20rT7dVAtzK453Oxx+VAHCXumx/Y53WDOEY5C+gri69r8Qk/2ReKkaoohfpn+7Xip4oAKKKKACiiigAooooA+n/grqT2fhqeLGd9yxyQfbNegQXNvJcHzFILHhsHGc9K8z+GKf8UogA27ppOfTn/61dTattnG1QSQcnPTtmgDobqzNlIZo4/Mt5hyMEcHrXEanpP2KceW5kiIyH24xz0Nd7pFwQjrJsctjKnkZxS6hpxuiwtovNjK8qSPl96AOBgjLADJ46jtV7SLcNfJu5BPRunTinRWM0UzQyhVKnnLCr9rDHBKJDJvYHoF6e9AGzFoNpqUTQyRiJyPvY4/I1wHirwDBHcuihreVecqOG444r0i1uRPIDHtEo4xjGa0NWjS707bIFEylirHqOOmfSgD5q1PwpfWrEonmpzyv+FURpdyrqQkytnupFewX1vKQEjVS27kEdBu579hmmfYQq42gk9RigDgdHn1G0O0lp4TjKSgsAPQeldrolnDqqnyR5c2ATCw9+xq5b6UsoPyhVzg/IM1s2OiMyr5MQSNernA/GgCOx0B7RyVDSHHI28flU+paNpUIzcuLOdsE7VJ3deo7VJc+J4dLRbcnzVUbWlVcMD6VzV7qNtN/x6jejdCBk5oAydX1N9PlIjtlVAQNzZOePWuC8QeKtSumeIS+XFn7qDGfrXbajqsr2rCRFdOwIxzXnt5pqyuxicgnorf40AYz30w3EknPXiq76jKDwcfTIqe8t5YDiQHJ6Z6VSkQsQCKANOy1qYHbI+VI685rsvDc6PcZjOJOoAHXmvOWjK/dHatXRbxoZ1ViRjoaAPcdPuTLEbaULsKqTkEZ6n+tTT2sIwZt7REbtmevPrWL4K1FLiVY7pQ0mCFJ+nr3rqdTl8uAK0SqB04zmgDybxdcQyar+7gCtEOCSTgg8frXG6pIJpY2mG5yoLN3J9TW74pugbx2b5CTxgdq5eSRGlzndmgDS0K1jN0hEgH1B44r0PS3S3jjWaZ2jCkbRkZOOB+dcl4OiWWdgE/4ERnFd82nwRqryyZCpuxt/LJzQBmzxeeGdVIz8oH4Vj6hd29lGyKxe4PGBnj6mp/EusBIDFbhQhyM49ua4O6uHaTK9uaANK71a8c/JKY/aMkUtnrl9bMrCYsw/vkkVhF5JAM8+lIsUjNgKTQB6n4e8TJeARX+1CejKvH411h0wXKBreMvuHBiB9a8U0+Ag7piVI7DrXofhTxbcaSixQ8RggbTzu570AdJJ4FjlAmuZsPx+6AwT7E1FBpr2u6G2thCo7Bck/nXUaP4htdVwtxGLeRsYbHyk/0rYv3gtUUxwpcTbRjgbfxNAHnMuhzzEvIwQHqWye1Zz/2XaErPeGSUfwIhOfx6Vs6/aXOpFndvkzxEowF/WucGmtGT8u4joelAEPiLULWTQ9QSGDBEEnzEkn7prwjFe9vYpMssMigpICrAjggjBrKfwbpnJ+wRAYOOf/r0AeM4pcV7lo3w80++lZfsKYVdxPPA/OtSf4c6GZViXTo1JOMhj1/OgD54xRivbtR+HOnrP5cNrtIznDf/AF6pL8OLd3CrbnJIA+fHf60AeO0c+9evD4bwu21YHJ/3xXTQ/BiwMSGWZkk2jcu3OD3GaAJPhxezW/hq2AjjkQtIfm6j5zXX2Gr2YmAuomQH5d6gED+Rrj/h9FHL4UtlVv3oV2PHbzH/AMKvGMLc4wGOQFUEc89KAPRktNyoIwhhdQVZeh47GtGOZVVUjDBgB06njvXGaPftpkxC8xSYEiDB6dMV2UbpOqTbsxtjDLjKn0NAHO6uySXrMAFkwMfl3rIe4ZWIcAMOta+r25ubqU223zQMkDHzDHXFUvs4nttrptYHGRQAy3u5Fl3IcHit1r9/LKsxCqMnNZcWlvaB2mQq+CUG7OeM9qhjMvm5mZV47kcUAXYIzMSzLyScYHvVyDTXnkOzj1yM4qS1iEzBIlJJ6f410MUUUUG0EBAPmd8DPPUmgCpZ6ZHERvXIUccZArmvG/imPTI2tIsCQjkLjj9ePpUPjjxomnxmx0iX98w+aYAHv2rySeU3Lu7sWkc7mJ7kmgC5fazNMCNqAE9WG4j+lZyahcQybw+6Mj5kzwarzK5cqV4A+mahEUgIHGCPUUAXL5zcxLJCCQCCR+FYcx2kgk5649qvLuUEggfXvxVYweYBsYFup5oAoSyuybQ34GmfL/EgP0GKvGwkB3BeDVaaBkY5Ug0ANNtGy7gex60sFm+7IGSPSpPK+UZzn2NaGnL+9UEZHfigDX8K3hS6iilH3SCCD2zXp+nulzCUuJFURjILd+vWvONPsY0mRzkbuRgD14FdBdzGLRWCFi0fBOOuT/8AroA5DX9NhkmlkmlUxgf8sxnvXICyAujGpDc8HpXdIi31vNnliQSOB/ntXNtZL9uIH97saAOk8HxG1jceWCoPLHirWva2u0wooOQOR34qnGFj06KKJtxL5I44NYzAyPvdsk0AUtQaSZzv4HpVdbNU3ZAY47itloBuPmYPfrUcuw5CA4HODQBl+TgYCKB9KCSvKjaPYdavysTyu1SM9hVaRWxuDdeDQA2Mk555rRs5jG67hnHYj3rMCEAOWxxUYmdm4ZsA+tAHXS60GxHFkcDkV0vhXxFLZuI5CJ4W6q/X8PevMVmYY3YP1GDWlBcqCgVyvHRhx+dAHvUKWt9afarUYU9VPUcfyrLvrKNl3IoB9AvXiuF8N69Np0qSByF6MOCGr0+2a31azW5sSN+MtGccHHagDk5LZWJwAGB59qZHZtNMqqDjOMYreurQH5wpD9weM0W6/Zyp6dMnFAGpYxR21uIYURc9TjlvqalEUa/McFjxnHC+496qNcwsjrnnJx04p1nOABkqfmGQxFADLiyAy7KNx6Nt6iqbQPv2lR6ZHetS/vo0hdQcnOFC4OKzbTdcS7VOT79qANfSdOKsj+UjSHG0FRx7106w4A3KCe521Bo8qQ2IhlO9ugfv9Pp1rOd5N7ZDk55wtAHlPw9lZfB+ngEKF3nPc/vHrWtoSJ2lJ+ZmyDnoDXPfD2TfoFjEWwADx65dsfzrrE2ibC4Jxxg0AIY9o3bhg/pWl4b1f7LdrZv8wn4VSe/NZN9fQwp8jK7YwVD5xWZp8rNqEVxM671wQRxj0oA7t5rWG5jjfdvQjEinG3nGPpWmksTFppECyDAEo78d6xdPRLq682Qgr3PTjHNUNZ1qS4maKLatoh2ooPagDZ1WYXK7BcxsADiRWArKh0+7iYlwJlwfnQ5/OqEE4KqPlIPPJ6V0uiwsM3CtuXlUyeVPHNAGzotr5ULYGJMEMc8KOpFYPjDW3W2a1tyFjBwTwc4PWtzVNQa2svIWTB2nczHOfavLPEl75xcIw5JGPxoA5O/lE968krFiWz196iidFG4MAFIyM9eaguFCSZmkC57d6py3u35YlUY6nuaAJh85O7P1JwKimKLysqhvY9KptNKyguST069qhDnIANAGkHgdAxfPPIxUEiw5ASTGeRkd6rCTBwOcVJwQJFJ/PoaANPz3WIxTOHAPDA9PrREjiRiCu0+vIFZoUyQyL1PXr1q5p9zhPLdgAMkZPX2oAnazEob5MY+8c8AetPhtDhnByM4AzyanF4h3quBkEDnpVqCQzsUGNirlccYoA6TRdKaWFHK/Nw2c5FV/EtnKtkZIhtVGzjPWuh8GkLCscxCgdAG6jPSrvi67bS0W2VI5I3USMe5yfWgDyOymkSR0VNjHAP19akSAr5kpzgEZI75zXf2P2G4jj8yCJGnAwfw6dKpatb2kIVVUc479f84oA5CaNRChDYG0fyrOaKIRlCVLA53e2K2tT8uN2+YkHGRu6fpWSbUNGT5mcD7vTigCAuu4jn0HNMaJy3yKcE9KWMjz8KB8pyKuSOxJOc85PNAFWS0Zk5I4yfrUcUKIh8xsljzz0rQDEbiWUDk/e61RDqWP7xR6fnQBVmhd2+XhR0+lRCzMfJ7+9bsUcX2V2aRC3HX61RwSzbXXGf71AGaYvmwRzU5XkcgHA61ZMTs3PQ8k+tObYRhxnHvQBFBPJABtbjuDyDXY+D/EL2N3G0Uh68xE9eOorjZo1IGG569f0qBJHhbhuR79KAPplZYr+BZoXUt2Kng8c1QvbMSIzp1/iH9a4X4f+KXZvsl2Qd7EhsgAnH0616NcMWBkQncv3hn9aAOWI8hsMx2nrjtSESwzAZyh6DNXLyYiRvTnB9as2SBQjT4KnJHtQBQWHevmbiqDsTWppKDy8jCp0Hv61e+ywKVmuJgFYfLHnBPPekjJ/fiOSMltuChztGelAGhprxkOkhCdGxuyeP5U8anYqNoLkDjO/wD+tXnev681vILexICLgswbOeelVE1lSilsgkcigDzjwrqs1rZQLFNIoC4wGIHWuz0++luR5hllUsPuhiR17V5lpZP2OIDGcCuq8PzSCN1JORjBz05oA6xtiIOJCxPJxjA9qfaKWnVthGOBn6VkLKXdQc4AA5JrZssmQKMgYAxmgDso5Y7TRGKtmZyBxngYrkZJczhWzlskH1xWpNMRAI5CwO7PtjGB/Ws3ypJriOWRRGke7aoOSSRjJ9sZ/OgC5YxNLIqo2c8DBz+FdxYBYg7RswihQ9zjjGfzNc14fgHnu+zjb8p54JxWz4gmOnaMtuAPNmLZOTwBjP8AOgDI1fVxes4J2MM85OPpXnmu6hsZ44QcnPz59fSpdb1cIphg6DIc56mueuZnnjGVPB+9QBmzyyM7NKWyeM96rgsy8A+4qzIW35PIHB9KQOHQhBtA9KAIE38ggjA702VCsmRgDGKmdwMDGfeoQ2DkkYPbNACIMk5JJq5aKpDIScNwfTpVPd5fGflz1FXrPCYbtnjnGTQBf+wi3h8wsGLjpWc0ErEunbqe1auoXEcZRhnaBg46dulNJDpiMkKelAFSHcS24Hoc4/zxWjocjf2ioJ+VgQVzxUCKImYEDGT3rQsbXbcRSQ7sk5xjrzQB22jnyfMfJy5BAJzgDsDXP+IdRlluXV5JCc4G8noDxWz5q2umP5rYlYAqRn5a5PVX+0SMWw2MY5OR+NAHRaFMZntUwcRlT0yOvNP1R3Nyzqo+QbeRWX4YExk2IwDMyYLHlRnk1rayht0aQvuVmxjPPFAHOa3Nb+SJX5kLjeMnnisiS5ijUjAJPQe1M1y7jDbWyADzjucVkec0vbPvQBZklPm/u8AdqdHMC3zMyj2qDYQhcdOnHbikjJ3EGgB0jsWcByevSoocrJjjJ4q0EiKk5O4jnNPtokddwydv3vagBsGfunnPQelMmVslQCo9auDylZdqncenWo7wbRuXk4wQDyKAKLzPEmFJUn0JFQrcNjLfOD3PWnyvnJEYPFQOSRlupxxQBKJQwwrfUHrQpOAGGR6GqZYqRz09KninyuxyCfXuKANbTGaO5V4mIIzx36V7p4Rv01Sw8yVx58fyOpOdw45rwi1DRNnJKnjNd54H1UWV+GdittKPLbk8ZxzQB6LqEdpaSF0iM2QWyTgDHbFZg1YpJ8oRQOhU4IrQ1RY/KkgXOQrFR3Jri5vMEnzHkHjJPH4UAdTc3C3cLbZGX69xmqVneC0kYo7FduMZrGtZXFyOScnnnHerGoIYlLADaeeDQBhTxCRunOcZI60LbKVB46e9ErAsNxIx3pgaTA5FAHnFgn+iQkf3RXSeGwTPsOcMQB6554rHsUP2WMH+6uPyrW0oFJEk9GBwB70AdGbURMzY6n3rX0iItOnbp1qG6AJVwF5API6Vb0dk84AEAdOo60AW7tSbmQL8oU4A56gf/rpBCcAdc1Jc4a9kOernIFSwJl1XjPpigDpfDNrtt3nbgZ2gH14rnPifqL20sNspO7YeeQRmu70+BIIFVeVjUliO57mvJvHc32rUpbqZPnY4VCPujAx+lAHDXoG/Mm4k5yucYpERpR+75GOg+tLfpn963yoRnpyfwrPkumkbEabU9P8AGgB9wEiLDO584244HPrVUyOsZ2gLnsB0pJAJJWKtznFSOgSAMxyTwB/WgCiZOhYn0qPfz3GakkXg4HQVESSRwMAAcDrQA9WwQSTjrV22kwRnBUnJqi3ygAA+tOif5CCODzmgC7qNwCpIOSOlS6VqBaAo3J7Vk3BLKR26020Zkc8D6UAdA0+H3cY9RXTaU5KxF2OMALn1z0ri3DMoLLj0rpfDEqTzWiEncr4P50Abuob0iWPeTtTce+DkmsqOSO5BEqgsOAVyK3vEYIuTEqqGwFz6j61zkCYuwEXGD8w9aAOt8M2m2ZJPLbG4Dp0Aq94rtYyywwoWKnJPqee9a2iaW62trKvKqFJ+XPPWr+o2HmqZcqWAxtIHzUAfP+uAG8lBXgMMdfSqSSBI8BcfhXsV7oenyTsstnDz1bYMg4/yK5HXvDcEYZYk46hgAO3WgDj4rn5SHOR3zQZAOVJwc/lUGp2z2r7Yz5ijqQMVWjuMnBHHpQBoeeqngk8dKtW1yqByCygjnisppCDnj6YpY52C9jk4oA1/PRcOWOQeAR1OaheZpgxG0Z54+tVgdwXPQdjQ2QpAAweKABxtOSf501Uy2XPBppRlw3QCkaYlRvQexAoAidFB45PrTPlVuSQ30p+N3zDn8KlWPYPmGTjPSgC5ZXAiGxyCp7fhWva3Lxy4ONp+vSuZkyQxx9TV7TZwytC3B6gn+VAHuFreNe6ba3nUsvUDqQcViauhW6fAwCSw+lSfD6Q3OiSWpGTES6n69qua1CSiMVOeR0+lAGCjkNuU8YP1qd5nltVVmOF4x+NVTgMBjFTwqPs5IHfigCjONzk9x1oT7oypzj3pWjDSZAyf500QMRnKj2x0oA4qzGbeMgdEFXbTPQf/AF6qWSgQhcjoOtWY8heQOvFAHblt9jbsOmwZxVvTIkkkVZBlTjOcetZNm+bO3DE52rx0rY0pT5uep7ZoAu7N00jHnkk5Fa2jxB7tSQOBnGPRc1jxAPITg5/Cuj0OIbXyMnhev+fSgDfEgt9Eu52IzsKD8s1474kbzPNnkwABkf7RHYV6x4pP2XRo4lIGd5bpycCvDfEV4JrmRAwKJ0A/DNAHNXs7yTF3PPPA6AVB5zDaQAcUtwrF2PY+1OaHdGuflbPI4oAg3HduAGCc1ZZWktwdvzE1H5BVScfjUlvlXwc80AQCNjwcA9qb9mJOex4FXL2FoynUAjNRWzfMikjr1PFAFaeIKMEHn0ohgZ0woBxzj8KuaggE2ARt9jUaxBSGB4HbPtigClPDtXBPOPSq8J/enNalzGDtGMHFZ7r5bZ4A5GKAL9qCy+XjJ69a3/DEUkWqwoAN27JrntJcfbYupyentmu/0qwVdTaVVIKg4wKAJ9cnWcyEgeZ3z9ar+Frf7TeFXCsdwxu7cml1S23TsVzuBAJBGOtbngrStsolkDDBBPAoA74bbax8tUCldvb61XjkZ12Mw+YA8+tOvVGxAGPzVDawFpVQNnAzkHpQBi6nuNwQEwueCB0NUNXCS2Kxjb5o4yB7f410euWwijjlHQ8fpXMXMio2UCkjuRnigDiNU0hhJIGQEjtjFclqFi1pKGCgo3fFevzobh8nALLjkCuU8RacvlSq3XaSBx1oA4aRQ/JwuKUwOoUkcE9hTUJLuh7Ej8at27fwN60AS6avmZUpnB604RNNciKJc7OpIwOtX7BVErbl+XtjHNFpLFBfsJFPlynG7jA5PWgBNT0i/t7OGaa3K27puR9hG8evvWI8ZJAC9uuK9DS+UabNARGsDld5JBztJxtz0zntXE3CIxIX7o9OKAM5FIYZOMd6maVGDBhtb1HSmNxjaOQepqs5ILbe9AErEKcdcUQ7o5xIMDnrUCSfMVbkevvVmIYYL1z0zQB6x8OZyG3YAWRe3bFdhrkRFuHPCsdw+n/668/+HUjAmDJyn70cdsjNeiayQ1gnBwG/Q8/0oA4uVMybiB19KvtCFgbAGCBjFVpFHngcfeycHtV12zEdpPB44oAy44dzr/TrUrvEGIKrkHmpolAbjp3rEnf99J0+8f50AchZvlOvUDpVsex4PNZ1o+VXk8c/rWxbgSQ+Yd249qANy2OLe2zgDy12kH2rdsZMOp4x0yOM+9YMDYKKTwFAIJ5PFbdqMoMkHjnPWgDTh5dTu5PvXW+GUwnOSF+bjtgcfrXKwDEancDkA/jiuy8OoFtCRjJIHp0FAFD4lXn2TRYlHLSK49uQM14dc/vZSwwT1+letfFSR5pYbRCGCJk56nIB/wAK8tkhMPAwx74PX/61AFVrQBQT827OPbms+SLEu04JHvXQGIpb7pZFXrhSeTWFeXRk/dxqEAGM5zmgCN2EaEZzn0P86gWYx5/DqaiwwyM4/rRsw2C2QPSgCxNKZIxuYlcAYJ6VAqgMuWz700vgjpgVaslWWQ4IzjoaAIyDPyW96evTByRU9pCVkIGdp5+n1qU2ZUckbepJ47UAVJCcuvBBHFY12WMu3sPU1p3EuJMDpjGaz7pf3m7eo+p68UAXtEws8Z3/ADFhwenWvY9Iije5UThtqoSApHXPWvEoAY2UZBPXg16t8O7trrUzDOwb923OeDyM0AXr+xVpJkiYkyEDqOOc1qaErQOsJJAUhar6gBHcnawCk4+nPelsrzypkVmQtnn5sHrQB11wrSKASxxjj602yUI/znaABg5pZbnEEYR1OVXkH6U0TBxjHTk80AUdavXjaWLIK8Hr14P+Ncbcy/MF3KQOp/Ctu+cvJlxkFj057VkG3+8QhHJJ5+lAEbyyR+WUZc8jrms3xAJHiZidoKknj2rbtYlYAEZK5YsTwBisDxPdn7Kd20Ak4I4oA8xuMreSHOQGJ+tXY5PMAYHaRzVO9ffcPlskk1d0yHfhGOR9fegDY0/zChdW4Xv1zUck4SQZGWJyfepxKLez2xEbm689PasyQgqWP3j2AxQBJLdo9wCpxjBx2qCVnIyWyfXPWqrD93gKRJ3OaWJjGcjk9dv+NACurSDHQdqidG2fKcj261bVxPyzBG+tMVNrbT1NAGZIuGPNX7U+aNpbLf0ps1v8rODge9NtGMUu/Iz6Z60AekeAnKazbRsRlsx/h6V6TqmHtJFGOme3rXmHgzP/AAkFk8Z4Ei/jXqGoIwlmXO0fMo/OgDk3QJKxDAY5/KnoxMJx/F6d+abcAopPylj0poYeVnHA/WgBIjhxyTj04rm5GBkblepreWYHIwAa5dnUsTvHX1oA5u0b92MDk9639MUva+WOuccVztid0Ssp4Poa6TRm4XPc/wBaANYKCyY4xwf/AK9atu42EAEkdwazo0wMMpIzlRnGat2+SpXPBwOhoA3LGYSRAZJOff0ruNJ+W2gwcA8nP+favPNN3CeIfw5xXoVgCLeAc4A9aAOe8erjXpy68bFVCeOdoyf6VwGp24tGkuOkePlB7V6H8R4wNYQZLBkAAHrgf415p4iuck26MzLFnJz1JxQBzeo3b3ErSE4HOFzxVLa7rlUPTkVLcqWU8DnPSkhjfYoZ9o6cHpQAxQd6F42Cnrn0qa5tl8sNCDt7j8akhjl8wbcuAMYIySfY/wBK27fTLryA8seA/KKc/MR2HGM/jQByi27+o5HUmlgJjIwfmHGRxWpqFk8blCjcHkc5FZDDZKu4HGOmcZoA0gcyowPUDIzitPWUSCwjQE+Y65PsCKl8N6Jc6r81vGOOBk9e9Utfglt5fLuAQyfKd3TigDD8sNlmUgdB71UuowX2jqKuTuEJUH5sdumarISZMuTk880ANtIzJchQCT2HNesfD+zezElyflLgqnXsev6Vw/hbTxeaptjC7VUtuboK9mlsbSwtRb24HA2Akk7ieuO/c0AchqN008jFGYnPOD1JPWsxp5VuwSWDZHc9K3XtBbTO7MCityBz3xUN/aNLexSxAbCcjPWgDY0HUTdKsLsQdoxk5z2rbtpdzSKODyTzyRXEacrw3sDEFcAZ46810+pQTmFLuCQgbQrBTznnjFABII8KpA2g85zWfM0fmFNzlF56nk4qO0uvtEyqzneO47//AF6lvISHB3FyTkE9qAIwjumI8on93dnPFc540sJ3sUmjV2jTcSPTp1rqbaJmyBkDOa0BbRy20kMoDwsCpBz+NAHzlcq/nj5GJJPH410GlW8kMO24iZHblSQeldN4g8OW9lqBaCMyIWIRRnk+1PukS4sGZsoYDj5hyvPQ/pQBh2sQkvIo9jAP0LdByat+I7fT4IY1tXVrhQAxXOOtZ01vfBy6HEYA5U9MnikNu8YdZzy2OeTQBjgOT3zTSjKNxBGeBxWh+6gySpY+571HJKbhsMqqO2KAKYX5cjNWkmUoPNO49M1DMpiIVGyOvBqEEqnPBPOaALkqMSME7T2qCaPacgcd6s20qyAAgs3Xr1qWZOCjLn1NAHXfDkiW5gP8UBz78mvXNSQ7UkwfmXpmvI/hWhTVLkOPvQtgc84INeuX5H9njI246/jQBxt/zJgjP4VS5MZJJ54qzqTfOSBnk8CqZdvJyO/c0AVN7K3qOuK5p2Iducc+lb9wxGeeQKwZD87ZznJ7UAc5pUn7tRz+VdPpZ2hSpxhgc1xmnSEBcc11umOfK+YDBwc4oA6d85TGOegJP41YgJC57+1UFy0MTAYJXHY9quQAs+MDBFAGhprj7REO27BPocV6PopWRIM4yvJ/AV5nYn/SUBUYz0r0PwwW8uR3AGAFFAFP4i7Ujnu2A/cwt5Z/2iox+orxFWa4mbjJbJORivavifGz6FtXhnLcDvhR/jXik0QtZMR4I6GgCO5txGCqgnIP1NRQQZJPIVeWOcCte52G1WVxtZBkj1/zxWHNevKuMYQHhRxmgDU066t7a9hZlWRC2CCDgV3F/wCI1n05LQBY4024UA7Ex0KjPU9z9fWvKmZQwbGQBnFRvKzu3PBPQ9KANzWNQF7cvOHwMAcZGe2ao2tnA3zs2QfrWaW7dB2q1Yo88+5V+5g9aAPd/htbWMXh1JkADhtpPPXAzXJ/EPw+Lq8aW3dSpYZPrx35rF07XZbOzW3jHybiWPQ52itOKdtR2K7bVH8R5zx9aAOIn0URpI7nLHOB06VDZaX9qkO87FUZJrU1i4ijncCQHH8OODWbFPJM37qNR14HAoA6/wAH2UFkWkRwzLzg9Tz3FdPc6l57r5Y2SDpgHdx+Ncdo5ETSZ9QMd66K2LC8hleDcF4GehGec0ASXQTyiu4iZj6nOM9/0pYYpRa+YGY7W4A54zUttaPJLLLIvyFuFx2ycVLBJ5VykeMZagDl71p0vV3M+0ADuAB612Gi3Ky2TQTMMOOOp5FYPiGylSZJNoKlQc+vJxVzT0eG0jbGCB6dKAKMxNvfjkEjqRz2rdH+k2kchbaBwQB+PWuat7pXnVblc5ONwrsNOgEunsU5UNwMdOBQBShVVZk3fNnuvHStK2R5QfNJAx271mNFi4YnkdOK6C0j3KMAFT2IoAwfEtm0tuktsn72HLhhnI/WvJtevrppZoRlfMcvIoGBnNfRSWnmRNvQcg8Yrzvx14ejS0lu7aOPdCx3EIMtzzzQB5vZx3jWzhd7gDJAyTxVZ7lplCsQjD+EZ9eaf9pu5BLGj7ELZbBwD6ZqSS3iRcswabBHGOuaAMuaTGQCCAcc0wOJGAHDegqNoZFbGAf/ANdPT92ARjP0oAmZJETeV+YetH2YywmQHBHp3pkdyVXbL9w84NW4ZWjjzGAUNAEem2V3LMWt43LL3x0rSvbWaKXZNG0ZIzgjFLZahPbwl0Ubi3GR1/WrGn6nNqGouLqONi4+XcvcUAdL4GtjFqtk0ecSEo+M969T1h9tk6DsOpHTkCvOPCG6bWbSNT86yBgB7Gu31EuxucE46dePvCgDj9QlYyN37HFUi7NFgnC54PNW9Q2h2+uMelVSAqfMoyD3GaAM6diW69ulc88x3t161vz5VWOBjHpXMM3zH60AcrpdxlRnqK67T7giLHrivPdMl2uuTxkZrstOfKYBzk9KAOwsbseUUKhgMHpWvb3C/KxXgfpXJ2L4YjJ5FdDp6M4Vm5UCgDds2QSjKL1yOPau88MyqLTGAQxzyMc4rz2xR3VD1deMmu18PBhHDuzneQOmOgoA0fHip/YUYK8yBgpxk9BmvDNW8q0lPnLll/h9+1e8+PoQdPs8dF3jI9gOa+cfFzGTVJAjFowfk9+BQA8XDPudtoDAgqaqlQFzlMAnjvVaAGRBtGSOKese1sNy36UAOGxlIXkn0GKdBZSOWKnGOQD9aZ5bE5Tge/1q3ZCcTKE2E5AOTj5c80AQ3OnNGYtm0ggEitbSrCRmBi2g8Fsrx3pvks3IUZYA89c1o2kgis8RlUkP3icA96AKtjp0JvZf7SnkSI/MipjJx+PFWbjVAEjt7REVAepXBPHT6VVFkZGCyOAXI6uCcevFaVtpFrbXIn3iRuNwBzjigDntY02UylyvJGQOlSWGm3cMah12FxuUnrW34svra41EmzQRIoChWHPAHP8AOqP2l2LymVl4x+g4/SgDU0u1dNwMZZ89cV1cUTQzIJBwQPlA4rD8NXjzxIY41Mgzu4U9/Su0Z7ny1cwqMcn5Aec/nQBUaedIT+6Xyz2xVAwmSTzVBCg5IyPWtC9up/KcPErMByVAOKo2Nw3mAy27c8f/AF6ALQid3UvEJFODgrkc1al0fz49kOFkK9/6flVyFo/KRvI5wM5wPxqU3lupGYSMDOQRQBw+r6Q8Mj7QoZSA3tx61b0yeSzg8oNnK56Y6iumvZrOZQzplWOD0yOKqrp9hJGxjkkVsdDjHSgDHtb0LcMlyrcH5vb9a37LVYEIxIW5xgj29axNZ0XZZNJCQWXsrDOKx7SIwbWkd16nnmgD0pNXWRyI0wuMbuM1zWp+bdfaLYEGNsgrjg81a0O3VwfNlXHQZHBHFbaabDGWkiIO89v60AfPuuaJLY3LYwYtxO7gDOemKzPKeQHgYHf8a9W+KWjpDY+db7s/fP1J5/xryqJ1SxdC37xiPpjNADL4iOMBRgnHJrPZ/l+bqK0AwdSDtbPbiqoj2uTJgCgCBELKScgVZiuPIOdoPtjrUcrLu64XtioSUw2MnHrQBelmMvzI+E7L6e1TWheOSO5jBJVhnFZVvII5RuyUPBrbjXggBimMdqAPS/BWP+EpXAXC7myAOn+TXYampjSbcPm6fjuFcp4Et2M63O05aBRkevQ/yrqteBVpcj70n9c/4UAcdqAPm8joec1nyuNpHAGR1rR1AFSWHfnp3rMbncePrQBQunEcEhwAAuOea5Fn+Y/Wum1phHaPng8d/euRJXJoA4qzba4+tdfpMu6IHIznFcXGcMCK6fQ5iYyM88UAdbYuyzKxbP17V12lKxiZRgZz1NcXYycg+nSu30Ft1vnAAB9fY0AbukW5+8F68dK7Pw1FhkP91z/LvXM6WNqYUnjj6112g4EMjYHTBycf56UAWfiJL5fhGWRT83KD8RzXzvfWxuGZ2YAdevWvofx7hvCLBsNu3k9+w5/nXi7W+9GA4PYA+1AHHMuyRWQgen09auPHEQkiSgZHzbjjHak1DbbOUbLSCs1rlnfDEsp9O1AF5Fyeu8NxuzgVd01ZDKwRkREbkAZzWbDe7evDD7uD096safI7PlG6sCfzoA05C0rRqG6Huf1zT7e0kubgCEbXOevQcVd0uBZ5H4OVA5B4NO8PXiWl08hPPTPbNACRaW8Ega4ZVfGMZxnirEEjwl42UEE56+1XNRvEuLveGG09TuHHp9KntYxcRtGo3M2Npz04oA5WSx+0XYcngsRgHr0q/e6fEY1RwV2nHB+ldHeabHp0B3FJGA/vZP8AkVkyEySMyurPjkbsr/KgA0O3azuc27BVKE8nJHP0rrUu2OF8z5iMHnAP0rmNJkZppFkw5VTk8DHIrehheaRTwir1b1oAkWIs7DeSWJ+UnrRFbNFN8x+XcPx5q4lqS3mEfJnOfT2onlA+8dvTjPoaAEJdoQAcnjINQMCrHccnGOvY1dUZReuMc89+lV5EUL9/B46+lAEEke1CCwwTnrU8OSAvOMZ60pGYx0HIOM1PERtC8Z9f6UAOuI/MgJzzjjnrWNdadlVePoSc5PSuhEeXwWG3p6ipWiRI8EBlJ7DpQBnaJGynysrtPJzzmui1FGW2QwDCHqB1+tVbSJYrhHA5x04GOa3Rt8j5sYoA47X0WbTJPPIORtIBwRk+vavAdVMdtfzW7OGKuVAzx19a938Y6sLdWtIUB3DDOT3z/wDqrwTxDZu13JOCSwY5J5zzQBXWNICGD/eweDU19bs3lSDGwqCOetZ9jKQwV8MO3NaEl680aDAUphRQBVEBaIklQM4xVZoigwGz9DWq8aSwqWcKR3zwagMLKcZHqKAMsI+7qfxrd0uR3t2AOSowee1U5IlKjDDOOeat6AAdRWD/AJ7fJ+fSgD3TwUjL4T0eQkbn8xT+Dn+hFXfEs7eeiEjJ56j2rQ8HWqnwxZJwDDvbHp83NVNcjD3TH2HvQBxupSNsA4x61jtKWUAkH8K3NViJ79PesvyQEYn1AP50Acr4mmyAuc8c1zO6t3xJxcDt8uevvWBkUAcYnUVuaG+2TYf4qxYxzWrp4IZSOxoA7GwbJAyOK7jQX4RSSBx61wOnOd64r0DRsrHEAcM3OQfagDt7RdkY3ZI/+tXTaMrNbHaSdzfnxXMadNtiRHXeoGBnr0rqtAcsmUGFGeB6445oAseNYh/ZNtChJUI+4D8K8K1y7MMxhgLb0zlwcdq9y+IDmDRl2kh3V1GDjHGK+e9Xy0zMT14yRQBk6iWlYsHJ3e/I/GqLK6Phs59M1dkyYwM85OD61UdGBOc/5NAEaOMjfnPSpoJmhlLJkjniohC0j7e5xjIqWEfZnJY+Yem05xQB0elSzwwmUNIisAcA9/arVtOZ7oh0IQALkfSqEWoLNDAgATGOAM449a2YBhx5eecE47daAM62M8qurFs55bP6Vs6fqrWHyyhm24xj+tZaYhfCjaeoOCcVGxZ5G6ZYZw3rQB0Gt3VxfPujyFXt+VQxeYUEfllcHuasabbGS2QM4345DHJ/nV1bRdx+f5QcH1oAs+HbH7Q0kg7DGOv9K6iyt4cESMAemD35qj4fjVbaTpnPQVqMkRUFnwWzhR3oAUtEqsqMMemTWPqRjMrDzEwM8c1dungVNiFxjk8HnFZbRxyAuN3I5496ALEbho0HmqTgDjIpkijK4fI4GS1PEUYhbachcZ47/nxVbbHvGd3qeTQBYBVcbXBHXrinW0ySINgYDpnnrVU7CAyszHHKkHnjGKSwZsA4zk5zjigDYWXjBBPOcntVlJMKSRx9eKpK3GBkZ9OOlWFdlJGTmgC8GPUDODwRxxWrHILiB1XA44Ge9YKXDKoHYDoM8Vf0++XzV5BzxjmgDmNd01pPNlmUsAfu8jvXm2vafLJHJII9hB29xivc9TMYjfb0bn8c9K4fxPpb3OlSSW2PL4D5HfNAHgF1CbecZBx1+lTwyKqKNu4g5IrZ1zTpdrGRdr7c8A+vrWCj7GG76E9aANWGWOaHyzF83ZsnpUPPI52g8E/Sq8DZYbeH69Pao5XYk4JA9PTigCeR1B9+tT6afL1CGVTgqwOc9KoIxfKvnrkH+laGmoPNbcSOOuOn+c0AfT/hkpHpZGeGZtueOv8A+usjVZMTHk56dan8Oyt/wi2mSHPmSRgnrnqRz+VUNbI+1uN2AGPAzQBzmrSg9ADzyaw7if8Adnrgn1rW1MkZKtnPpmudmY57j654oA5bxJITdgYPCAZ/E1zpfk8GtrxI+Lx8f3RjOa50scnmgDAi6jmtnTkJwKyLccit/TY+F4oA6TQoGlnRQDye1eh2cBSVV5BAGPyrnfBliS/nFeB398Gu40+2LOGJJHagDY0yItGCSxz/ACrtPD0C/Zozt+9J6dqw9Ltf3aZ5AwOldfpsXlpAowQq5GBjtmgDB+JhX7KgJH3SR+leCa6Al02AShJz+Ve8fEZ2Ma4UEiMnH5V4frEJd3dgM+g6CgDBhglmbATp7dqlktFRj5Zzz05JqUTfdQfKRnnHX60/zRGoMgBcc8DmgDIuI3jJ2569QPeoJAyjdyBjuK0pmJJkbAUdvxqg8oVGUr9/lcjpQAkEywRpJ3U9OeeK2bPVWkt8RsoOeeMVzcr/ADZ46YFUUuXhlBX6YoA727uFmtY/nPnjGe3arHh+yluwJZASoOORx0rlra8N1CoQZboAfp0r17w1pbQaLCCmGKgtgDqRk0AMgtjCmCAGbvjFWVhaFFWQ5YZI4xx2rQ8kRDzJF+bkquP1qnd+YX+ZQSRnPpwOKAL1hhY22n5icgire4ed0+bBBYfn/Sq+nRFrdML1YnJ9K0VtmDFioyRtycUAZpjPzl8kfT/PtUK4DhQcAYzgHpmrsyE5zgYP9ayZsrNjaw+bqcEHFAGheKixMQ+AcMcDvn/69Zv35Ad33uDnt9anmfg5HLDAz0NV9hUDdnBwc+lAB5jxRkKCFJHOKdatv5UjIOM5qvM3mQhSTuVgfYUy0crKARjHIAoA3xM235PlXJOMnNKbhnbLMQfxxVSNsr8ox17Y7UsON528jrQBegdmJY4IAP5VaRcSK6oVyeWHas9VPBAOPpWgjfuiQOevT3oA0UKTQbZSQU9M5aua1VDGrR+aRA+MgZ6g8Gr0txOsodTkINpXHXmob+UXlrJtRQ6HBVhzQBw+u6UZo/3ewkpwu3nrXlWqWcltKTKpjbuCK9cnlPzRlPbI7VzWv6et7GQ+0yDkAL1GDQB5zHOY3BXr1FNaQlyWP61Pc2pikZCMY9artGUb5uRQBJu6Ed+tbOkM0sbEJkg4xnrWPg7eF4rY8MjOqQxkAh22k0AfRulL5PhrTFGcqhHT0NUtXCm4dsjDckHI61q6dEToUK7RiOR/1/8A1VlaxEdynBbII3fj6UAcrqZHRSDyc4rl5M7m5Oc11t/GMcDJB5rmLtCJW+UDn+tAHD+I2/0x8Z6CucLcnr+ddD4lXZdkY/hFcwTyeaAKNv1Ga6LSULMigckgVztsa6vwpEbjU7dB/fBOfTNAHrfh60FtYQrjkgZOOc11Wk2275ug6529vzrIsbfkYA2jqQa6exj2IuMdOnFAG7ZxExoAOeBjHBNdDZBiCwAwBgVg2J+6eCfTHtW9AQlkXPfp+VAHG/ESYZ2nHKn0ryW9R5Y5NijCZJyPpmu98f3Re6b5h8gz29K89vSrySPhlVuSOMnigDBuEwdi4JweTUUcnzgOASPXvzU04IJ46jjPpVN2DhkXAIPU4oAn80yuV8sbP7vrVfU1VTEdgGF7dOtWbTahZpQM5wvHGfeoZcPMRNggHpQBiXTYIIGCeaoT4ySOo9q07oxhjtUVmSgkHauDQBu/D+3N5r9tDt3AkkjHoM177bRlIuFwBwAB046V4z8LLcrrCTngKG59Dtr2UFQA2dueeCMjigCGQsSWfr6nmmOhlVU2gH1ApZmDMSTz6HGTUsUbMAVI3HrzxigDT06LyU2fxKCAcVPJJhcY3YOBxnvUU2I4gBjI5yaYbhmClemf1oAJvMQf6oevODWbN975kUkHoP61NdSowYjcMH1ByKoMyPk7tpJ6YoAmPzAZjUjvx1xUSgFdgi6d8DAFMLKUZtzfLgHP0pplAZfmwoHIoAVooUAJYEdMAVTiUmYN29cVbmMMkQdFIHcnAqrHgNkZGT2HIoA1ACImGO39KIQYySVGOuKAQYztxj8KjUbSdq5YkDtxzQBcMgaQ5AAJwBjirkR45B246gd81QQLj/ax26Gric5APXj6UALJ8xIQ8nA6cdahlUwzrLjB/i4wM+tPCZbr365HFSzL5ilVxx/PNAHPataGZGkhhUNnnA61zosXeVU2/MejbetdjdyrbMI2ZSuAfrzWbczpHKm1NuehwMUAcFr2iJMd5RVJwMAe1cZNYNHKVK8ggY9a9muBa3gETRAMTwccGuf1bRQltIyAb1/1bYA7ZxQB53PatEoyuCDyPStHwvBnUjIBlUGTgVHeCT7Q4mBWXvn6VqeHkVFmZehO3p3oA+gfDrC50N5EA2snmAY6HrVHUom8hSAe46e9T+Aj5nhW1JJyFZTj6mn6hB8gU8kE5oA5K8h+XG0Y9cda5fUIW3k4/TgV29/DgcAYz7Vy+owZWRh+dAHmHiuPF2CVH3Bg7enJrkSTk123i+PDxv8A7OD+dcOx+Y0AUoCOK7r4cIH1gHPKr6+9cFEcY5rv/he4GrMCRyo/nQB7hpi4jUME/A5GOcdvTH+ea3bRDtA7cCsbTRlBnBOOgPatm2bBXaRn0PSgDZsVO9AOv16VsXrqunhNxHHJB5GKzNKJYlwcY/wp2s3OyEqG7bevNAHm3jO4LarndgfdHt0rn8Lh1PUD5cnFaviJ1eSWXkMC341zS3zeWQCDJ3zQBT1IYAbCnr04wKx5IwibwODzyelbUlwzhpJRyBkKBjNYd9LK24S5wecAe9AFO4kdnBByPY8U5Z3CgMQSxA+lVpJMOd5II96hDNO+Ezx1NACXI3OAMY6VWEfBzyTWj5JG0kE+hNTWmnyXkgIwE7k0Adz4As3t7GKUbFMnzZbpjHFdslxH5Z3uHI5xmsHSYls9OghiyxVRkntgVftYt3UdeRigDSibzHAHBPXJyK2rSFY8scAAcAn2qrplix+c8evbFaNwcBcY4HXjigCreSrycAduuM1VBJBwMAdTmpxHvZi5/djvkcmmyyqqbEBZc560AZtwQEbLc9KrRRr8gBwe5J96t3OCcqpCjpz71XT5Gz7jv2zQAkhUqBnAY8jPeq5jKyENgHHAJ7VaaUoq4yDwOnapdYuBeapPMp3RsQEPYgACgDPiJMQAIznGcg8YojCLKDk+wzTGIAYKCB1Bz+lQRt853457+nFAG0HUR4UZ5HORnpSFldu4BPrnmohjYSHAGcDnrQrYc4POMmgC8gwCQ31FTwknJ5P/AOuqUbnGANx9faraOVUgDC9yO3NAFiEnzH3Nx2zTIyYpFwSAx9ffrRCwwx4HbBIqG5OGVtwU54z1oAh1m3LMWQDdjg8VmG3M0AjON3f2NbkrB4tu8Z6DmoDGWXCntj6GgDDt4SqqGVSVP3TirNzi5s/KIwM8kDvj/wDXV4IwXLEqw4LCqdxIscbBGIY4/lQB514ptbdZ3QK6SJjDDoeKh0iURWxjb5dx5B+n6V0espFcA+aMvg4I6n6/nWTLbq7ZQ5k6Pg/qOPrQB694BdhpMlucfuvm4+ta2opkgnsT04rA8COMsBgboSNueevGa6i7G6MHt6ZoA5vUY9ynJ/HtXNanCPLYA/1rs71A0ZVsH8feuf1GAeU3Xrz6YoA8h8Wxf6E7AHAIP615y33j9a9Z8UW4a1mBOcr/AFryVsbj9aAM5DzXYfD648nXbfk4dgv5nFccODWzoM5ttQt5VbBV1P60AfTunbgo9wMH1ratlORkY6Vz2gzi5s4ZVGQ6buOe1dDbNgYBJX6daAOi0fKxqG4Gd5P4Vk6hOZs5BG4n3xWlbkpaMTzjC/pzWDNuLfKPmyc4BzQBxfiCEqjKU3Nkg4PSuHvjJFIUKMrc5PPFeualpRumO1SQwz3qmfCsU25biFsEc9f8aAPJZbphbkNliCeSe1ZlzLLKAFRt3tXtcXgmwDMslsCD05Of51Z/4RGyjbdFAi4PQAn+ZoA8Fh025nYmSN1Q9dwINa9lpLjKhGCZHJB5/wDr163P4WtyWZYsE8nOTTY/DUSLjbxu3YOaAOBsdIXcpmQEYzznArRs9Nka8QYG0DjC8V28Hh1TsLjAPOPatiy0u0sjuiiBf+8STQBz1jpFzKuDEVB6M2cVv6VowtwJLgqxHYZ9K2lTCr6ewpkhXB5P+RQBDdSBcKoIByCMGs+WYkHjk8Zqa4bLdapyMWmJJ4z09OKAEuZeiDkj1NRHlA0YVR2JzzSSBRNmQDABweahlcyAbzjnOQO1AFe5mbzRmSRgOwpksafISsgDjKMc/MN2Mj8QfyqO72ozYYr3yBT9QvVu5YvKzFFDGEVSOgGTzz1JJNAA52qNsmOmOaikAUDJVgwzwaapSSOT5sbSByp5qMjft5GF4xg8UANMiDAKL7DPtVWWbdOpXIPBwM4qzdwQleHUSEdQD+VZwRuCc7M+h4oA2YiDCBnBBPTvTmbHTOO+M1FAB5fOD6HFThd2STn8KAHoxHrgVZabMYHOec1WAIByCOPzqZMlemB9OlAEhkCJyCDkc8881HJJwCOufu/zoYljgk8859KqSE+cOpx60AXYZMg5baenINWraRWQqxwWP+f6Vmuhwh3nt8vTNSANBtIDcn0OKAL5CMm3IDKfcc1j3KqX2uwwD1Pf6VbF5HwGJEhPGPTFU7lvOQA5LdF49qAMe9j3MzFRtAyMdRx2rnLWQxamc8hTnH94V1WpQSJC6x7vMCnjr261xoVorly6t5rDacjtQB614OX/AE5ZF5Ro9vU11lyh2oDxye9cZ4EnDxhW+8oyPpn/AOtXcXmWHyg885oAyrpOvpisXUYiYjgE9xxW/LhcA5HGMmsvUEJRxz+GaAPL/E8ICP8ATnt3rxBwQ7D3r3rxOG8t85xtz9ea8HlH71/qaAModauWjEEEduap96t2woA95+GWrfadPWNyu+NRt4xxjmvSrBwWRXJx1x7V81+CNZfStSQjlW7H8a+hdCvo762imiIIK557cc5oA6iGUiFEBPzMT+GKqi2LPtO4t3xSrMdiLtHT06VoQviMH26j6UARLaKF5yPY1YXYcjqe+aecNnIAP0qCVSG+UdeuKAGyjCk4G71AzTFUEk5z+dTkEptYYIFN8r1HH0oAjKAru7fWoPLUuOg9avbQMZwMEVCxTcfTNAEaxbmAzgEVNs2nI4JGc5pAdpAUcUjnKg89hQA2SQjADe9VJXKhuSPbHtUk7sWAVRgd6oSSFjhlAA6FfpQASsWz2P8AKqsnPf8AHmpnIxzg885wDUf3nIGO9AEHmMxWM5b2AyaZKioAC3z5wfarsexORhiQQfpVO8UB2LNhc85oAy7lcyYyWxwTioWjwiuG4HXjvVicZZ+AG7dOefSowA6cMCy/wmgAt8ENggAEFuPamI26Xg579KmGEUllA6dqbbKGP3QPyNAFW8RpQCX2scc/h0pEZBGImBZfXB4/yc1fW28yMsRgqeen881RdMNtIAIH5UAWwUjAweozggjAqRW3lhk7Qaz9u9goBPcdjV6EFZCQWx9KALqDJ7k08gbsAAeop0IypfrweoqQqwwCqk59OfpQBWmDKjt/dwCazgxeUE8tnqfStC++W2cY4OOv1rNSQCRWUdP880ATn95bsigFhjn0q1GSLYCXBTGMGs+BmE/yg/ORjI4qS+uPs4CY+8fpQBnzsfPYjPBwDVi0MkkxJACbcg5z8w9f0/Wq7sVGdv7rsQOnFJ5yRMjDj3OP50ATaoRMSY2wR3/Dp9K5XUiDMTk7l6Z7fjWtdXhkkZCgUn5v8isu7czGTKgBVJzjnFAHV/D+6Zbv5gNrDHFenyNuhQDg47/UV454KZvtQYMRz1H1r2NNstorjuu7p7igClODk8Hbnv7mszUQwRt3Tj+dbbIF7DjrkVk6qpEbnA6evSgDy/x1OLewlfOBtH868BeUl2Pqa9O+KerCSZrWNsqqjcffNeUEnNADUGWFX7ZPbmqUIy9atmue1AEsaEYOSK9N+HHiF43eGRwMKq152secHpWnpUciSB4vlcHgigD6X0+5F0qspwML/KtYSBYgT09cY4ryzwjr4SOG2ujsk2gFzjB4/Su9gvIZogFkU5HJBGKANjzm3HGDkdhSiQFtx+761nQyg7u47GpjJgcHj1oAvmflsMenSm+fkEZ9s1R3gjGQevXvSeZ8xbPGenB70AWpZC2T0GeaiBbJ4/zmq01yiglmHHTmoHuPM6ICRggsBwexFAGix2kZ5wOuKj88FxtGSKqq5Y8847CncDoOTzg0ADMz4PU5qB89VAIx0p54fAy3GaRQCvyjnPcUAQS7sYAA98frUCELIQV5HBzVyZcZBHWqkiEzc9xg0AEhMgwAB3wKz7+ULgLyQcEEitKUBY9oUZCkk5rKuLZQpldWXdnjrQBWgkjeJt0Q3A45pqsA+BEODziqbRiGUD51APAyKlRvvt8+QevGQTQBLOQSoYMDjggcCrUWE2lWU8dDx2rPhYugVW5BHUD/AD/+unW6uzEbvbrQBoGZ9oXJbbjk/jWbKxaU8KV6VadG2Dym6YOMjPT3rL8zczZz19KAL8QLPngnPQf41pQZkXLYbnr0xWTDIA2OcnvitGK5iiUq24kn8qAL4PlxgKVJ5zSy3SRRuzkEjggVnz3REgAIIHqKivLV7xCFIZsk8cY/GgBt7ciYDnjpk9veo4oyeeBnBqmlleW8uJIcpjggg9/1rSjgZF3srEYzkCgCNSyoGPylRkDFRSXP2o+VKoDJ8obHNUrm8aN9jEgjGBjtVY3YZgSQpP05oA2YgxgdZEHTORWBfyGNtoGVHPI4q6+o4t5AW5HAHauP1nVty7QQTz2H5UAXZL5GmYsPvHGe3+elTugwPnQoe/8A9auMbUJHkPTn1Ga6DR7k3UJUncw7EAcUAdn4VXZOSg4PtXsGkfvdJtyBnKkYHfBNePaINsAZARknv1969a8OtjQ7XcCMFunJ6mgCZ4sBiuPp+PWuT8ZamunWMhB/fEZUf1roNVvEtFfPIGeOP1rxz4h6wWSTdIc/hQB474nuzNctk9f8a5z8Ku6hL50rOaokjNAD4Ota1kayYDz1rUsjz1oA2ogGHatvRoxljngAdKyLTBAwa6PRIwVl/DgUAbcKeUyHpjB5rZ0+a5gwYpSuSSe4P51myAeZFtwwAGea2bZMxoTj0NAGjbavdorhtjtn6VqJrU5UKUXgetZCRAPnOM9cGrSxhhkcjP1xQBeOp3LdkAPIwM4oNzPLje5IPGAMfyqtsPODxnmrUKkdGB56DoKALEKcgkjOc8mraKAp5xz61XSQglWxtPvUgkYn5cYB5GaALSdBjAP1qRTwNoJOOeO1V0lYZ9/cc0qy4CnoBxjNAEwz/wDWzSbwQckA/XioBOoTuAPU0nmf3SCOp5oAluD82dwJ7c1WmUHdyy9QMd+O1OL85JI9v6VFLKMEDFADEYO7K5J+Uknt1+lV9RcMjoGwFJAyferNmySNIy5DuMHnGKo38ZQt5nDHqR165oAzZlV3T5hkHPX0oMwIMJK7SeT7ZOafFE3nSK5QRggJhu/fPpzS3Fk+7CMr8+ooAhiVFOF5Y4wcgZq5BEjbVJ4A+bnv6ZpIrcowyRxjGD+lSsjY2gAAenegCtqIzGDCQAx6Z5qiICYSytn5+ue2Oa15lDRKxyu7p6gjr/n3qvCI4/l7kcntQBRmjlRA8YBI6j0FQxRSyvleFB/Ot+OEIWQupOemeoIq2tihOUYYPYkcUAZ8EIYYKncf8a07e08h15JH16c1HNOLVCqOuTkZzVWK6lkbcXXj3Hr6UAdAltE6Zldchsnnms+7lhtnJWQ7j2zxiqiamFO1znHXJqlqt/C43vtT5cZLDigBbo2F8ux32ORgZIHHsazLvw0oQmGUkYzjOR/Ksi6vYXztmRdv+11qfRNbn88orh1UYU7sdPegDmdYN7YyFg+Nrc47Vy93MXQsMCTPO017rcWdpe2sLzKq+YMnd9K5jVfAVrcqzWVyEfqAT8v54oA8iV2JBHI71t6ZP5Uy4YLjjk9qt6p4WutNmIlGQP4gcgisu6KRzZDbRn7poA9X0RyttGXxk5ya9P0KVY9EiyMYJ/ma8U8PaojWUSs4O0bSCfxr0SPxBa2ui7nlQE/w7hn8qAG+MNVigExZsYJPXmvAPGWrtfXMiow2A8kV0vjTXbjUbiRUJSIE9+v6V57ecZ5oAyJx15qqRz3q5NjFU/wNACxHBrRtHww5rKQ81dtjyPWgDp7GfaRXU6NchIyWGRtLGuItWwQe+K6OymPkAA5wFXA+hoA6q2uh8p25P8NdJpt8kkC70x6/41xNodyAZ5962tPJQDbkgjPfrQB15uIhhgoA7rV9Lq2VOFO0jkE4rlkcuvOeenWr9opfKsp+XnvQBuo0BGduBzwTU0bxfwZ4OetZWCBwM8Z5zikZ8LgDAOc0AbZMYP3jz25pygZJD/mfrWDubI5fI+tSCZ8Dl+nBJ60AdBGMhfn7Zx0INGzIGTnp+HWsASyY3eY2Rj73T6VL9pkYAK7DJHTOf88igDZaLI4bqMd6YYjgEnJHck1lfaJgN25s+vOR7UG5nwcuf1oA1TCfTn3Paop45HIwMAe56VmtfzM5JfK4/Wmf2jcK3DHJHOegzQBeeOSN3KKc4ODgisozXK3ALqz/AMJG7pUtzeTbiok+bnP161lC4nLtIWGM8gnigC9cwSLIwXIHrzk81Naeanyybn5x/wDWqubu4dTJuUjvz70+bUZldRGuQO65oAPOlY/LuAzwMngVoC8EBi3qHYjOD2rLjv54woMPAxnIPNTyaibplJg24G3I60AT3l0LiIxqNvcY6DiqUMu/DMCp7gmnSX8UHKwgvxzk+nWq6XsBI3RA57888UAaqTiR3YYwp2kA9DjGKtvNiKTehHBwM1Xs7iyUFWhCjduJA6nueKdqWo6cbCcwltyxsQeeCRxQBw2reKClzJA2Aq5UkMcj/wCvWXD4pImZBv2Z67j09uK4/XrxTdSZLbi53N61Ut7yNerHOOtAHpMPiFbg4DY55HPFN1iV5oSQ52kDua4WDUo0f5myM56V0uh6hbTI0U9wfLONpKnAoAy3dy+GbPrg1u+Ho5HulGDgc8Z6YqmLGB7rZBOH3d8EV6j4A8KQMVeWdXwAWXBHPPAoA29MsWOk2qyrwV756dqgurAJEPLRsZycE5PFP8XawmnyfZba5RWj6kHHb1rmrPxBeSTDdcRuM42tyDQAzXdInuLKTy2buVya8i1nTr1bponUl0z2NfStnbJewA/Jk9QD14rlvFXgx5dQEyLjAJYg9cD60AeC2M1xHO0ZmkXk8Zxmu80yJzpgaRmLe5/z61UvvCstve+YsbAlj2PWunk0ySz0gbomHJyDn6UAefawMSON2eSa5a+PzNg11WtRlXbKmuRviQx4oAzZqpEjPWrU5NU80AIDip4ZQp5NFFAF+C8RTy36Gtqz1KAKAZPT+E+lFFAG/p2oxOy4kzn2PpXQ2t3GrAA4x9fT/wCvRRQBt2k6twzlSWx3rTjuYon4znHQ9qKKANISx7ThuMdMUwMDgBv0oooAemOSQT2PP1qUBQOP0oooAYhB2r26Cnoqghg3t0oooAVip4PHORkZOcUMFZd27AHHTpx2oooAi8vpnbznrULp1I6g8UUUAWIbdHt/tEjHBB6+g61ReNEUrjCEkD9KKKAIYdoJzgr+PP8AnNRXS5njZcxqxyF7DmiigCZ1KMybyVOOc9RVyztVmJZSy4ADNnk4zgUUUAZl0u+4RSxOPlB/nTY4gHALHkfdx0oooAq6tfm2jVQcHPbOaxNR1VlRwy4LqVGKKKAPOdWJkmdmIzk1nZOOOKKKAGmQ5HNaOkXzRy7GPBPFFFAHeeHl8yRMffYqBz0r2pLm18L+Fvt1020+UMYUnc2OPzoooA8E1LXZ9RvXnuJWZmYtjnFWNNvmSVGSRuDnFFFAHqXhfU5DPF85IyR39K7eeYyxsXfJIA4FFFAHEeJoNuJl4A3E/WsDxHfynS1IY84JGT6ZoooA8y1e6clvnJ+tcrdylnJzRRQBmSuT3qHNFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph demonstrates cephalization of pulmonary vascular flow, as well as pulmonary arterial hypertension with dilated central pulmonary arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40789=[""].join("\n");
var outline_f39_53_40789=null;
var title_f39_53_40790="Chloroquine: Pediatric drug information";
var content_f39_53_40790=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloroquine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"    see \"Chloroquine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/35/1589?source=see_link\">",
"    see \"Chloroquine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7885889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aralen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aralen&reg;;",
"     </li>",
"     <li>",
"      Novo-Chloroquine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amebicide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"      see \"Chloroquine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of base (10 mg base = 16.6 mg chloroquine phosphate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Malaria:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppression or prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: Administer 5 mg base/kg/week on the same day each week (not to exceed 300 mg base/dose); begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 10 mg base/kg and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 300 mg base on the same day each week; begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 600 mg base and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute attack:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 10 mg base/kg immediately (maximum: 600 mg base/dose), followed by 5 mg base/kg (maximum: 300 mg base/dose) administered at 6, 24, and 48 hours after first dose for a total of 4 doses (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 600 mg base/dose immediately, then 300 mg base/dose at 6, 24, and 48 hours after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extraintestinal amebiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 10 mg base/kg once daily for 21 days (up to 600 mg base/day) (Seidel, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 600 mg base/day for 2 days followed by 300 mg base/day for at least 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis, lupus erythematosus: Adults: 150 mg base once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose (Arnoff, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 250 mg [equivalent to chloroquine base 150 mg], 500 mg [equivalent to chloroquine base 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aralen&reg;: 500 mg [equivalent to chloroquine base 300 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Administer with meals to decrease GI upset; chloroquine phosphate tablets have also been mixed with chocolate syrup or enclosed in gelatin capsules to mask the bitter taste",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light. Store tablets at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression or chemoprophylaxis of malaria in chloroquine-sensitive areas [FDA approved in pediatric patients (age not specified) and adults]; treatment of uncomplicated acute attacks of malaria due to susceptible",
"     <i>",
"      Plasmodium",
"     </i>",
"     species, except chloroquine-resistant",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     [FDA approved in pediatric patients (age not specified) and adults]; extraintestinal amebiasis (FDA approved in adults); has been used for treatment of rheumatoid arthritis, discoid lupus erythematosus, scleroderma, pemphigus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aralen [U.S., Mexico] may be confused with Paralen brand name for acetaminophen [Czech Republic]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, ECG changes (rare; including prolonged QRS and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals), hypotension (rare),  torsade de pointes (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, confusion, delirium, depression, hallucinations, headache, insomnia, personality changes, polyneuritis, psychosis,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme (rare), exfoliative dermatitis (rare), hair bleaching, lichen planus eruptions, photosensitivity, pleomorphic skin eruptions, pruritus, skin/mucosal pigmentary changes (blue-black), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Rare cases of agranulocytosis (reversible), aplastic anemia, neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Depression of deep tendon reflexes, myopathy, neuromyopathy, proximal muscle atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation disturbances, blurred vision, corneal opacities (reversible), nyctalopia, retinopathy (including irreversible changes in some patients long-term or high-dose therapy), visual field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing reduced (risk increased in patients with pre-existing auditory damage), nerve deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, angioedema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to 4-aminoquinoline compounds (eg, chloroquine, hydroxychloroquine) or any component; retinal or visual field changes",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver disease, G-6-PD deficiency, severe blood disorders, seizure disorders, pre-existing auditory damage, or in conjunction with hepatotoxic drugs; use in pregnancy should be avoided, except for the suppression or treatment of malaria when, in the judgement of the prescriber, the potential benefit outweighs the potential risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Physicians should be familiar with chloroquine before prescribing",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Resistance of",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     to chloroquine is widespread, including everywhere that",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria is transmitted, except for areas of Central America (northwest of the Panama Canal), Haiti, the Dominican Republic, and most areas of the Middle East; cases of",
"     <i>",
"      Plasmodium vivax",
"     </i>",
"     resistance have been reported. Irreversible retinal damage has been reported in patients who received long-term or high-dose therapy; baseline and periodic ophthalmic exams should be performed. Periodically examine patients for evidence of muscular weakness; discontinue chloroquine if weakness occurs. Chloroquine may precipitate a severe attack of psoriasis in patients with psoriasis; may exacerbate porphyria in patients with porphyria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Alfa: Chloroquine may diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Beta: Chloroquine may diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: Chloroquine may decrease the serum concentration of Ampicillin.  Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Chloroquine. Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of Chloroquine. Management: Separate administration of kaolin and chloroquine by at least 4 hours to minimize any potential negative impact of kaolin on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Chloroquine. Management: Administer chloroquine at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rabies Vaccine: Chloroquine may diminish the therapeutic effect of Rabies Vaccine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using chloroquine during pregnancy. However, based on clinical experience and because malaria infection in pregnant women may be more severe than in nonpregnant women, chloroquine prophylaxis may be considered in areas of chloroquine-sensitive",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria. Pregnant women should be advised not to travel to areas of",
"     <i>",
"      P. falciparum",
"     </i>",
"     resistance to chloroquine. Consult current CDC guidelines for the treatment of malaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, examination for muscular weakness, and ophthalmologic examination (visual acuity, slit-lamp, fundoscopic, and visual field tests) in patients receiving prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to and inhibits DNA and RNA polymerase; interferes with metabolism and hemoglobin utilization by parasites; inhibits prostaglandin effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed in body tissues including eyes, heart, kidneys, liver, leukocytes, and lungs where retention is prolonged; crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic; main metabolite is desethylchloroquine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;70% of dose excreted in urine (~35% unchanged); acidification of the urine increases elimination of drug; small amounts of drug may be present in urine months following discontinuation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Minimally removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/35/1589?source=see_link\">",
"      see \"Chloroquine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any visual disturbances, muscular weakness, or difficulty in hearing or ringing in the ears; tablets are bitter tasting. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9777275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      P. vivax",
"     </i>",
"     and",
"     <i>",
"      P. ovale",
"     </i>",
"     infections treated with chloroquine only can relapse due to hypnozoites; add primaquine to eradicate hypnozoites",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F149763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 15 mg chloroquine phosphate/mL oral suspension (equivalent to 9 mg chloroquine base/mL) may be made from tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush three 500 mg chloroquine phosphate tablets (equivalent to 300 mg base/tablet) in a mortar and reduce to a fine powder. Add 15 mL of  the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well before using&rdquo; and &ldquo;protect from light&rdquo;. Stable for up to 60 days when stored in the dark at room temperature or refrigerated (preferred).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Alprazolam, Chloroquine Phosphate, Cisapride, Enalapril Maleate, and Hydralazine Hydrochloride in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(18):1915-20.",
"     <span class=\"pubmed-id\">",
"      9784772",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/53/40790/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for Treatment of Malaria in the United States.\" Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Malaria Prescription Drug Information for Healthcare Providers.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/travel/drugs_hcp.htm\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/travel/drugs_hcp.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Treatment of Malaria (Guidelines for  Clinicians).\" Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Amebiasis,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 206-8. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/3.3",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seidel J, \"Diagnosis and Management of Amebic Liver Abscess in Children,\"",
"      <i>",
"       West J Med",
"      </i>",
"      , 1984, 140(6):932-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/53/40790/abstract-text/6146229/pubmed\" id=\"6146229\" target=\"_blank\">",
"        6146229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria Chemoprophylaxis for the Traveler,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/53/40790/abstract-text/8505942/pubmed\" id=\"8505942\" target=\"_blank\">",
"        8505942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13147 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40790=[""].join("\n");
var outline_f39_53_40790=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885889\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149782\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149783\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046248\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046241\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149758\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149743\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046252\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046244\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046251\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149831\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046256\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046240\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046239\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149821\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149752\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046247\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046238\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046255\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046246\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9777275\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149763\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=related_link\">",
"      Chloroquine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/35/1589?source=related_link\">",
"      Chloroquine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_53_40791="Rheumatoid arthritis and pregnancy";
var content_f39_53_40791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rheumatoid arthritis and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40791/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/53/40791/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) affects 1 to 2 percent of the adult population in the United States. There is a female predominance in RA, and many female patients are of childbearing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the management of RA during pregnancy is a common challenge. In many patients with RA, disease activity improves substantially in the gravid state. However, modification of treatment so as to minimize the potential for fetal toxicity while maintaining adequate disease control can be difficult in patients whose RA flares or remains active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HORMONES AND RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased incidence of RA in women suggests that sex hormones may have an influence on RA. As an example, women have noted improved symptoms during the luteal phase of the menstrual cycle, the time when the production of gonadal steroids, particularly progesterone, is maximal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, oophorectomized female mice demonstrate a heightened susceptibility to collagen-induced arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy-related changes in circulating hormones may contribute to alterations in the immune system that may affect disease activity. Both premenopausal and postmenopausal women with RA appear to have lower serum levels of adrenal androgens (eg, dehydroepiandrosterone [DHEA]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. DHEA, cortisol, estrogen, progesterone, and norepinephrine, all of which are elevated in pregnancy, contribute to the Th2 dominant cytokine profile that emerges in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Immunology of pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, no significant differences in the serum estrogen concentration have been found between patients with RA and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, hormone replacement therapy has no effect on the course of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data on the effect of oral contraceptives on RA are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study that reviewed the records of 229 women with RA and 458 controls reported no association between RA and the use of oral contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other reports noted a decreased risk of RA among current users of oral contraceptives, as well as a lower risk among women who had used oral contraceptives in the past [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Nurses&rsquo; Health Study found that the risk of RA was not altered by a history of oral contraceptive use but reported that a modest protective effect of current users could not be excluded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, data do not support the concept that oral contraceptives protect against the development of RA, at least among women who have used these medications in the past. The use of oral contraceptives appears neither to worsen nor to improve disease activity.",
"   </p>",
"   <p>",
"    The United States Center for Disease Control modifications of the World Health Organization eligibility criteria for contraceptive use, including the use in rheumatoid arthritis of oral and other contraceptives, are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMMUNOLOGY OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many immunologic changes must occur during pregnancy in order to maintain the viability of the fetus. Immunologic alterations occur at the maternal-fetal interface to prevent &ldquo;rejection&rdquo; of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/13\">",
"     13",
"    </a>",
"    ]. Among these are changes in cytokine secretion from a Th1 predominance to a Th2 predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/14\">",
"     14",
"    </a>",
"    ], an estrogen-induced increase in the synthesis of complement components by the liver, diminished activity of natural killer cells, increases in soluble tumor necrosis factor (TNF)-alpha receptors, and increases in serum plasma levels of interleukin (IL)-1 receptor antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Increased binding of circulating TNF and antagonism of IL-1 may contribute to the symptomatic improvement of RA symptoms in some women during pregnancy.",
"   </p>",
"   <p>",
"    In one study, improvement of RA symptoms during pregnancy correlated with greater human leukocyte antigen (HLA) mismatch between mother and fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/19\">",
"     19",
"    </a>",
"    ]. This effect could be mediated by antibodies against HLA class II antigens or by the induction of suppressor mechanisms. However, this correlation with HLA disparity has not been observed in all reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISEASE ACTIVITY DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 to 80 percent of women with RA improve during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. The decrease in disease activity generally starts in the first trimester and lasts for a number of weeks or months into the postpartum period. Disease characteristics (duration, functional class, rheumatoid factor positivity) do not appear to predict whether a patient will remit during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all studies have found improvement in symptoms with pregnancy. As an example, one report that evaluated the clinical course of 140 pregnant women with RA noted only minimal improvement in Health Assessment Questionnaire (HAQ) scores and in joint symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/26\">",
"     26",
"    </a>",
"    ]. However, because RA symptoms and signs are difficult to distinguish in some cases from the changes of third-trimester pregnancies, the results of this study must be interpreted with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postpartum flare",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of patients flare during the postpartum period, usually within the first three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, one study suggested an increased risk of developing RA in the first three months postpartum, particularly after a woman&rsquo;s first pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/23\">",
"     23",
"    </a>",
"    ]. Many clinicians advocate reintroducing medications in the immediate postpartum period because the stress of caring for a newborn can be compounded by the possibility of an RA flare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians believe that breastfeeding increases the risk of RA, that this effect is mediated by increased prolactin levels associated with the postpartum state, and that the risk is higher following first pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The interpretation of these data is difficult because of the known association between disease flare and the immediate postpartum period, the time in which breastfeeding begins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/23\">",
"     23",
"    </a>",
"    ]. The observation that lactation exerts a protective effect against the development of RA clouds this issue further [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk of developing RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some data suggesting that early parity and later menarche diminish the risk of developing RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one report, for example, the adjusted odds ratio of developing RA was 0.49 among women who had ever been pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/33\">",
"     33",
"    </a>",
"    ]. On the other hand, the postpartum period following a first pregnancy can be a particularly vulnerable period, with an increasing risk of developing RA that lasts for nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although one case-control study demonstrated a slight increase in spontaneous abortion in women with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/35\">",
"     35",
"    </a>",
"    ], most reports have failed to show any increase in fetal morbidity or in fetal losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy outcomes in women with well-controlled RA are comparable to those in the general population. However, women with RA (or other inflammatory arthritis) who experience a higher level of disease activity during the third trimester",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who take glucocorticoids are at risk for small gestational age babies and for preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDICATION USE DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For RA patients who require continued treatment or who experience a disease flare during pregnancy, therapeutic choices are governed not only by disease severity but also by concerns regarding fetal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Medications typically used for RA may be divided into four categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drugs with a moderate to high risk of fetal harm",
"     </li>",
"     <li>",
"      Drugs that may be used selectively during pregnancy",
"     </li>",
"     <li>",
"      Drugs with minimal fetal and maternal risk",
"     </li>",
"     <li>",
"      Drugs with an unknown level of risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly used medications are reviewed briefly below. Other medications and a detailed discussion of the use of specific antiinflammatory and immunosuppressive medications in pregnancy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Moderate to high risk of fetal harm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications with a high risk of causing birth defects should be avoided during conception and pregnancy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H19#H19\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Leflunomide'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Selective use allowed during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following drugs are potentially safe during pregnancy, but certain limitations apply to their use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      cross the placenta at very low concentrations and are relatively safe to use during pregnancy in low to moderate concentrations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link&amp;anchor=H23#H23\">",
"       \"Pregnancy in women with systemic lupus erythematosus\", section on 'Minimal fetal and maternal risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAIDs and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &mdash; Nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin, can be used safely during pregnancy at certain times but not others. The following should be noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Use of NSAIDs or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      near the time of conception or during early pregnancy may interfere with implantation. Thus, these agents should be avoided during a conception cycle and during early pregnancy.",
"     </li>",
"     <li>",
"      NSAIDs may be used in the first trimester after a positive pregnancy test and during the second trimester but should be avoided during the third trimester of pregnancy because of risk of premature closure of the ductus arteriosus and inhibition of labor.",
"     </li>",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may be used throughout pregnancy if being given for certain obstetric indications. High-dose aspirin should be avoided during pregnancy.",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H7#H7\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'NSAIDs and aspirin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TNF inhibitors &mdash; Although the risk of congenital defects is likely to be relatively low, some uncertainty remains regarding such risk. We avoid these medications if possible but may use them in patients whose disease is not adequately controlled by other measures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H10#H10\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'TNF inhibitors'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H17\">",
"       'Persistent or flaring disease activity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Minimal fetal and maternal risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following medications can generally be used during pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      &mdash; Antimalarials such as hydroxychloroquine may be used during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H3#H3\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Hydroxychloroquine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      &mdash; Sulfasalazine may be safely used during pregnancy but should be avoided in men for several months prior to conception because it may cause reversible oligospermia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H4#H4\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Sulfasalazine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following general guidelines in our approach to the treatment of patients with RA prior to and during pregnancy:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prior to pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with RA who are contemplating pregnancy, it is helpful for the rheumatologist, obstetrician, and patient to discuss medication use prior to conception.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      should be stopped one to three months prior to conception.",
"     </li>",
"     <li>",
"      Pregnancy should be avoided in patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      until undetectable serum concentrations (&lt;0.02",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      are verified. This may be accomplished by the use of an enhanced drug elimination procedure using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"       \"Leflunomide in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       \"Leflunomide: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In most patients with mild to moderate disease, we suggest that medications be discontinued prior to conception to minimize any risk.",
"     </li>",
"     <li>",
"      We generally advise discontinuation of TNF inhibitors at the time of confirmed pregnancy testing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Persistent or flaring disease activity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Routine management during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients whose RA becomes active during pregnancy, we advise use of NSAIDs up to the beginning of the third trimester. In patients in whom high-dose daily NSAIDs would be required to control symptoms or in whom NSAID use is inadequate, we use the lowest dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      necessary for disease control. We try to limit prednisone dosing to no more than 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      can be used in patients with an inadequate response to NSAIDs or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Persistent or flaring disease activity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids in doses higher than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      can be used to manage disease flares or persistent moderately to highly active disease that is not adequately controlled with other medications. Patients should be counseled that use of glucocorticoids before 14 weeks of gestation can increase the risk of cleft palate formation and can contribute to pregnancy-induced hypertension and to gestational diabetes later during pregnancy.",
"     </li>",
"     <li>",
"      In patients with disease refractory to routine management or with continued flares during pregnancy despite the use of glucocorticoids, the decision to initiate or resume therapy with a TNF inhibitor can be considered although the patient needs to be aware of the balance of benefits and risks of this treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H10#H10\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'TNF inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medication use during breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the same restrictions on medication use apply also to breastfeeding mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40791/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs can be used, but",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be avoided.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      can be taken in low doses. In patients taking 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more, it is recommended to wait four hours after the dose prior to nursing.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      should be avoided in nursing women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/14/39138?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95776428\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased incidence of RA in women suggests that sex hormones might have an influence on RA, and pregnancy-related changes in circulating hormones may contribute to alterations in the immune system that may affect disease activity. However, oral contraceptives do not appear to protect against the development of RA, and the use of oral contraceptives appears neither to worsen nor to improve disease activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hormones and rheumatoid arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 50 to 80 percent of women with RA improve during pregnancy; the decrease in disease activity generally starts in the first trimester and lasts for a number of weeks or months into the postpartum period. However, approximately 90 percent of patients flare during the postpartum period, usually within the first three months. There may be an increased risk of developing RA in the first three months postpartum, particularly after a woman&rsquo;s first pregnancy. Many clinicians advocate reintroducing medications in the immediate postpartum period. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunology of pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Disease activity during pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Postpartum flare'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early parity and later menarche diminish the risk of developing RA, although there may be an increased risk of developing RA that lasts for nine months during the postpartum period following a first pregnancy. Most reports have failed to show any increase in fetal morbidity or in fetal losses associated with RA, and pregnancy outcomes in women with well-controlled RA are comparable to those in the general population. Women with RA who experience a higher level of disease activity during the third trimester",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who take glucocorticoids are at risk for small gestational age babies and for preterm delivery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk of developing RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For RA patients who require continued treatment or who experience a disease flare during pregnancy, therapeutic choices are governed not only by disease severity but also by concerns regarding fetal toxicity (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Medication use during pregnancy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medications with a high risk of causing birth defects, which should be avoided during conception and pregnancy, include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Moderate to high risk of fetal harm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that are potentially safe during a portion of or the duration of pregnancy but that have certain limitations to their use, include glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and tumor necrosis factor (TNF) inhibitors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Selective use allowed during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medications that can generally be used during pregnancy include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Minimal fetal and maternal risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with RA should consult with their rheumatologist and obstetrician to discuss medication use prior to conception.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      should be stopped one to three months prior to conception, and pregnancy should be avoided in patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      until undetectable serum concentrations are verified. In most patients with mild to moderate disease, we suggest that medications be discontinued prior to conception to minimize any risk, and we generally advise discontinuation of TNF inhibitors at the time of confirmed pregnancy testing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prior to pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients whose RA becomes active during pregnancy, we advise use of NSAIDs up to the beginning of the third trimester. In patients in whom high-dose daily NSAIDs would be required to control symptoms or in whom NSAID use is inadequate, we use the lowest dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      necessary for disease control. We try to limit prednisone dosing to no more than 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      can be used in patients with an inadequate response to NSAIDs or prednisone. The relative risks and benefits of medications should be reviewed with the patient, particularly in those requiring higher doses of glucocorticoids or in those considering resumption of TNF inhibitor therapy because of the level of disease activity. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Routine management during pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Persistent or flaring disease activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who are breastfeeding, NSAIDs can be used, but",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be avoided.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      can be taken in low doses; in patients taking 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more, it is recommended to wait four hours after the dose prior to nursing.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      should be avoided. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Medication use during breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/1\">",
"      Dugowson CE, Koepsell TD, Voigt LF, et al. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum 1991; 34:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/2\">",
"      Case AM, Reid RL. Effects of the menstrual cycle on medical disorders. Arch Intern Med 1998; 158:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/3\">",
"      Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986; 29:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/4\">",
"      Masi AT, Josipovi DB, Jefferson WE. Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion. Semin Arthritis Rheum 1984; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/5\">",
"      Masi AT, Feigenbaum SL, Chatterton RT. Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Semin Arthritis Rheum 1995; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/6\">",
"      Straub RH, Buttgereit F, Cutolo M. Benefit of pregnancy in inflammatory arthritis. Ann Rheum Dis 2005; 64:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/7\">",
"      Masi AT. Sex hormones and rheumatoid arthritis: cause or effect relationships in a complex pathophysiology? Clin Exp Rheumatol 1995; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/8\">",
"      Liang MH, Karlson EW. Female hormone therapy and the risk of developing or exacerbating systemic lupus erythematosus or rheumatoid arthritis. Proc Assoc Am Physicians 1996; 108:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/9\">",
"      Linos A, Worthington JW, O'Fallon WM, Kurland LT. Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1983; 1:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/10\">",
"      Hazes JM, Dijkmans BC, Vandenbroucke JP, et al. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum 1990; 33:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/11\">",
"      Spector TD, Roman E, Silman AJ. The pill, parity, and rheumatoid arthritis. Arthritis Rheum 1990; 33:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/12\">",
"      Hernandez-Avila M, Liang MH, Willett WC, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum 1990; 33:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/13\">",
"      Nelson JL. Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 1996; 39:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/14\">",
"      Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 1992; 11:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/15\">",
"      Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/16\">",
"      Johnson U, Gustavii B. Complement components in normal pregnancy. Acta Pathol Microbiol Immunol Scand C 1987; 95:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/17\">",
"      Branch DW. Physiologic adaptations of pregnancy. Am J Reprod Immunol 1992; 28:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/18\">",
"      &Oslash;stensen M, F&ouml;rger F, Nelson JL, et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 2005; 64:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/19\">",
"      Nelson JL, Hughes KA, Smith AG, et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993; 329:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/20\">",
"      Brennan P, Barrett J, Fiddler M, et al. Maternal-fetal HLA incompatibility and the course of inflammatory arthritis during pregnancy. J Rheumatol 2000; 27:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/21\">",
"      Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrosis and intermittent hydrarthrosis. Mayo Clin Proc 1938; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/22\">",
"      Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976; 27:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/23\">",
"      Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 1992; 35:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/24\">",
"      Ostensen M. The influence of pregnancy on blood parameters in patients with rheumatic disease. Scand J Rheumatol 1984; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/25\">",
"      Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/26\">",
"      Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999; 42:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/27\">",
"      Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994; 37:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/28\">",
"      Chikanza IC, Petrou P, Chrousos G, et al. Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. Br J Rheumatol 1993; 32:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/29\">",
"      Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 2000; 43:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/30\">",
"      Brun JG, Nilssen S, Kv&aring;le G. Breast feeding, other reproductive factors and rheumatoid arthritis. A prospective study. Br J Rheumatol 1995; 34:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/31\">",
"      Silman AJ. Parity status and the development of rheumatoid arthritis. Am J Reprod Immunol 1992; 28:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/32\">",
"      Deighton CM, Sykes H, Walker DJ. Rheumatoid arthritis, HLA identity, and age at menarche. Ann Rheum Dis 1993; 52:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/33\">",
"      Hazes JM, Dijkmans BA, Vandenbroucke JP, et al. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 1990; 33:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/34\">",
"      OKA M. Effect of pregnancy on the onset and course of rheumatoid arthritis. Ann Rheum Dis 1953; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/35\">",
"      KAPLAN D, DIAMOND H. RHEUMATOID ARTHRITIS AND PREGNANCY. Clin Obstet Gynecol 1965; 17:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/36\">",
"      Morris WI. Pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Aust N Z J Obstet Gynaecol 1969; 9:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/37\">",
"      Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 1983; 26:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/38\">",
"      de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 2009; 60:3196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/39\">",
"      Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol 2001; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/40\">",
"      Soscia PN, Zurier RB. Drug therapy of rheumatic diseases during pregnancy. Bull Rheum Dis 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/41\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/42\">",
"      Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40791/abstract/43\">",
"      Roubenoff R, Hoyt J, Petri M, et al. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18:88.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7514 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40791=[""].join("\n");
var outline_f39_53_40791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95776428\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HORMONES AND RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMMUNOLOGY OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISEASE ACTIVITY DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postpartum flare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk of developing RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDICATION USE DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Moderate to high risk of fetal harm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Selective use allowed during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Minimal fetal and maternal risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prior to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Routine management during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Persistent or flaring disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medication use during breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95776428\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=related_link\">",
"      Leflunomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/14/39138?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_53_40792="Function and clinical applications of immunoglobulins";
var content_f39_53_40792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Function and clinical applications of immunoglobulins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40792/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/53/40792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin (Ig) molecules are multifunctional components of the immune system that mediate interactions between antigen molecules and a variety of cellular and humoral effector mechanisms. Important mechanisms in which Ig molecules are essential include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation and signal transduction in B cells (in the case of surface Ig receptors)",
"     </li>",
"     <li>",
"      Interactions with receptors for the constant region of IgG on a variety of cells, with different functional outcomes",
"     </li>",
"     <li>",
"      Activation and modulation of the complement system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different parts of immunoglobulin molecules have distinct functions. These functional fragments can be generated by digestion with the protease papain, which cleaves immunoglobulins near the hinge region, yielding two identical Fab fragments, and one Fc fragment (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"mobipreview.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fab",
"      </strong>",
"      &mdash; Papain cleavage yields two identical fragments called Fab (antigen-binding), since they react with antigen. A Fab fragment contains a complete L chain, and the VH and CH1 domains of the H chain. Each Fab fragment contains one antigen-binding site.",
"     </li>",
"     <li>",
"      <strong>",
"       Fc",
"      </strong>",
"      &mdash; The other papain cleavage product is called Fc, an abbreviation for the fragment that is &ldquo;crystallizable.&rdquo; The Fc portion contains the binding site for C1q of the classical complement pathway, although Fc, in isolation, cannot bind or activate complement because it is monovalent. The Fc portion of IgG is comprised of the CH2 and CH3 domains. Several distinct receptor systems on leukocytes interact with the Fc of various Ig isotypes (collectively referred to as Fc receptors) and influence a variety of cellular processes influencing both innate and adaptive immune functions. The function and clinical application of the Fc portion of antibody molecules are discussed separately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The function of immunoglobulins, the derivation of monoclonal antibodies, and various laboratory and clinical applications of Ig-derived reagents are reviewed here. Basic aspects of immunoglobulin structure and genetics are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF THE Ig VARIABLE REGION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable regions of the immunoglobulin heavy and light chains form the antibody combining site. The function of the variable region primarily involves antibody-antigen interactions, including precipitation, agglutination, and neutralization of antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibody-antigen interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strength of an antibody-antigen interaction is often described in terms of the affinity of the antibody for that antigen. For the reaction of antibody (Ab) with antigen (Ag), where Ab-Ag denotes the antibody-antigen complex, the association constant for the reaction (Ka) is given by the equation below, where terms within brackets denote the molar concentration of those substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Ka = [Ab-Ag]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    ([Ab][Ag])",
"   </p>",
"   <p>",
"    The association constant is often called the affinity constant or simply the affinity of antibody for antigen. Antibody affinities are most often in the range of 10(5) to 10(11)",
"    <span class=\"nowrap\">",
"     L/mol.",
"    </span>",
"    High-affinity antibodies react with their complementary antigens even when the concentration of either is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affinity refers only to the reaction of a single combining site with a single monovalent antigenic determinant. However, all antibody molecules in solution have at least two binding sites; dimeric IgA has four and pentameric IgM has ten. Furthermore, many antigens are multivalent for many antigenic determinants. Thus, it is common for antigen-antibody reactions to involve multiple sites of interaction between two macromolecules.",
"   </p>",
"   <p>",
"    If multiple contacts are possible, the apparent affinity of the two ligands for each other may be vastly greater than the intrinsic affinity of a combining site for an antigenic determinant. The apparent affinity may be of the order of Ka-squared. For an antibody with good affinity (eg, 10(9)",
"    <span class=\"nowrap\">",
"     L/mol)",
"    </span>",
"    this would produce an apparent affinity of 10(18), a virtually irreversible binding reaction. Multivalent binding enables productive interactions even when intrinsic affinities and antibody and antigen concentrations are low.",
"   </p>",
"   <p>",
"    The situation is even more complex with the reaction of antisera containing many specificities with a multideterminant antigen which may be multivalent for several different antigenic determinants. In this setting, one may experimentally define the avidity of an antiserum for antigen by the tendency for aggregation versus dissociation with varying amounts of each reactant present. High-avidity antisera precipitate antigens at low concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibody specificity and cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specificity of an antibody for a particular antigenic determinant is relative, not absolute. The antibody may bind several antigenic determinants with similar or different structures. A single antigenic determinant may also react with several antibodies differing in structure. These differences in the structures of antigenic determinants and antibodies are reflected in the different affinities of their interactions.",
"   </p>",
"   <p>",
"    Although some changes in the structure of an antigenic determinant may permit interaction with the same receptor (with different affinities), other changes may entirely abolish the interaction. As an example, some antibodies binding influenza hemagglutinin (HA) are neutralizing since they block attachment of the virus to its receptors and prevent infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Neutralization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Influenza viruses gradually accrue point mutations. When enough mutations causing amino acid substitutions have accumulated in antigenically important sites, previously protective antibodies are no longer able to neutralize the virus and prevent infection by the new strain. This process of \"antigenic drift\" continually maintains infectivity of the influenza virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/5\">",
"     5",
"    </a>",
"    ]. A similar process can occur even during a single infection in one host. HIV infection is a good example, as mutations in gp120 accumulate and permit viral escape from neutralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/6\">",
"     6",
"    </a>",
"    ]. Similar selection processes occur in a multitude of additional infectious organisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1550679\">",
"    <span class=\"h3\">",
"     Natural antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of literature provides examples of immunoglobulins reacting with multiple endogenous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exogenous antigens bearing no readily identifiable structural similarity (eg, histones, polynucleotides, immunoglobulins). These \"polyspecific\" Igs are referred to as \"natural antibodies\" and are primarily of the IgM isotype. They are produced by a distinct subset of B cells known as B-1 cells, which produce antibody without any requirement of prior antigenic stimulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant fraction (up to one-third) of the natural antibody pool appears to recognize \"oxidation-specific\" epitopes, which are epitopes generated during the oxidative processes involved in metabolism, aging, and inflammation, such as occurs in arterial vessel walls during the process of atherogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/7\">",
"     7",
"    </a>",
"    ]. Oxidation-specific epitopes are ubiquitous on both microbes and aging and apoptotic host cells and represent a class of pathogen- or damage-associated molecular pattern (PAMP or DAMP) recognized by receptors of the innate immune system. Thus, natural antibodies appear to function as a type of pattern recognition receptor (PRR) for these molecular structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Natural antibodies have at least two important functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They provide the host first-line protection against infections by mounting a rapid immune response against pathogens before adaptive immunity can initiate specific antibody synthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/8-11\">",
"       8-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They assist in homeostasis by binding to aging and apoptotic cells and cellular debris, which if not cleared, could create a proinflammatory and immunogenic environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/7,12\">",
"       7,12",
"      </a>",
"      ]. In keeping with this, mice deficient in natural antibody are more susceptible to autoimmune disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/11,13\">",
"       11,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Precipitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complexes form and precipitate when complementary antibodies and antigens are mixed in solution. The amount of precipitate is related to antigen and antibody valence, reactant concentrations, and antibody affinity, which also may depend upon the pH and ionic strength of the solution.",
"   </p>",
"   <p>",
"    The valence of an antibody refers to the number of binding sites it has for antigen. The valence of an antigen is the maximum number of antibodies that can bind to the antigen at one time. Precipitation requires antibody and antigen valences of at least two; an Fab fragment (with a valence of one) cannot precipitate antigen. Similarly, a monovalent antigen cannot interact with more than one antibody and so cannot precipitate.",
"   </p>",
"   <p>",
"    Since secreted IgM molecules are pentameric (10 combining sites), these molecules are very good precipitators. However, not all combining sites are necessarily accessible, depending upon the size of the antigen. For large antigens, pentameric IgM is pentavalent, although this still represents a tremendous binding advantage over an Ig monomer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnostic applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The properties of immunoglobulins are utilized in a variety of laboratory tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immunodiffusion",
"      </strong>",
"      &mdash; The addition of complementary antibodies and antigens to a semisolid medium, such as agar, results in the formation of a visible zone of precipitate at the interface where the two components diffuse together. This is known as immunodiffusion. It can be used to detect the presence of specific antibodies or specific antigens.",
"     </li>",
"     <li>",
"      <strong>",
"       Immunoelectrophoresis",
"      </strong>",
"      &mdash; A variant of immunodiffusion is immunoelectrophoresis. In this method, electrophoresis in one dimension is coupled with immunodiffusion in a perpendicular direction. Much more complex mixtures of antigens and antibodies can be analyzed with immunoelectrophoresis than with simple immunodiffusion. This technique is frequently used to detect abnormal (monoclonal) antibodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       ELISA and SPRIA immunoassays",
"      </strong>",
"      &mdash; Two additional methods related to precipitation of antibody-antigen mixtures have revolutionized the study of antigen-antibody interactions and clinical chemistry. These are the enzyme-linked immunosorbent assay (ELISA) (",
"      <a class=\"graphic graphic_figure graphicRef74627 \" href=\"mobipreview.htm?10/17/10525\">",
"       figure 2",
"      </a>",
"      ) and the solid-phase radioimmunoassay (SPRIA). In these methods, a solution containing one reactant is placed in a well in a plastic dish. Some plastics will (more or less) irreversibly bind many types of macromolecules. Subsequently, the plate is washed, and the labeled (radioactive or enzyme tag) reactant added. After washing again, the amount of bound labeled antibody is measured. This is a direct binding assay. The labeled component may be either antigen or antibody.",
"      <br/>",
"      <br/>",
"      An indirect binding assay may also be used (",
"      <a class=\"graphic graphic_figure graphicRef74627 \" href=\"mobipreview.htm?10/17/10525\">",
"       figure 2",
"      </a>",
"      ). Binding of the antibody of interest to the antigen is detected by a secondary reagent. As an example, binding of human IgG to an antigen coated on a plate may be detected with labeled anti-human globulin from an animal.",
"      <br/>",
"      <br/>",
"      ELISA has found wide and ever-increasing application in immunodiagnosis in clinical laboratories. For example, ELISA techniques are routinely used in the diagnosis of HIV infection and of various allergic disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=see_link\">",
"       \"Overview of in vitro allergy tests\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry refers to the combining of the immunologic techniques described above with histological methods. Immunohistochemical methods are powerful tools for localizing particular molecules within cells and tissues. In these techniques, samples of tissue are treated with solutions of antibodies against the molecule in question and then washed. Various labels are then used to detect the adherent antibodies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies labeled with an enzyme (eg, horseradish peroxidase) produce pigment deposits when incubated with a substrate.",
"     </li>",
"     <li>",
"      Binding of radioactively-labeled antibodies may be detected when the specimen is coated with a photographic emulsion; the radioactive emissions create silver grain deposits.",
"     </li>",
"     <li>",
"      Antibodies labeled with fluorescent compounds may be visualized in a fluorescence microscope.",
"     </li>",
"     <li>",
"      Antibodies labeled with gold can be detected in electron micrographs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Agglutination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitation and agglutination are conceptually identical. Precipitation involves soluble antigens and antibodies; agglutination denotes the formation of complexes of antibodies with relatively large particles, such as bacteria or erythrocytes. Both precipitation and agglutination require antibody multivalence. Pentameric IgM is a good agglutinator and precipitator.",
"   </p>",
"   <p>",
"    Agglutination tests are often used to detect serum antibodies with a particular specificity. The specificity may be one normally present on the target cell, or it may not. If not, then the antibody may be artificially coupled to a target cell, such as an erythrocyte (hemagglutination). Serial dilutions of serum are mixed with target cells, and antibody levels are quantified as the highest dilution causing agglutination.",
"   </p>",
"   <p>",
"    In sera with high titers of specific antibody, agglutination may not be observed until some initial dilution is made. Lower dilutions not causing agglutination are called the prozone. At low dilutions, target antigenic determinants are rapidly saturated with antibody, preventing binding of one antibody to two particles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Coombs' test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Coombs' test is a widely-available agglutination test that is used clinically to detect anti-erythrocyte antibodies (Coombs' antibodies), which are present in autoimmune hemolytic anemias. The direct Coombs' test is performed by adding anti-human globulin (Coombs' reagent) to a patient's erythrocytes. If the patient's cells are coated with Coombs' antibodies, this will result in agglutination of the red cells.",
"   </p>",
"   <p>",
"    The indirect Coombs' test evaluates for anti-erythrocyte antibodies in the serum. In this technique, control erythrocytes are incubated with a patient's serum, washed, and then exposed to anti-human globulin. If the red cells agglutinate, this indicates the presence of anti-erythrocyte antibodies in the patient's serum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neutralization",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the binding of antibody to a virus renders it incapable of infecting a cell, the virus is said to be neutralized and the antibody is called neutralizing. The same terminology is used when antibody binding inactivates a toxin. This effect is responsible in part for the host immunity that results after certain natural infections and after immunization. Administration of exogenous Ig may also be used therapeutically in the treatment or prevention of infections, toxic disease, or to counter medication overdoses. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digitalis overdose can be treated with digitalis immune antibody fragments. The preparation contains Fab fragments of antibodies generated against digitalis, which bind the drug and promote clearance by the kidney. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=see_link&amp;anchor=H16#H16\">",
"       \"Digitalis (cardiac glycoside) poisoning\", section on 'Antidotal therapy with antibody (Fab) fragments'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Envenomation by pit vipers (rattlesnake, water moccasin, or copperhead) can be treated with polyvalent Crotalidae ovine immune Fab (FabAV, Crofab&reg;, BTG International) antivenom. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\", section on 'Crotalinae (Pit viper) antivenom'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"       Varicella Zoster immune globulin",
"      </a>",
"      can be use for post-exposure prophylaxis in high-risk patient populations. The primary function of VZV specific IgG antibodies is believed in neutralization of viral particles at sites of inoculation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"       \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF THE Ig CONSTANT REGION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constant region of immunoglobulins has two well-characterized functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of the classical complement system, a group of serum proteins and cell membrane receptors that are important in host defense against a variety of pathogens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=see_link&amp;anchor=H2#H2\">",
"       \"Complement pathways\", section on 'Classical pathway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Binding to cell surface receptors on granulocytes or macrophages to initiate phagocytosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other activities. Surface Ig can also serve to transduce signals leading to B cell activation as part of the B cell receptor complex. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complement fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both IgG (predominantly subclasses 1 and 3) and IgM antibodies are capable of activating complement. One mechanism of complement activation requires interaction with the constant heavy domains of two Ig molecules bound to an antigen or cell surface in close proximity. Since IgG is monomeric, this requires that two distinct IgG molecules be fixed near one another. In comparison, one molecule of pentameric IgM may activate complement. Once an antigen-antibody complex has formed, the Fc portion (abbreviation for fragment that is crystallizable) of the antibody molecule attaches to C1q, activating the classical pathway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interaction with Fc receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of Fc receptors are capable of binding to IgG, IgA, IgM, or IgE. Specific sets of Fc receptors are expressed on leukocytes, dendritic cells, and epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/14\">",
"     14",
"    </a>",
"    ]. High-affinity receptors, such as Fc&epsilon;RI, can bind even a single (monovalent) antibody molecule at low concentration, while others are low affinity and bind only to multivalent immunoglobulins, such as those that exist within large antigen-antibody complexes. These Fc receptors mediate a range of cell processes including cell activation, initiation of ADCC or phagocytosis, and feedback inhibition. The antiinflammatory effect of immune globulin therapy may rely in part upon the interactions between the Fc portions of IgG with receptors on various immune cells. Proposed mechanisms of action of IgG therapy involve upregulation of the inhibitory Fc gamma receptor (FcgammaRIIB) as well as downregulation or blockade of activating Fc gamma receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific Fc receptors on various cell types are discussed in other topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6650?source=see_link&amp;anchor=H3#H3\">",
"     \"Neutrophil functions other than movement\", section on 'Opsonins and opsonin receptors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link&amp;anchor=H4#H4\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\", section on 'Functions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPLICATIONS OF IMMUNOGLOBULINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulins have therapeutic uses in a variety of illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Polyclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal human immunoglobulin purified from plasma has been used clinically since the 1940s, at first to prevent viral diseases such as hepatitis, measles, and polio and a decade later, in the treatment of antibody deficiencies. Immunoglobulin preparations were initially given intramuscularly, although since 1981, most antibody-deficient patients receive replacement therapy either intravenously (IVIG or IGIV) or subcutaneously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with primary or secondary forms of immunodeficiency, administration of immunoglobulins reduces the incidence and severity of infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human immunoglobulin has also been used as an immunomodulator in a number of diverse conditions, including hematologic disorders, arthritides, neurologic disorders, vasculitides, and skin diseases (",
"      <a class=\"graphic graphic_table graphicRef61294 \" href=\"mobipreview.htm?21/62/22508\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17175?source=see_link\">",
"       \"Intravenous immune globulin in hematologic disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibody (mAb) technology has revolutionized research in many biological disciplines, as well as the diagnosis and treatment of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Normally, a series of Ig gene rearrangements gives rise to a B cell expressing unique Ig genes. As the B cell divides, its progeny cells carry the same Ig genes. These genetically identical cells constitute a clone, and the antibodies they secrete are all identical, hence, monoclonal.",
"   </p>",
"   <p>",
"    A normal in vivo antibody response to a particular antigenic determinant is polyclonal. Several clones of B cells participate, each interacting with different antigenic determinants of the antigen and each producing their own monoclonal population of antibodies. The result of their combined output of antibodies is a polyclonal response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Production techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies of a desired specificity can be produced in large quantities for therapeutic use. The production technology utilizes properties of myeloma cells (malignant B cells that will proliferate indefinitely in culture) that are monoclonal and secrete Ig. Myeloma cells can be grown by serial passage in animals or they can be adapted for growth in tissue culture. The fusion of myeloma cells with normal B cells yields hybridomas. To obtain a hybridoma that will produce the Ig encoded by the normal B cell, a non-secreting myeloma line must be used as a fusion partner. A method of selecting for fused cells is required.",
"   </p>",
"   <p>",
"    Non-secreting myeloma cell lines have been established that possess a defect in the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/20\">",
"     20",
"    </a>",
"    ]. This enzyme operates in the salvage pathway of purine nucleotide synthesis, and permits a cell to use xanthine and guanine as nucleotide precursors, rather than synthesizing them de novo. A cell with this enzyme defect will not die unless it is cultured in the presence of an inhibitor of de novo nucleotide synthesis (such as aminopterin) since it will be unable to make any purine nucleotides.",
"   </p>",
"   <p>",
"    When a normal cell is fused with a HGPRT-deficient cell, the normal HGPRT gene is expressed. When a mixture of fused and unfused cells is grown in the presence of aminopterin and hypoxanthine, fused cells survive because they can use hypoxanthine to make purine nucleotides. Thymidine is also added to the culture medium since its synthesis is also inhibited by aminopterin. This selection medium is referred to as HAT medium (hypoxanthine, aminopterin, thymidine). Because of this medium, unfused myeloma cells die and unfused B cells do not grow for extended periods if the culture medium is not supplemented with trophic factors (",
"    <a class=\"graphic graphic_figure graphicRef71530 \" href=\"mobipreview.htm?27/8/27778\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hybridoma technology can be used to produce large quantities of mAbs of almost any desired specificity. As an example, to obtain an antibody against protein X, the following procedure should be employed. First, immunize a mouse with protein X, remove its spleen cells and fuse them with a myeloma. After HAT selection, use an ELISA or RIA to screen surviving cells for secretion of antibody binding X.",
"   </p>",
"   <p>",
"    Although this scenario is simplified and many pitfalls may be encountered, the production of mAbs is clearly a powerful technology. Following this scheme, the different mAbs produced by researchers worldwide number in the hundreds of thousands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, at least 18 monoclonal antibodies are licensed for clinical use, and many more are under study. Most are used for immunosuppression, cancer therapy and rheumatologic conditions. The first mAb used clinically was the murine anti-human CD3 mAb OKT3. This was administered in conditioning regimens prior to bone marrow transplantation, and as immunosuppressive therapy to prevent and treat rejection of grafts. Since that time, the number of mAbs entering clinical studies has been steadily increasing.",
"   </p>",
"   <p>",
"    Most mAbs function through activation of the immune system. They can selectively bind and destroy target cells by recruiting and triggering the cytolytic function of other components of the immune system. Alternatively, mAbs can bind to key proteins and disrupt processes that are essential for continued survival and growth of target cells. Cytotoxic agents have been conjugated to mAbs in attempts to kill selective populations of cells, although these techniques have met with varying success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One example of an effective mAb is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , an antiangiogenic antibody that binds and inhibits vascular endothelial growth factor (VEGF). The addition of this agent to standard chemotherapy for the treatment of metastatic colorectal cancer was found to significantly increase median survival compared with chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major difficulties of human in vivo mAb therapy is the immunogenicity of the reagent itself. There are still several technical challenges for producing human mAbs, and most mAbs used to date have been derived from rodents. Rodent and other foreign proteins can elicit antibody production when injected into humans, although this is believed to happen in a small percentage of recipients. The resulting antibodies may be human antimouse antibodies (HAMAs), human antichimeric antibodies (HACAs) or human antihuman antibodies (HAHAs). The presence of these antibodies may severely limit the efficacy of the drug after repeated administration due to immune complex formation and rapid clearance from the circulation by human anti-mAb antibodies. These complexes can also produce undesirable inflammatory phenomena, including serum sickness or infusion reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H29#H29\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Ibritumomab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional problem with the use of rodent antibodies is that rodent Fc structures do not interact well with human Fc-dependent effector mechanisms. Human antibodies are clearly desirable for these applications, but obtaining activated B cells specific for various tumor antigens or pathogens from human donors is technically, and often ethically, problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Modified monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibody technology evolved further to address some of the problems described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Humanized monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant DNA techniques are increasingly being applied to produce \"humanized\" antibodies, or mAbs that contain a greater proportion of human protein. One method joins mouse variable region genes encoding a particular specificity to human C region genes to create a chimeric antibody. Another method uses expression of human V genes in bacteria. Colonies can be screened for proteins (antibody fragments) with desired specificities. The genes can then be linked to C genes to create an intact fully human antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4347748\">",
"    <span class=\"h3\">",
"     Antibody Fab fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fab fragments of antibodies lack the Fc component and thus are not capable of interacting with Fc receptors or activating complement. Clinical applications include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"       Ranibizumab",
"      </a>",
"      is a recombinant humanized monoclonal antibody Fab fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss. This agent is used in the treatment of some forms of age-related macular degeneration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H8#H8\">",
"       \"Age-related macular degeneration: Treatment and prevention\", section on 'Ranibizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      is a Fab antibody fragment of a chimeric human-murine monoclonal antibody (7E3), which binds to platelet",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptors, resulting in steric hindrance and thus inhibition of platelet aggregation. Clinical uses of abciximab include unstable angina and clot prevention in various coronary stenting procedures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link&amp;anchor=H4#H4\">",
"       \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'Abciximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bifunctional antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic engineering has created additional types of antibodies that may have important clinical applications in the future. Bifunctional (or bispecific) antibodies are created by the union of two different specificities in a single antibody molecule. That is, the divalent four chain unit is made up of two different heavy-light chain pairs, each with its own specificity. Such antibodies are made by fusing two hybridomas, creating hybrid-hybridomas.",
"   </p>",
"   <p>",
"    These molecules may be used in a variety of ways to enhance immune effector mechanisms, eg, the specificity for a cytotoxic T cell receptor may be linked with specificity for a viral, parasitic, or tumor antigen. This results in a bifunctional antibody that enhances cytotoxic activity against a specific target. The effectiveness of this strategy has been demonstrated in animal models. As an example, replication of influenza virus in mice can be inhibited by a bifunctional antibody nonspecifically targeting cytotoxic T cells to virus-infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A different form of bifunctionality endows an antibody specificity with a new biological activity by actually linking another active molecule (eg, a cytokine) directly to the antibody either chemically, or using recombinant DNA methods. A reagent to target human tumor necrosis factor to colonic carcinoma cells is being developed in this way [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antigenized antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another type of modified immunoglobulin is the \"antigenized\" antibody. These are created by replacing part of the antibody polypeptide with a fragment of a microbial antigen. Any sequence can be inserted into various portions of the antibody molecule. These reagents are potentially useful as vaccines since they have a longer serum half-life compared with the isolated antigen fragment, and may be better tolerated than some microbial fragments. The successful presentation of microbial peptides contained in antibody molecules has been shown in a variety of animal systems (eg, for influenza virus in mice) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     IgG1 fusion proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG1 fusion proteins are another class of biologic therapeutics that takes advantage of immunoglobulins properties. In these molecules, the Fc portion of human IgG1 is combined with an effector protein, which increases the half-life of the effector protein and prolongs its biological activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/26\">",
"     26",
"    </a>",
"    ]. These fusion proteins can be identified by the \"-cept\" suffix that is added to the end of the generic name of the preparation. An example is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a fusion protein that contains the TNFalpha receptor. It works as a TNF inhibitor by preventing TNF from binding to cell surface receptors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monoclonal antibody nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been established for the naming of monoclonal antibodies (",
"    <a class=\"graphic graphic_table graphicRef80356 \" href=\"mobipreview.htm?4/11/4284\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All monoclonal antibodies end with the suffix \"-mab.\" Preceding this are various prefixes, called &ldquo;infixes.&rdquo;",
"     </li>",
"     <li>",
"      Preceding the &ldquo;mab&rdquo; is a letter denoting the source species from which the mAb was derived (eg, &ldquo;u&rdquo; for human, &ldquo;o&rdquo; for mouse).",
"     </li>",
"     <li>",
"      Preceding the source letter are additional letters that denote the target organ or disease for which the monoclonal antibody is used (eg, &ldquo;vir&rdquo; for viral disease, &ldquo;mel&rdquo; for melanoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Useful descriptions of monoclonal antibodies, fusion proteins, and other biologic therapies that are approved for clinical use can be found at the website of the Clinical Immunology Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40792/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin (Ig) molecules are multifunctional tools used by cells to mediate interactions of antigen molecules with a variety of cellular and humoral effector mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The variable region of the immunoglobulin molecule interacts with antigen to effect several phenomena, including precipitation, agglutination, and neutralization. These properties are utilized in a variety of diagnostic laboratory tests, including immunoelectrophoresis, ELISAs, immunohistochemistry, and agglutination tests. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functions of the Ig variable region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The functions of the constant region of immunoglobulins are activation of the complement system, and binding to cell surface receptors on granulocytes or macrophages and other cell types to initiate phagocytosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other activities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Functions of the Ig constant region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyclonal human immunoglobulins, given intravenously or subcutaneously, are used to reduce the incidence and severity of infections in various immunodeficiency states. These preparations also act as immunomodulators in hematologic disorders, arthritides, neurologic disorders, vasculitides, and skin diseases (",
"      <a class=\"graphic graphic_table graphicRef61294 \" href=\"mobipreview.htm?21/62/22508\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Polyclonal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monoclonal antibodies to specific antigenic determinants can be produced in large quantities for treatment of a variety of conditions. Production techniques have been further refined to produce humanized, bifunctional, and antigenized monoclonal antibodies. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monoclonal antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Modified monoclonal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines have been established for naming of monoclonal antibodies (",
"      <a class=\"graphic graphic_table graphicRef80356 \" href=\"mobipreview.htm?4/11/4284\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monoclonal antibody nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/1\">",
"      PORTER RR. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 1959; 73:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/2\">",
"      Goldberg ME, Djavadi-Ohaniance L. Methods for measurement of antibody/antigen affinity based on ELISA and RIA. Curr Opin Immunol 1993; 5:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/3\">",
"      Getzoff ED, Geysen HM, Rodda SJ, et al. Mechanisms of antibody binding to a protein. Science 1987; 235:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/4\">",
"      Tedford MC, Stimson WH. Molecular recognition in antibodies and its application. Experientia 1991; 47:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/5\">",
"      Drescher J, Aron R. Influence of the amino acid differences between the hemagglutinin HA1 domains of influenza virus H1N1 strains on their reaction with antibody. J Med Virol 1999; 57:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/6\">",
"      Wolfs TF, Zwart G, Bakker M, et al. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 1991; 185:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/7\">",
"      Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/8\">",
"      Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/9\">",
"      Baumgarth N, Herman OC, Jager GC, et al. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc Natl Acad Sci U S A 1999; 96:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/10\">",
"      Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005; 26:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/11\">",
"      Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/12\">",
"      Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 2007; 29:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/13\">",
"      Boes M, Schmidt T, Linkemann K, et al. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000; 97:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/14\">",
"      Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/15\">",
"      Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/16\">",
"      Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/17\">",
"      Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/18\">",
"      Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/19\">",
"      Liossis SN, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 2005; 116:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/20\">",
"      K&ouml;hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/21\">",
"      Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/22\">",
"      Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/23\">",
"      Moran TM, Usuba O, Kuzu H, et al. Inhibition of multicycle influenza virus replication by hybrid antibody-directed cytotoxic T lymphocyte lysis. J Immunol 1991; 146:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/24\">",
"      Xiang J, Moyana T, Qi Y. Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor. J Biotechnol 1997; 53:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/25\">",
"      Zaghouani H, Steinman R, Nonacs R, et al. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 1993; 259:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/26\">",
"      Cox GN, Smith DJ, Carlson SJ, et al. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp Hematol 2004; 32:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40792/abstract/27\">",
"      Bussel JB, Giulino L, Lee S, et al. Update on therapeutic monoclonal antibodies. Curr Probl Pediatr Adolesc Health Care 2007; 37:118.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     The Clinical Immunology Society. file://biologics.clinimmsoc.org (Accessed on February 11, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3970 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40792=[""].join("\n");
var outline_f39_53_40792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONS OF THE Ig VARIABLE REGION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibody-antigen interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibody specificity and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1550679\">",
"      - Natural antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Precipitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnostic applications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Agglutination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Coombs' test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neutralization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FUNCTIONS OF THE Ig CONSTANT REGION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complement fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interaction with Fc receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THERAPEUTIC APPLICATIONS OF IMMUNOGLOBULINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Polyclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Production techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Modified monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Humanized monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4347748\">",
"      - Antibody Fab fragments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bifunctional antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antigenized antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      IgG1 fusion proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monoclonal antibody nomenclature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3970|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/2/1071\" title=\"figure 1\">",
"      Antibody structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/17/10525\" title=\"figure 2\">",
"      ELISA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/8/27778\" title=\"figure 3\">",
"      Monoclonal antibody generation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/62/22508\" title=\"table 1\">",
"      Autoimmune disease Rx with IGIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/11/4284\" title=\"table 2\">",
"      Monoclonal Ab Nomenclature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17175?source=related_link\">",
"      Intravenous immune globulin in hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_53_40793="Spontaneous pneumothorax in children";
var content_f39_53_40793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous pneumothorax in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Ibrahim A Janahi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/53/40793/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/53/40793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax in children is an unusual disorder that can be life-threatening. It may be idiopathic or associated with underlying pulmonary disease. The prognosis is usually good, although recurrence is frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax is defined as a collection of air that is located within the thoracic cage between the visceral and parietal pleura (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72656 \" href=\"mobipreview.htm?22/63/23538\">",
"     image 1",
"    </a>",
"    ). Air can enter the pleural space through a leak in either pleural surface. It may flow freely within the chest or be loculated by fibrous bands or other tissues. Rarely, air accumulates due to infection with gas-producing bacteria.",
"   </p>",
"   <p>",
"    A pneumothorax is characterized as either spontaneous or traumatic. Traumatic pneumothorax is caused by blunt, crush, or penetrating trauma to the chest, by injury from a diagnostic or therapeutic procedure, or as a consequence of mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous pneumothorax, the subject of this topic review, occurs in the absence of any identified trauma. It is subdivided into primary and secondary types (",
"    <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary spontaneous pneumothorax (PSP) is diagnosed when a thorough investigation reveals no underlying lung disease that would predispose the individual to air leak.",
"     </li>",
"     <li>",
"      Secondary spontaneous pneumothorax (SSP) occurs as a complication of underlying lung disease, such as asthma, cystic fibrosis, necrotizing pneumonia, and interstitial lung disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between these types of pneumothorax is not always clear; many individuals with PSP have subtle indications of previously undiagnosed pulmonary disease, such as obstructive airway disease. In addition, apical blebs of unclear etiology have been detected by computed tomography or at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of PSP in the general population is estimated to be 5 to 10 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The peak incidence occurs between 16 and 24 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of pneumothorax is relatively high in the newborn period. The reported incidence of pneumothorax in newborns and infants depends upon the setting and method of ascertainment. Small asymptomatic pneumothoraces probably occur in 1 to 2 percent of live births, whereas symptomatic pneumothoraces occur in about 2 in 10,000 live births (0.02 percent). Rates of PSP are increased among infants that are premature or large; infants with underlying lung disease including meconium aspiration are also at risk for SSP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=see_link\">",
"     \"Pulmonary air leak in the newborn\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    There is a strong male predominance for PSP in adults. Spontaneous pneumothorax is approximately three to six times more common in males than females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ], although women of reproductive age occasionally develop spontaneous pneumothorax triggered by menstruation (catamenial pneumothorax). (See",
"    <a class=\"local\" href=\"#H18497240\">",
"     'Catamenial pneumothorax'",
"    </a>",
"    below.) There is also a male predominance among adolescents, but probably not in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4789334\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSP typically affects patients with a tall, thin body habitus. In adults, smoking increases the risk of pneumothorax 22 times in men and 9 times in women, perhaps accounting for the higher incidence of the disorder in adults than children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/13\">",
"     13",
"    </a>",
"    ]. Pneumothorax has been reported with marijuana smoking and cocaine inhalation (",
"    <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of pneumothoraces occur at rest. However, in some cases, there is a history of an activity or event unrelated to thoracic trauma but associated with an acute increase in transpulmonary pressure; reported precipitating events include military flying, weight lifting, and Valsalva maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Rarely, contact sports such as football or ice hockey can cause pneumothorax through this mechanism (barotrauma) or through blunt chest trauma with pulmonary laceration, but these would be considered a traumatic pneumothorax.",
"   </p>",
"   <p>",
"    Familial cases of spontaneous pneumothorax have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The majority of patients are adolescent or adult males, although newborns may be affected. Autosomal dominant and X-linked recessive inheritance has been proposed. In some cases, the familial predisposition is associated with pulmonary cysts, as in Birt-Hogg-Dube syndrome. In other cases, the exact predisposing factor cannot be identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Underlying pulmonary conditions associated with spontaneous pneumothorax (secondary spontaneous pneumothorax, SSP) are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/22\">",
"     22",
"    </a>",
"    ]. The overall incidence of SSP is similar to PSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the incidence of PSP peaks in adolescence and young adulthood, whereas the peak incidence of SSP occurs at an older age, largely due to the presence of chronic obstructive pulmonary disease in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .) In preadolescent children, rates of PSP and SSP are approximately equal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air leak through either the visceral pleura or the parietal pleura can cause pneumothorax, but spontaneous pneumothorax occurs exclusively via rupture of the visceral pleura. &nbsp;",
"   </p>",
"   <p>",
"    Two mechanisms appear to explain most cases of alveolar rupture and spontaneous pneumothorax, and sometimes there is evidence for both mechanisms (eg, coughing in a patient with lung disease): &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute increase in transpulmonary pressure",
"     </li>",
"     <li>",
"      Defects in the visceral pleura &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18497226\">",
"    <span class=\"h2\">",
"     Acute increase in transpulmonary pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary spontaneous pneumothorax is thought to be caused by large increases in transpulmonary pressure which cause alveolar distension. With sufficiently high pressure gradients, an alveolus can rupture. Rapid, large shifts in pressure can occur during spontaneous respiratory efforts, positive pressure ventilation, Valsalva maneuvers, or when a ball-valve mechanism is created due to airway obstruction.",
"    <br/>",
"    <br/>",
"    Superficial alveoli can form subpleural blebs that rupture directly into the pleural space. These blebs are usually found in the lung apices, presumably due to the selective ventilation and higher transpulmonary pressures seen in the upper lobes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/23\">",
"     23",
"    </a>",
"    ]. Alveoli located more centrally rupture and then dissect along the perivascular tissue planes centrifugally toward the hilum or peripherally toward the visceral pleural surface. Pneumomediastinum may occur if the alveolar rupture is into the mediastinum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75787 \" href=\"mobipreview.htm?18/58/19361\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34999?source=see_link\">",
"     \"Spontaneous pneumomediastinum in children and adolescents\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Air confined to the interstitial spaces results in pulmonary interstitial emphysema. If pressures are sufficiently high, gas can rupture centrally or peripherally from the interstitial space into the pleural space to produce a pneumothorax. Similarly, gas under significant tension can track along tissue planes into the pericardium, abdomen, or subcutaneous tissue, resulting in a pneumopericardium, pneumoperitoneum, or subcutaneous emphysema, respectively (",
"    <a class=\"graphic graphic_figure graphicRef67176 \" href=\"mobipreview.htm?21/9/21649\">",
"     figure 1",
"    </a>",
"    ). &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18497233\">",
"    <span class=\"h2\">",
"     Defects in visceral pleura",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases a pneumothorax develops from direct injury to the visceral pleura due to underlying lung disease; these are considered secondary pneumothoraces. This mechanism may explain pneumothorax associated with infectious processes (such as tuberculosis, necrotizing pneumonia or abscess, Pneumocystis jiroveci [carinii] pneumonia, or infection in cystic fibrosis), metastatic or embolic malignancies, congenital cystic anomalies, and catamenial pneumothorax (",
"    <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"    <br/>",
"    Air leak associated with infection is probably due to localized inflammation and tissue necrosis that lead to the creation of a connection between the airways and pleural space (bronchopleural fistula), thereby allowing the free passage of gas into the pleural space. With tumors near the pleural surface, infarction and necrosis can lead to air leak by a similar mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18497240\">",
"    <span class=\"h2\">",
"     Catamenial pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catamenial pneumothorax refers to recurrent pneumothoraces that are triggered by menstrual cycles; it is particularly unusual in adolescents but has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In many cases, it is associated with thoracic endometriosis, which occurs when endometrial tissue migrates from the peritoneal cavity into the thoracic cavity through congenital diaphragmatic defects or possibly through microembolization through the pelvic veins. The mechanism for the apparent association with thoracic endometriosis is unclear; it is possible that air leaks through defects left by sloughing of endometrial implants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25254?source=see_link\">",
"     \"Thoracic endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When pneumothorax occurs, the free passage of air into the pleural space allows equalization of intrapleural and atmospheric pressures, which predisposes to partial lung collapse (",
"    <a class=\"graphic graphic_figure graphicRef54660 \" href=\"mobipreview.htm?8/18/8483\">",
"     figure 2",
"    </a>",
"    ). A small pneumothorax may be well tolerated and asymptomatic. A large pneumothorax generally causes restrictive changes in lung mechanics with tachypnea and sometimes inspiratory retractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4789320\">",
"    <span class=\"h2\">",
"     Tension pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tension pneumothorax is caused when air enters the pleural space during inspiration but cannot be exited through the same pathway, similar to a one-way valve. This results in air accumulation within the pleural space, generating an intrapleural pressure that is substantially higher than the atmospheric pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/27\">",
"     27",
"    </a>",
"    ]. The inward elastic recoil of the pulmonary parenchyma causes the involved lung to collapse, while increased intrathoracic pressure causes the mediastinum to shift away from the side of the pneumothorax (",
"    <a class=\"graphic graphic_figure graphicRef77092 \" href=\"mobipreview.htm?35/22/36196\">",
"     figure 3",
"    </a>",
"    ). Tension pneumothorax is often associated with hypoxemia due to lung collapse, an increased work of breathing due to restrictive lung disease, and in some cases, hemodynamic changes with reduced venous return to the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pneumothorax depends upon the volume of air in the pleural space, rapidity of onset, extent of lung collapse, tension within the pleural space, and the patient's age and respiratory reserve. The latter is influenced by the presence of any underlying pulmonary disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pneumothorax most often occurs when patients are at rest or with minimal exertion. Patients with a large pneumothorax usually complain of the sudden onset of dyspnea and pleuritic chest pain that is described as sharp or stabbing and may be preceded by a popping sensation. The pain typically is diffuse on the affected side with radiation to the ipsilateral shoulder. A dry or non-productive cough is occasionally seen in association with pneumothoraces. The pain often resolves spontaneously during the first 24 hours, even if the pneumothorax persists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history should investigate potential causes of secondary pneumothorax, such as use of inhaled drugs, undiagnosed asthma, foreign body aspiration, upper or lower respiratory tract infection, and connective tissue diseases (",
"    <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"     table 1",
"    </a>",
"    ). The presence of apical blebs supports the diagnosis of PSP. Otherwise, PSP is largely a diagnosis of exclusion. &nbsp;",
"   </p>",
"   <p>",
"    A small pneumothorax may be asymptomatic. It may be detected as an incidental finding on a chest radiograph obtained for another indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic physical findings associated with a large pneumothorax include decreased chest excursion, diminished breath sounds, hyperresonant percussion, and decreased vocal fremitus on the affected side. Other signs of respiratory compromise may include tachypnea, increased work of breathing, and cyanosis. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Signs suggestive of tension pneumothorax include deviation of the trachea towards the contralateral side. Other signs of tension PSP include tachycardia, hypotension, and cyanosis (",
"    <a class=\"graphic graphic_figure graphicRef77092 \" href=\"mobipreview.htm?35/22/36196\">",
"     figure 3",
"    </a>",
"    ). Heart sounds may be diminished and the apical impulse shifted to the contralateral side. Tension pneumothorax is a respiratory emergency and requires urgent decompression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H254983688#H254983688\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Tension pneumothorax'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Subcutaneous emphysema with crepitation, or abdominal distension due to pneumoperitoneum, is occasionally present as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pneumothorax is established by chest radiograph. When possible, the radiograph should be taken in the upright position. A pneumothorax tends to appear larger on an expiratory film and may enhance detection of small pneumothoraces. However, to monitor changes in the size of the pneumothorax over time, only inspiratory films should be compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16059641\">",
"     'Estimation of size'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Anteroposterior and lateral views can confirm the presence of even small volumes of intrapleural air (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51728 \" href=\"mobipreview.htm?16/63/17394\">",
"     image 3",
"    </a>",
"    ). Characteristic findings are air in the pleural space outlining the visceral pleura (pleural line) and hyperlucency and an attenuation of vascular and lung markings on the affected side. Flattening or inversion of the diaphragm may occur on the affected side, and the mediastinum and trachea may shift away from the pneumothorax. Atelectasis due to compression by the pleural gas may be present as well. There is a left-side preponderance in both pediatric and adult patients with PSP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34903?source=see_link\">",
"     \"Atelectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants, anterior-posterior radiographs typically are obtained in the supine position. In this position, the pneumothorax is difficult to detect because the air accumulates anteriorly. However, if the pneumothorax is large, the affected side may appear hyperlucent. Detection of smaller pneumothoraces may be improved by obtaining a radiograph taken with the infant in a lateral decubitus position, with the affected side up.",
"   </p>",
"   <p>",
"    The plain chest radiograph may be difficult to interpret in disorders such as congenital cystic lung disease (eg, congenital lobar emphysema) or congenital diaphragmatic hernia. In these cases, the lung cysts or loops of bowel filled with air may mimic air in the pleural space. Computed tomography (CT) of the chest or contrast studies (upper gastrointestinal series with small bowel follow-through) usually can distinguish these conditions. Chest CT is also helpful in the detection of small apical blebs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61782 \" href=\"mobipreview.htm?14/7/14453\">",
"     image 4",
"    </a>",
"    ) and in assessing chest tube placement when needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, CT scanning is not necessary unless abnormalities are noted on the plain chest radiograph that require further assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of apical blebs (&lt;2 cm) discovered on a CT scan is unclear. The frequency of such blebs reported in the literature varies widely, ranging from 28 to 45 percent in children with PSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/22,31,32\">",
"     22,31,32",
"    </a>",
"    ], and 0 to 15 percent in healthy children and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Several studies in children suggest that the presence of apical blebs on CT does not predict recurrence risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10,32,34\">",
"     10,32,34",
"    </a>",
"    ]. In our practice, we do not consider small apical blebs to be an indication for surgical intervention in a patient with a first occurrence of PSP. However, we observe patients with apical blebs closely, and tend to move more quickly to surgical intervention if the patient does not improve with conservative management. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Surgical intervention'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In a newborn or very young infant with suspected pneumothorax, transillumination of the chest with a high-intensity fiberoptic probe in a darkened room may help make the diagnosis and guide treatment. When the fiberoptic probe is placed against the chest wall, the presence of a pneumothorax lights up the affected hemithorax and the air can be immediately evacuated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=see_link\">",
"     \"Pulmonary air leak in the newborn\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16059641\">",
"    <span class=\"h2\">",
"     Estimation of size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods have been used to estimate the size of a pneumothorax in adults, based on measurements from the chest radiograph. A clinically practical measure in adults is to define a large pneumothorax as one with &ge;3 cm of air between the pleural line and apical chest wall, or &ge;2 cm between the entire lateral lung edge and the chest wall. These measurements correspond to about 20 to 30 percent pneumothorax, but the accuracy of these methods is limited by uneven distributions of air in some cases and by distortion from digital imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=see_link&amp;anchor=H26873522#H26873522\">",
"     \"Imaging of pneumothorax\", section on 'Size of pneumothorax'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Methods to measure size of pneumothorax have not been standardized in pediatric populations, but use of the adult parameters is probably reasonable in adolescent patients. For smaller children, the clinician generally categorizes the pneumothorax as &ldquo;small&rdquo; or &ldquo;large&rdquo; based on the relative size of the pneumothorax compared with the thoracic cavity. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood gas measurements should be obtained in patients with respiratory distress. Pulse oximetry may not be accurate if perfusion is poor, as may occur in patients with tension pneumothorax. Hypoxemia commonly occurs because collapsed and poorly ventilated portions of lung continue to receive significant perfusion. Hypercapnia is unusual in patients without underlying lung disease because adequate alveolar ventilation can be maintained in the contralateral lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute respiratory alkalosis may be present if pain, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia are substantial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2009?source=see_link\">",
"     \"Arterial puncture and cannulation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Electrocardiograms (ECGs) may be obtained in adults with chest pain and undiagnosed pneumothorax. These may demonstrate axis deviation, nonspecific ST changes, and T-wave inversion, particularly with left-sided pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/12\">",
"     12",
"    </a>",
"    ]. The role of ECG in children with spontaneous pneumothorax has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pneumothorax has not been fully standardized, particularly for children. The British Thoracic Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ] and the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/37\">",
"     37",
"    </a>",
"    ] have published guidelines on the management of adults with spontaneous pneumothorax, and other recommendations have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1,5,12,38\">",
"     1,5,12,38",
"    </a>",
"    ]. Because little direct information is available, management in children is largely based upon the adult experience.",
"   </p>",
"   <p>",
"    In general, treatment depends upon the size of the pneumothorax, the extent of respiratory distress, and the presence or absence of underlying lung disease. The goals of treatment are to remove air from the pleural space and to prevent recurrence. (See",
"    <a class=\"local\" href=\"#H16059641\">",
"     'Estimation of size'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment can be conservative, limited to observation and supplemental oxygen, or invasive. Although indications for conservative therapy are fairly well accepted, criteria for specific drainage procedures are controversial. Options include simple aspiration or chest tube drainage, with or without pleurodesis, and more invasive surgical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4673137\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following initial management strategies for children and adolescents, which are similar to those used for adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For clinically stable patients with an initial PSP that is small, we recommend observation in hospital. These patients should be given supplemental oxygen to enhance absorption of the air in the extrapleural space. Longer periods of observation are suggested for younger children and those with underlying lung disease (secondary pneumothorax). Criteria have not been developed to guide how long to observe such a patient and how long to wait before intervention if the pneumothorax persists. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Observation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with a first occurrence of a pneumothorax that is large (eg, occupying &gt;30 percent of the hemithorax), or for patients with significant dyspnea, hypoxemia, or pain, we suggest evacuation of air from the pleural space. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evacuation of the pleural space'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Needle aspiration is appropriate for clinically stable patients with PSP, and for some patients with underlying lung disease (secondary spontaneous pneumothorax, SSP)",
"     </li>",
"     <li>",
"      Clinically unstable patients with PSP and most patients with SSP should undergo chest tube or pigtail catheter insertion &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult patients who are having a first PSP that is small (eg, less than 2 to 3 cm of air between lung and chest wall on the radiograph) and is not enlarging can be safely managed with a conservative approach. An ambulatory setting may be appropriate, as long as serial chest radiographs are obtained and emergency care is available if needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H10#H10\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since no specific outcome predictors have been established for children with pneumothorax, a cautious approach is appropriate; we recommend an initial period of hospital observation in any child with a pneumothorax. If the PSP is small and is resolving during the first 12 hours, observation may be continued on an outpatient basis. Younger patients (eg, under 12 years of age) should be observed for longer. All patients with SSP should be hospitalized for observation and treatment of underlying lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend supplemental oxygen therapy for all patients hospitalized with pneumothorax, to hasten reabsorption of intrapleural air. 100 percent oxygen should be delivered using a nonrebreathing facemask and a minimum flow rate of 15 liters per minute. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This recommendation is based on limited evidence from small studies in adult patients and animal models. Without supplemental oxygen, the rate at which the air in the pleural space is reabsorbed is approximately 1.25 percent of the volume of the hemithorax per 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/11\">",
"     11",
"    </a>",
"    ]. This rate can be increased if supplemental oxygen is given, because the increased alveolar oxygen tension creates a steep gradient between the partial pressures of nitrogen in the pleural gas collection and the capillaries. In a small clinical study, administration of 100 percent supplemental oxygen increased the rate of reabsorption four-fold; the beneficial effect of oxygen was most pronounced in patients with large pneumothoraces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H12#H12\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Supplemental oxygen'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Analgesics, anti-tussives, and other supportive care are provided if necessary. More invasive therapy is needed in patients who fail to respond to conservative treatment or if the pneumothorax worsens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Evacuation of the pleural space",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H793506\">",
"    <span class=\"h4\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, evacuation of air is recommended for large pneumothoraces or for patients with significant dyspnea, hypoxemia, or significant pain. A large pneumothorax is often defined as &ge;3 cm rim of air between the pleural line and apical chest wall in adults. We also use these guidelines in children. However, an individualized approach and careful monitoring of pathophysiologic consequences is important regardless of the management strategy because estimates of pneumothorax size and clinical outcomes are not well defined for this age group. (See",
"    <a class=\"local\" href=\"#H16059641\">",
"     'Estimation of size'",
"    </a>",
"    above.) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For clinically stable patients with a large PSP, we suggest needle aspiration. Clinically unstable patients should undergo chest tube insertion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H11#H11\">",
"       \"Primary spontaneous pneumothorax in adults\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an underlying lung disease (ie, secondary spontaneous pneumothorax), management also depends on the size of the pneumothorax, but insertion of a thoracostomy tube, or a pigtail catheter, is generally preferred over needle aspiration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H10#H10\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with recurrent PSP should have their lung expanded with a tube thoracostomy, then undergo surgical intervention &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4212115\">",
"    <span class=\"h4\">",
"     Needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For clinically stable patients with a large PSP, we suggest needle aspiration; this is also the management strategy recommended for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H11#H11\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Initial management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Simple aspiration is done percutaneously with a large-bore intravenous catheter connected to a large syringe via a three-way stopcock and can be life-saving. Air is withdrawn manually until no more can be aspirated. Continuous aspiration of a substantial volume of air indicates that the air leak is persistent and lung expansion has not occurred. In this case, tube thoracostomy should be performed. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Thoracostomy tube'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If no further air can be aspirated, the stopcock is closed and the catheter is secured to the chest wall. A chest radiograph should be obtained after four hours of observation. If adequate expansion has occurred, the catheter can be removed and the patient observed for an additional two hours. Although an adult patient can be discharged if the lung remains expanded on chest radiograph at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/11\">",
"     11",
"    </a>",
"    ], we recommend that children who require aspiration of a pneumothorax continue to be observed in hospital for at least 24 hours with close monitoring or telemetry. A repeat chest radiograph should be obtained prior to considering hospital discharge.",
"   </p>",
"   <p>",
"    In patients treated with needle aspiration, the air will reaccumulate in 20 to 50 percent because of a persistent air leak, so close follow-up with serial chest radiographs is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. If the air reaccumulates, these patients should be treated with thoracostomy tube. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Thoracostomy tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail aspiration treatment because of a persistent air leak, or those who present with a recurrent spontaneous pneumothorax, and many patients with secondary spontaneous pneumothorax should be managed with a thoracostomy tube or pigtail catheter.",
"   </p>",
"   <p>",
"    A thoracostomy tube requires the use of a one-way Heimlich valve or water seal device to prevent reaccumulation of air. If the lung does not fully expand after drainage, suction should be applied to a water seal device. Early use of strong suction is not recommended because rapid expansion of the lung is associated with a risk of reexpansion-induced pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H18#H18\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Re-expansion pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no bubbles emanate from the thoracostomy tube for 12 hours or more, we recommend clamping the chest tube for an additional 24 hours to observe whether air reaccumulates, although the utility of this approach is unproven. The chest tube can be removed after 24 hours if there is no radiographic or clinical evidence of recurrence of the pneumothorax.",
"   </p>",
"   <p>",
"    Pleurodesis (the injection of sclerosing agents such as talc,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    , fibrin glue) performed at the time of thoracostomy tube placement can decrease the risk of recurrence. The optimal method for pleurodesis in children has not been established. However, current guidelines in adults advise performing pleurodesis at the time of surgical intervention for patients requiring a preventive procedure; chemical pleurodesis through the chest tube is suggested only if the patient is unable or unwilling to undergo the surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H792648\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgical intervention in the treatment of spontaneous pneumothorax is somewhat controversial. There is good evidence to suggest that surgery is warranted to treat persistent air leaks. It is not yet clear whether surgery is appropriate for a first occurrence of spontaneous pneumothorax and whether such intervention will ensure the prevention of recurrence.",
"   </p>",
"   <p>",
"    Most case series suggest that 50 to 60 percent of children with a first occurrence of primary spontaneous pneumothorax (PSP) will have a recurrence after conservative management with chest tube drainage; this recurrence risk is as high or higher than that reported in adults with PSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10,32\">",
"     10,32",
"    </a>",
"    ]. Thus, some experts suggest that surgical intervention should be considered for first occurrences as well as recurrences, if expertise in minimally invasive techniques is readily available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Other authors suggest that surgical intervention is warranted only for recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10,42,43\">",
"     10,42,43",
"    </a>",
"    ]. Even if pleurodesis is undertaken, it does not protect against recurrence of the PSP on the contralateral side. &nbsp;",
"   </p>",
"   <p>",
"    Based on limited evidence from case series in children and extrapolation from the observational studies and guidelines in adults, we draw the following conclusions about surgical intervention:",
"   </p>",
"   <p>",
"    <strong>",
"     Primary spontaneous pneumothorax",
"    </strong>",
"    &ndash; We suggest surgical intervention for children and adolescents with the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A first PSP and an air leak that fails to resolve after about five days of thoracostomy drainage. This is the time period typically suggested for adults, but is based on panels of experts rather than empiric evidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Recurrence of PSP (either ipsilateral or contralateral).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Secondary spontaneous pneumothorax",
"    </strong>",
"    &ndash; For pediatric patients with pneumothorax and underlying lung disease (ie, SSP), management strategies depend on the type and severity of the underlying lung disease. We suggest surgical intervention and a preventive intervention (eg, VATS with pleurodesis) in the following groups of patients: &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent SSP (either ipsilateral or contralateral).",
"     </li>",
"     <li>",
"      Patients with cystic fibrosis and recurrence of a large SSP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/44\">",
"       44",
"      </a>",
"      ]. Pleurodesis using mechanical abrasion rather than chemical pleurodesis is preferred, and does not preclude subsequent lung transplantation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H33#H33\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Spontaneous pneumothorax'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H5#H5\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'Cystic fibrosis'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Patients with a first episode of SSP due to other causes, if the underlying lung disease is severe or progressive, or is known to be associated with recurrent pneumothoraces. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We perform a preventive intervention for patients with bullous lung disease.",
"     </li>",
"     <li>",
"      We do not usually perform preventive interventions for patients with mild or moderate asthma after a first occurrence of pneumothorax. Instead, the primary treatment for such patients is to optimize asthma treatment.",
"     </li>",
"     <li>",
"      Children with necrotizing pneumonia are treated with proper antibiotics and pleural space suctioning. If they develop broncho-pleural fistula, surgical intervention is warranted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27882?source=see_link\">",
"       \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of other lung diseases in children can be associated with pneumothoraces, including congenital cystic lung disease and interstitial lung disease. The recurrence risk and risk of intervention varies with the type and severity of the underlying lung disease, so treatment decisions must be made on a case-by-case basis, including the timing of surgical intervention for patients with persistent air leaks. In all cases, the occurrence of a pneumothorax should prompt efforts to fully evaluate and optimize treatment of the underlying lung disease.",
"   </p>",
"   <p>",
"    Surgical intervention to prevent recurrence is generally recommended for adults with SSP, because recurrence is more common and more likely to be clinically severe for adult patients with underlying lung disease as compared with those with PSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ]. However, extrapolation from adult data and guidelines is questionable because the type of lung disease underlying SSP varies substantially by age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H793389\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for pneumothorax consists of stapling or oversewing ruptured blebs or tears in the visceral pleura and resection of abnormal lung tissue, if present. The approaches used include video-assisted thoracoscopic surgery (VATS), mini-thoracotomy, and conventional thoracotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. None has been shown to be superior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39637?source=see_link\">",
"     \"Therapeutic uses of medical thoracoscopy\"",
"    </a>",
"    .) We usually use VATS, which provides adequate exposure for resection or stapling and an opportunity for abrasion or chemical pleurodesis. The morbidity of VATS is less than with conventional or mini-thoracotomy, and recurrence rates are about 5 percent in adults, although open thoracotomy and pleurectomy have the lowest recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleurodesis (intrapleural instillation of a sclerosing agent) is often performed at the time of surgery to decrease the risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Multiple sclerosing agents have been used including talc, fibrin glue, and antibiotics (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/20/43334?source=see_link\">",
"     minocycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Alternatively, pleural abrasion with dry gauze may be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/58\">",
"     58",
"    </a>",
"    ]. Pleurodesis using talc (poudrage) is sometimes used in adults, but we do not use this technique in children because its long-term risks have not been sufficiently studied in this age group. In addition, technical difficulties arise because the currently available medical trocars are large and cannot be used in small children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described above, pleurodesis may be indicated for the first episode of a secondary pneumothorax, due to the high incidence of recurrence that could be life-threatening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ]. With no underlying lung disease (primary pneumothorax), the procedure is usually reserved for a recurrence. Pleurodesis also is recommended for individuals who participate in activities associated with increased risk of pneumothorax, such as deep sea diving or flying in small, unpressurized aircraft. (See",
"    <a class=\"local\" href=\"#H792648\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon experience in adults, we routinely perform pleurodesis during VATS, using manual abrasion. We avoid chemical agents because they are very painful and can increase postoperative morbidity. We do not typically instill sclerosing agents through chest tubes, though this technique has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Thoracostomy tube'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4671806\">",
"    <span class=\"h3\">",
"     Other preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with PSP or SSP should be strongly advised not to smoke tobacco. Smoking is strongly associated with PSP in adults, and smoking cessation probably helps to prevent recurrences.",
"   </p>",
"   <p>",
"    Commercial air travel in pressurized airplanes is not thought to precipitate recurrence of pneumothorax. However, because the consequences of a spontaneous recurrence occurring during air travel may be serious. Therefore, guidelines for adults suggest avoidance of air travel until at least one week after full resolution of the pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, most authorities suggest avoidance of sports that involve extreme exertion and physical contact until the pneumothorax is fully resolved.",
"   </p>",
"   <p>",
"    Activities such as deep sea diving or flying in small, unpressurized aircrafts are associated with increased risk of pneumothorax and should be avoided in individuals who did not undergo pleurodesis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about the prognosis after spontaneous pneumothorax is based primarily on experience in adults, in whom there is a substantial recurrence risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1,4,11,12\">",
"     1,4,11,12",
"    </a>",
"    ]. In one review of 11 studies, pneumothorax recurred in about 30 percent of cases of primary spontaneous pneumothorax managed with observation, aspiration, or chest tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/4\">",
"     4",
"    </a>",
"    ]. The recurrence risk is similar for secondary spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of recurrences develop within one year of the initial event, after which the risk decreases. Late recurrences are unusual.",
"   </p>",
"   <p>",
"    Data on recurrent pneumothorax in children are limited to smaller series, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 58 children (median age 16.7 years) with primary spontaneous pneumothorax, the risk of recurrence was 51 percent after one episode and 56 percent after two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 31 patients with PSP, 19 had ipsilateral or contralateral recurrences (61 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/60\">",
"       60",
"      </a>",
"      ]. In a similar series of 58 patients, there was a 51 percent recurrence risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, approximately 50 to 60 percent of pediatric patients with PSP will have a recurrence if managed conservatively (ie, without surgery or pleurodesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10,32\">",
"     10,32",
"    </a>",
"    ]. There are insufficient data on pediatric patients to determine if the recurrence risk is similar to or higher than adults with PSP. Surgical pleurodesis greatly decreases the probability of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/32,52,53\">",
"     32,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrence risk for pediatric patients with SSP is unclear, but probably depends substantially on the underlying lung disease; patients with cystic fibrosis and pneumothorax have a recurrence rate of 50 to 80 percent if a preventive procedure is not performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/61\">",
"     61",
"    </a>",
"    ], whereas a small series reported recurrence in one of seven patients with PSP associated with an acute episode of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/53/40793/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/30/40418?source=see_link\">",
"       \"Patient information: Pneumothorax (collapsed lung) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18497078\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumothorax is defined as a collection of air that is located within the thoracic cage between the visceral and parietal pleura. Spontaneous pneumothorax occurs in the absence of any identified trauma. It is subdivided into primary and secondary types (",
"      <a class=\"graphic graphic_table graphicRef65455 \" href=\"mobipreview.htm?8/8/8333\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary spontaneous pneumothorax (PSP) is diagnosed when a thorough investigation reveals no underlying lung disease that would predispose the individual to air leak.",
"     </li>",
"     <li>",
"      Secondary spontaneous pneumothorax (SSP) occurs as a complication of underlying lung disease, such as cystic fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peak incidence of PSP occurs between 16 and 24 years of age, and it is more common in males than females. PSP also occurs in younger children and newborn infants. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4672226\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous pneumothorax most often occurs when patients are at rest or with minimal exertion. Patients with a large pneumothorax usually complain of the sudden onset of dyspnea and pleuritic chest pain that is described as sharp or stabbing and may be preceded by a popping sensation. The pain typically is diffuse on the affected side with radiation to the ipsilateral shoulder. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings associated with a large pneumothorax include diminished breath sounds, hyperresonant percussion on the affected side, tachypnea, increased work of breathing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyanosis. The trachea may be shifted to the contralateral side. Arterial blood gas measurements often reveal hypoxemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pneumothorax is established by chest radiograph. Anteroposterior and lateral views can confirm the presence of even small volumes of intrapleural air (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51728 \" href=\"mobipreview.htm?16/63/17394\">",
"       image 3",
"      </a>",
"      ). Computed tomography (CT) of the chest may be helpful for patients with underlying pulmonary conditions or thoracic anomalies. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4672178\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For clinically stable patients with an initial PSP that is small, we suggest observation in hospital, rather than initial aspiration or tube thoracostomy to evacuate air from the pleural space (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend that all patients hospitalized with PSP be given supplemental oxygen to enhance absorption of the air in the extrapleural space (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Longer periods of observation are suggested for younger children and those with underlying lung disease (secondary pneumothorax). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a first occurrence of a pneumothorax that is large or for patients with significant dyspnea, hypoxemia, or pain, we suggest evacuation of air from the pleural space, rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evacuation of the pleural space'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Needle aspiration is appropriate for clinically stable patients with PSP, and for some patients with underlying lung disease (secondary spontaneous pneumothorax, SSP).",
"     </li>",
"     <li>",
"      Clinically unstable patients with PSP and most patients with SSP should undergo chest tube insertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children and adolescents with PSP, we suggest surgical intervention for those with an air leak that fails to resolve after four to seven days with chest tube drainage, or for those with recurrent PSP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H792648\">",
"       'Indications'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For children and adolescents with SSP, we suggest surgical intervention for patients with recurrent SSP, and for those with underlying lung disease that is severe or progressive, or is known to be associated with recurrent pneumothoraces (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with cystic fibrosis, surgical intervention is recommended for the first recurrence of a pneumothorax, but not for the first occurrence. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgical intervention'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      When surgical intervention is performed, video-assisted thorascopic surgery (VATS) with pleurodesis by manual abrasion is our preferred technique for most cases. (See",
"      <a class=\"local\" href=\"#H793389\">",
"       'Technique'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7112983\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Christopher Oermann, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/1\">",
"      Sahn SA, Heffner JE. Spontaneous pneumothorax. N Engl J Med 2000; 342:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/2\">",
"      Nakamura H, Konishiike J, Sugamura A, Takeno Y. Epidemiology of spontaneous pneumothorax in women. Chest 1986; 89:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/3\">",
"      O'Rourke JP, Yee ES. Civilian spontaneous pneumothorax. Treatment options and long-term results. Chest 1989; 96:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/4\">",
"      Schramel FM, Postmus PE, Vanderschueren RG. Current aspects of spontaneous pneumothorax. Eur Respir J 1997; 10:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/5\">",
"      Weissberg D, Refaely Y. Pneumothorax: experience with 1,199 patients. Chest 2000; 117:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/6\">",
"      Deslauriers J. The management of spontaneous pneumothorax. Can J Surg 1994; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/7\">",
"      Davis AM, Wensley DF, Phelan PD. Spontaneous pneumothorax in paediatric patients. Respir Med 1993; 87:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/8\">",
"      Wilcox DT, Glick PL, Karamanoukian HL, et al. Spontaneous pneumothorax: a single-institution, 12-year experience in patients under 16 years of age. J Pediatr Surg 1995; 30:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/9\">",
"      Poenaru D, Yazbeck S, Murphy S. Primary spontaneous pneumothorax in children. J Pediatr Surg 1994; 29:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/10\">",
"      Robinson PD, Cooper P, Ranganathan SC. Evidence-based management of paediatric primary spontaneous pneumothorax. Paediatr Respir Rev 2009; 10:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/11\">",
"      Kirby TJ, Ginsberg RJ. Management of the pneumothorax and barotrauma. Clin Chest Med 1992; 13:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/12\">",
"      Paape K, Fry WA. Spontaneous pneumothorax. Chest Surg Clin N Am 1994; 4:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/13\">",
"      Bense L. Spontaneous pneumothorax. Chest 1992; 101:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/14\">",
"      Luque MA 3rd, Cavallaro DL, Torres M, et al. Pneumomediastinum, pneumothorax, and subcutaneous emphysema after alternate cocaine inhalation and marijuana smoking. Pediatr Emerg Care 1987; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/15\">",
"      Feldman AL, Sullivan JT, Passero MA, Lewis DC. Pneumothorax in polysubstance-abusing marijuana and tobacco smokers: three cases. J Subst Abuse 1993; 5:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/16\">",
"      Soundappan SV, Holland AJ, Browne G. Sports-related pneumothorax in children. Pediatr Emerg Care 2005; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/17\">",
"      Partridge RA, Coley A, Bowie R, Woolard RH. Sports-related pneumothorax. Ann Emerg Med 1997; 30:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/18\">",
"      Marnejon T, Sarac S, Cropp AJ. Spontaneous pneumothorax in weightlifters. J Sports Med Phys Fitness 1995; 35:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/19\">",
"      Abolnik IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of primary spontaneous pneumothorax. Am J Med Genet 1991; 40:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/20\">",
"      Morrison PJ, Lowry RC, Nevin NC. Familial primary spontaneous pneumothorax consistent with true autosomal dominant inheritance. Thorax 1998; 53:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/21\">",
"      Engdahl MS, Gershan WM. Familial spontaneous pneumothorax in neonates. Pediatr Pulmonol 1998; 25:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/22\">",
"      O'Lone E, Elphick HE, Robinson PJ. Spontaneous pneumothorax in children: when is invasive treatment indicated? Pediatr Pulmonol 2008; 43:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/23\">",
"      Jenkinson SG. Pneumothorax. Clin Chest Med 1985; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/24\">",
"      Srinivas S, Varadhachary G. Spontaneous pneumothorax in malignancy: a case report and review of the literature. Ann Oncol 2000; 11:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/25\">",
"      Roe D, Brown K. Catamenial pneumothorax heralding menarche in a 15-year-old adolescent. Pediatr Emerg Care 1997; 13:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/26\">",
"      Ishikawa N, Takizawa M, Yachi T, et al. [Catamenial pneumothorax in a young patient diagnosed by thoracoscopic surgery; report of a case]. Kyobu Geka 2003; 56:336.",
"     </a>",
"    </li>",
"    <li>",
"     Montgomery, M. Air and liquid in the pleural space. In: Kendig's Disorders of the Respiratory Tract in Children, Chernick, V, Boat, TF, Kendig EL (Eds), WB Saunders, Philadelphia 1998. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/28\">",
"      Leigh-Smith S, Harris T. Tension pneumothorax--time for a re-think? Emerg Med J 2005; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/29\">",
"      O'Connor AR, Morgan WE. Radiological review of pneumothorax. BMJ 2005; 330:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/30\">",
"      Choudhary AK, Sellars ME, Wallis C, et al. Primary spontaneous pneumothorax in children: the role of CT in guiding management. Clin Radiol 2005; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/31\">",
"      Guimaraes CV, Donnelly LF, Warner BW. CT findings for blebs and bullae in children with spontaneous pneumothorax and comparison with findings in normal age-matched controls. Pediatr Radiol 2007; 37:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/32\">",
"      Seguier-Lipszyc E, Elizur A, Klin B, et al. Management of primary spontaneous pneumothorax in children. Clin Pediatr (Phila) 2011; 50:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/33\">",
"      Amjadi K, Alvarez GG, Vanderhelst E, et al. The prevalence of blebs or bullae among young healthy adults: a thoracoscopic investigation. Chest 2007; 132:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/34\">",
"      Laituri CA, Valusek PA, Rivard DC, et al. The utility of computed tomography in the management of patients with spontaneous pneumothorax. J Pediatr Surg 2011; 46:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/35\">",
"      Kuhns LR, Bednarek FJ, Wyman ML, et al. Diagnosis of pneumothorax or pneumomediastinum in the neonate by transillumination. Pediatrics 1975; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/36\">",
"      MacDuff A, Arnold A, Harvey J, BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/37\">",
"      Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/38\">",
"      Chan SS. Current opinions and practices in the treatment of spontaneous pneumothorax. J Accid Emerg Med 2000; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/39\">",
"      Northfield TC. Oxygen therapy for spontaneous pneumothorax. Br Med J 1971; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/40\">",
"      Sawada S, Watanabe Y, Moriyama S. Video-assisted thoracoscopic surgery for primary spontaneous pneumothorax: evaluation of indications and long-term outcome compared with conservative treatment and open thoracotomy. Chest 2005; 127:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/41\">",
"      Santill&aacute;n-Doherty P, Argote-Greene LM, Guzman-Sanchez M. Thoracoscopic management of primary spontaneous pneumothorax. Am Surg 2006; 72:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/42\">",
"      Qureshi FG, Sandulache VC, Richardson W, et al. Primary vs delayed surgery for spontaneous pneumothorax in children: which is better? J Pediatr Surg 2005; 40:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/43\">",
"      Cook CH, Melvin WS, Groner JI, et al. A cost-effective thoracoscopic treatment strategy for pediatric spontaneous pneumothorax. Surg Endosc 1999; 13:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/44\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/45\">",
"      Chan P, Clarke P, Daniel FJ, et al. Efficacy study of video-assisted thoracoscopic surgery pleurodesis for spontaneous pneumothorax. Ann Thorac Surg 2001; 71:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/46\">",
"      Yamamoto H, Okada M, Kanehira A, et al. Video-assisted blebectomy using a flexible scope and a bleb implement. Surg Today 2000; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/47\">",
"      Miller JD, Simone C, Kahnamoui K, et al. Comparison of videothoracoscopy and axillary thoracotomy for the treatment of spontaneous pneumothorax. Am Surg 2000; 66:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/48\">",
"      Nazari S, Buniva P, Aluffi A, Salvi S. Bilateral open treatment of spontaneous pneumothorax: a new access. Eur J Cardiothorac Surg 2000; 18:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/49\">",
"      Lang-Lazdunski L, de Kerangal X, Pons F, Jancovici R. Primary spontaneous pneumothorax: one-stage treatment by bilateral videothoracoscopy. Ann Thorac Surg 2000; 70:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/50\">",
"      Hatz RA, Kaps MF, Meimarakis G, et al. Long-term results after video-assisted thoracoscopic surgery for first-time and recurrent spontaneous pneumothorax. Ann Thorac Surg 2000; 70:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/51\">",
"      Ozcan C, McGahren ED, Rodgers BM. Thoracoscopic treatment of spontaneous pneumothorax in children. J Pediatr Surg 2003; 38:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/52\">",
"      Cardillo G, Facciolo F, Regal M, et al. Recurrences following videothoracoscopic treatment of primary spontaneous pneumothorax: the role of redo-videothoracoscopy. Eur J Cardiothorac Surg 2001; 19:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/53\">",
"      Ohno K, Miyoshi S, Minami M, et al. Ipsilateral recurrence frequency after video-assisted thoracoscopic surgery for primary spontaneous pneumothorax. Jpn J Thorac Cardiovasc Surg 2000; 48:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/54\">",
"      Bialas RC, Weiner TM, Phillips JD. Video-assisted thoracic surgery for primary spontaneous pneumothorax in children: is there an optimal technique? J Pediatr Surg 2008; 43:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/55\">",
"      Cardillo G, Carleo F, Giunti R, et al. Videothoracoscopic talc poudrage in primary spontaneous pneumothorax: a single-institution experience in 861 cases. J Thorac Cardiovasc Surg 2006; 131:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/56\">",
"      Bobbio A, Ampollini L, Internullo E, et al. Thoracoscopic parietal pleural argon beam coagulation versus pleural abrasion in the treatment of primary spontaneous pneumothorax. Eur J Cardiothorac Surg 2006; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/57\">",
"      Chen JS, Hsu HH, Chen RJ, et al. Additional minocycline pleurodesis after thoracoscopic surgery for primary spontaneous pneumothorax. Am J Respir Crit Care Med 2006; 173:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/58\">",
"      Casadio C, Rena O, Giobbe R, et al. Stapler blebectomy and pleural abrasion by video-assisted thoracoscopy for spontaneous pneumothorax. J Cardiovasc Surg (Torino) 2002; 43:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/59\">",
"      Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006; 11:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/60\">",
"      Butterworth SA, Blair GK, LeBlanc JG, Skarsgard ED. An open and shut case for early VATS treatment of primary spontaneous pneumothorax in children. Can J Surg 2007; 50:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/53/40793/abstract/61\">",
"      Flume PA. Pneumothorax in cystic fibrosis. Chest 2003; 123:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6340 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40793=[""].join("\n");
var outline_f39_53_40793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18497078\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4789334\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18497226\">",
"      Acute increase in transpulmonary pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18497233\">",
"      Defects in visceral pleura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18497240\">",
"      Catamenial pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGIC CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4789320\">",
"      Tension pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16059641\">",
"      Estimation of size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4673137\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Evacuation of the pleural space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H793506\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4212115\">",
"      Needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thoracostomy tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H792648\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H793389\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4671806\">",
"      - Other preventive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18497078\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4672226\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4672178\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7112983\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6340|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/63/23538\" title=\"diagnostic image 1\">",
"      Apical pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/58/19361\" title=\"diagnostic image 2\">",
"      Large pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/63/17394\" title=\"diagnostic image 3\">",
"      Large right pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/7/14453\" title=\"diagnostic image 4\">",
"      CT right pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6340|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/9/21649\" title=\"figure 1\">",
"      Soft tissue emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/18/8483\" title=\"figure 2\">",
"      Simple pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/22/36196\" title=\"figure 3\">",
"      Tension pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/8/8333\" title=\"table 1\">",
"      Causes spontaneous pneumothorax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2009?source=related_link\">",
"      Arterial puncture and cannulation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34903?source=related_link\">",
"      Atelectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/30/40418?source=related_link\">",
"      Patient information: Pneumothorax (collapsed lung) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34999?source=related_link\">",
"      Spontaneous pneumomediastinum in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39637?source=related_link\">",
"      Therapeutic uses of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_53_40794="Knee arthrocentesis";
var content_f39_53_40794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52630%7ERHEUM%2F63588%7ERHEUM%2F53804%7ERHEUM%2F81500%7ERHEUM%2F52531%7ERHEUM%2F75451%7EALLRG%2F51897%7EALLRG%2F72665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52630%7ERHEUM%2F63588%7ERHEUM%2F53804%7ERHEUM%2F81500%7ERHEUM%2F52531%7ERHEUM%2F75451%7EALLRG%2F51897%7EALLRG%2F72665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is inserted just posterior to the medial portion of the patella and is directed slightly posteriorly and slightly inferiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ankle arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the leg-foot angle at 90 degrees, the needle is inserted at a point just medial to the tibalis anterior tendon and just lateral to the medial malleolus (arrow). The needle is then directly posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shoulder arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the shoulder externally rotated, the needle is inserted at a point just medial to the head of the humerus and slightly inferior and lateral to the coracoid process. The needle is then directed posteriorly and slightly superiorly and laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wrist arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is inserted at a point just distal to the radius and just ulnar to the anatomic snuff box (arrow). It is then directed perpendicularly. If bone is hit, the needle should be pulled back and slightly redirected toward the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    First carpometacarpal arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb is flexed across the palm toward the tip of the fifth finger. The needle is inserted at the base of the metacarpal bone away from the border of the snuff box. It is then directed toward the proximal end of the fourth metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    \"Tennis elbow\" injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the elbow flexed and pronated, the needle is inserted at the most tender area on the anterolateral aspect of the external condyle of the humerus. A combination of corticosteroid and local anesthetic is injected in several areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacromial bursa injection in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral or posterior approach can be used to inject the subacromial bursa; the lateral approach shown here is safer to perform, since injection into the rotator cuff tendons is nearly impossible with this technique. The patient is to be sitting up, with the hands placed in the lap. The patient is asked to relax the shoulder and neck muscles. Traction applied to the flexed elbow may be necessary to open the subacromial space. The lateral edge of the acromion is located and its midpoint marked. The point of entry is 1 to 1 1/2\" below the marked midpoint. The angle of entry should parallel the patient's own acromial angle (averaging 50- to 65-degrees). The depth will vary according to the patient's weight and muscle development (1 1/2\" in an asthenic patient and up to 3 1/2\" in an obese patient over 30 percent ideal body weight). Ethyl chloride is sprayed on the skin. Local anesthetic is placed in the deltoid muscle (1 mL) and the deep deltoid fascia (0.5 mL). The needle is advanced through the subcutaneous tissue and the deltoid muscle until the subtle resistance of the deep deltoid fascia is encountered. If firm or hard tissue resistance is encountered (deltoid tendon or periosteum, often painful), then the needle is withdrawn 1/2\" and the angle is redirected 5- to 10-degrees either up or down. A \"giving way\" or \"popping\" sensation is often appreciated when the subacromial bursa is entered. Following 1 to 2 mL of anesthesia and leaving the needle in position, the patient strength is tested again. If pain is reduced by 50 percent and the strength of abduction and external rotation are 75 to 80 percent of the unaffected side, then triamcinolone acetonide (1 mg/kg of 40 mg/mL suspension, maximum 40 mg) is injected. Note, never inject under moderate to high pressure. If high injection pressure is encountered, first try rotating the syringe 180 degrees. If tension is still high and the patient obviously anxious, ask the patient to take a deep breath and try to relax the shoulder muscles. If tension remains high, reposition the needle by 1/4\" increments or by altering the angle of entry by 5- to 10-degrees. The subacromial bursa will accept only 2 to 3 mL of total volume before rupturing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trochanteric bursa injection in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trochanteric bursa injection, which may be multiple, not single as shown, may be made up of triamcinolone acetonide (1 mg/kg of 40 mg/mL suspension, maximum 40 mg) mixed with lidocaine without epinephrine (maximum 4.5 mg/kg, not to exceed 300 mg). After localizing the points of maximum tenderness by deep palpation, a 1.5- to 4-inch needle is used as a probe and the points of maximum tenderness are determined. The injection should be done by redirecting several places within the same coronal plane close to bone. The operator should not wander off the coronal plane of the maximal bony protuberance in order to be absolutely sure of avoiding neurovascular structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia, 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40794=[""].join("\n");
var outline_f39_53_40794=null;
var title_f39_53_40795="IC BPS clinical presentation";
var content_f39_53_40795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clincal symptoms at the diagnosis of interstitial cystitis/bladder pain syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary urgency",
"       </td>",
"       <td class=\"centered\">",
"        57-98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daytime frequency",
"       </td>",
"       <td class=\"centered\">",
"        84-97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td class=\"centered\">",
"        66-94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocturia",
"       </td>",
"       <td class=\"centered\">",
"        44-90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain with voiding/dysuria",
"       </td>",
"       <td class=\"centered\">",
"        71-98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suprapubic pain",
"       </td>",
"       <td class=\"centered\">",
"        39-71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineal pain",
"       </td>",
"       <td class=\"centered\">",
"        25-56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient sensation of bladder spasms",
"       </td>",
"       <td class=\"centered\">",
"        50-74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pubic pressure",
"       </td>",
"       <td class=\"centered\">",
"        60-71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspareunia",
"       </td>",
"       <td class=\"centered\">",
"        46-80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"       <td class=\"centered\">",
"        55-67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gross hematuria",
"       </td>",
"       <td class=\"centered\">",
"        14-33",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Teichman JM, Parsons CL. Contemporary clinical presentation of interstitial cystitis. Urology 2007; 69:41. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40795=[""].join("\n");
var outline_f39_53_40795=null;
var title_f39_53_40796="Oral versus intravenous amiodarone";
var content_f39_53_40796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral versus intravenous amiodarone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Oral amiodarone",
"       </td>",
"       <td class=\"subtitle2\">",
"        Intravenous amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolongation of action potential duration in atrial and",
"ventricular myocardium",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blockage of inactivated sodium channels",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slowing of phase 4 depolarization in the sinus node",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockade",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncompetetive blockade of alpha and beta",
"adrenoreceptors",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        + (faster)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AV node effective refractory period",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular effective refractory period",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        -/&darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QRS interval",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QTc duration",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"       <td>",
"        -/&uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A-H interval",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;&uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H-V interval",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Block conversion of thyroxine to trilodothyronine",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A-H interval: time from initial rapid deflection of the atrial wave to the initial rapid deflection of the His bundle potential; H-V interval: time from initial deflection of the His bundle potential to the onset of ventricular activity; +: yes or present; -: no or absent; &uarr; : increase; &darr;: decrease.",
"     <br>",
"      Comparison of the electropharmacologic effects of oral and intravenous amiodarone. Compared to oral amiodarone, the intravenous preparation produces a much lesser increase in the action potential duration in atrial and ventricular myocardium and a minimal increase in the atrial and ventricular refractory periods. As a result, there is little or no increase in QRS duration and the QT interval, respectively. Intravenous amiodarone also has little effect on sinus cycle length and has vasodilator activity that triggers an increase in sympathetic activity; both of these effects results in little or no slowing of the sinus rate. Lastly, the intravenous preparation may have more potent and more rapid antiadrenergic activity.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Desai AD, Chun S, Sung RJ. Ann Intern Med 1997; 127:294.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40796=[""].join("\n");
var outline_f39_53_40796=null;
var title_f39_53_40797="Nonpharm intervent refract gastroparesis";
var content_f39_53_40797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonpharmacologic interventions for refractory gastroparesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available procedures",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasogastric tube",
"       </td>",
"       <td>",
"        <p>",
"         Blind",
"        </p>",
"        <p>",
"         Radiologic (under fluoroscopy)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Decompression",
"        </p>",
"        <p>",
"         Access for feeding or medications",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Ease of placement",
"        </p>",
"        <p>",
"         Simple procedure",
"        </p>",
"        <p>",
"         Low cost",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Easily displaced/removed",
"        </p>",
"        <p>",
"         Short-term use only",
"        </p>",
"        <p>",
"         Discomfort",
"        </p>",
"        <p>",
"         Source of infection",
"        </p>",
"        <p>",
"         Risk of tube blockage",
"        </p>",
"        <p>",
"         Potentially increased reflux, aspiration of feeds",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrostomy tube",
"       </td>",
"       <td>",
"        <p>",
"         Surgical",
"        </p>",
"        <p>",
"         Radiologic",
"        </p>",
"        <p>",
"         Percutaneous endoscopic",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Decompression",
"        </p>",
"        <p>",
"         Feeding",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Superior for decompression",
"        </p>",
"        <p>",
"         Moderate ease of placement",
"        </p>",
"        <p>",
"         Bolus feeding may occasionally be possible by gastrostomy tube alone",
"        </p>",
"        <p>",
"         Potentially long term",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Questionable value for nutritional support without jejunal tube placement",
"        </p>",
"        <p>",
"         Source of infection",
"        </p>",
"        <p>",
"         Risk of tube blockage",
"        </p>",
"        <p>",
"         High risk of reflux, aspiration of feeds",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jejunostomy tube (direct)",
"       </td>",
"       <td>",
"        <p>",
"         Surgical",
"        </p>",
"        <p>",
"         Radiologic",
"        </p>",
"        <p>",
"         Percutaneous endoscopic",
"        </p>",
"       </td>",
"       <td>",
"        Feeding",
"       </td>",
"       <td>",
"        <p>",
"         Superior for nutritional purposes",
"        </p>",
"        <p>",
"         Potential for long-term use",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Source of infection",
"        </p>",
"        <p>",
"         Risk of tube blockage",
"        </p>",
"        <p>",
"         Requires enteral infusion pump for nutrition",
"        </p>",
"        <p>",
"         Does not provide for gastric decompression",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jejunostomy tube (trans-gastric)",
"       </td>",
"       <td>",
"        <p>",
"         Radiologic",
"        </p>",
"        <p>",
"         Percutaneous endoscopic",
"        </p>",
"       </td>",
"       <td>",
"        Biluminal enteral tube with separate gastric and jejunal ports",
"       </td>",
"       <td>",
"        <p>",
"         Single tube",
"        </p>",
"        <p>",
"         Single procedure for two tubes",
"        </p>",
"        <p>",
"         Single stoma/abdominal",
"        </p>",
"        <p>",
"         Can accomplish decompression and feedings through different ports of the same tube",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Risk of migration of jejunal tube into stomach",
"        </p>",
"        <p>",
"         Reflux of feeds into stomach",
"        </p>",
"        <p>",
"         Source of infection",
"        </p>",
"        <p>",
"         Risk of tube blockage (especially jejunal port)",
"        </p>",
"        <p>",
"         Technically somewhat more difficult to place the jejunal tube",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Separate gastrostomy and jejunostomy tubes",
"       </td>",
"       <td>",
"        <p>",
"         Radiologic",
"        </p>",
"        <p>",
"         Percutaneous endoscopic",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Decompression",
"        </p>",
"        <p>",
"         Feeding",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Two separate simultaneously working tubes",
"        </p>",
"        <p>",
"         Decreased risk of reflux, aspiration of feeds",
"        </p>",
"        <p>",
"         Provides gastric decompression",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Longer, more difficult procedure",
"        </p>",
"        <p>",
"         Higher cost due to two procedures",
"        </p>",
"        <p>",
"         Higher risk of infection due to&nbsp;two stomas/wounds",
"        </p>",
"        <p>",
"         Risk of tube blockage",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrojejunostomy&nbsp;with or without&nbsp;percutaneous jejunostomy (open versus laparoscopic)",
"       </td>",
"       <td>",
"        Surgical",
"       </td>",
"       <td>",
"        Surgical bypass for decompression and feeding",
"       </td>",
"       <td>",
"        <p>",
"         Drainage by gravity",
"        </p>",
"        <p>",
"         Potentially permanent",
"        </p>",
"        <p>",
"         Most useful in gastric outlet obstruction syndrome",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increased morbidity of surgery",
"        </p>",
"        <p>",
"         Needs careful patient selection",
"        </p>",
"        <p>",
"         Gastroparesis, if significant, may not be alleviated and may require jejunal tube placement regardless",
"        </p>",
"        <p>",
"         Higher cost of procedure",
"        </p>",
"        <p>",
"         High expertise required for the procedure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric pacemaker",
"       </td>",
"       <td>",
"        Surgical",
"       </td>",
"       <td>",
"        <p>",
"         Feeding",
"        </p>",
"        <p>",
"         Enteral passage of secretions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Physiologic",
"        </p>",
"        <p>",
"         Potentially eliminates the need for enteral feeding",
"        </p>",
"        <p>",
"         No foreign body on body surface (tubes)",
"        </p>",
"        <p>",
"         Decreased risk of infection",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         More expertise required",
"        </p>",
"        <p>",
"         Cost of procedure and device",
"        </p>",
"        <p>",
"         Unknown benefit for MG (currently, gastric electric stimulation is not used in MG and is still controversial in gastroparesis. Patients are required to have a life expectancy of &gt;6 years).",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MG: malignant gastroparesis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40797=[""].join("\n");
var outline_f39_53_40797=null;
var title_f39_53_40798="Suicide rates adolescents";
var content_f39_53_40798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Suicide rates per 100,000 population, ages 10-24 in 1997: National Center for Health Statistics (1999)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40798=[""].join("\n");
var outline_f39_53_40798=null;
var title_f39_53_40799="Bronchogenic carcinoma CT III";
var content_f39_53_40799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: CT scan of an advanced bronchogenic carcinoma shows right lower lobe atelectasis with accompanying right pleural effusion. Right panel: Barium esophagram from this patient demonstrates an esophagopulmonary fistula (arrow) that indicates mediastinal extension and invasion by this T4 tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_53_40799=[""].join("\n");
var outline_f39_53_40799=null;
